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ABSTRACT 
Xiaojuan Li: Comparative Effectiveness of Intravenous Iron Treatment Protocols in 
Hemodialysis Patients: Causal Inference with Dynamic Treatment Regimes 
 (Under the direction of M. Alan Brookhart) 
 
Decisions regarding intravenous iron treatment follow dosing protocols for anemia 
management of hemodialysis patients. These protocols are a type of dynamic treatment regimes, 
consisted of a set of decision rules with iron status values - transferrin saturation and ferritin - 
and corresponding iron dosing patterns. Multiple protocols exist in clinical practice, but their 
comparative safety is unknown.  
Using clinical data from a large US dialysis provider linked to healthcare utilization data 
from United States Renal Data System (2004-2012), our objectives were to (1) develop an 
approach to identify intravenous iron dosing protocols that were commonly used, and (2) 
evaluate the comparative safety of continuous exposure to commonly used protocols.     
The identification approach classified intravenous iron dosing protocols at measurements 
of iron status tests, where decisions regarding iron treatment occur in clinical practice. Using 
current test levels and iron treatment experience in a two-week assessment window, candidate 
protocols were assigned to a patient if they were consistent with treatment experience in the 
assessment window. Among 43,166 patients who initiated hemodialysis in 2004-2012, 79.1% of 
them were matched with candidate protocols. The prevalence of protocol matches increased from 
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75.0% in 2004 to 90.7% in 2012. Higher prevalence of knowingly implemented protocols 
confirmed the performance of this identification approach.  
In the comparative safety analyses, we estimated the effect of continuous exposure to the 
five most commonly initiated protocols in 2009-2012 on risks of mortality and infection-related 
events. Two less commonly initiated protocols were more aggressive, recommending a large 
amount of iron at higher iron status levels; their initiators were sicker at baseline. Compared with 
one commonly initiated and less intensive protocol, these two protocols were at elevated 
mortality risk (120-day risk differences (95% confidence interval): 1.5% (0.1, 3.1%), 3.1% (1.0, 
5.6%)). The magnitude of elevated risk increased with the aggressiveness of the protocols. We 
observed similar trends in elevated risks for infection-related events among more aggressive 
protocols.  
Protocols that recommend less intensive use of iron at high levels of iron status tests may 
lower risks of mortality and infection-related events, but further exploration is needed to address 
potential residual confounding and selection bias. 
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CHAPTER 1: STATEMENT OF SPECIFIC AIMS 
Anemia, a common complication of end-stage renal disease (ESRD),1 is associated with 
elevated morbidity, mortality, and healthcare costs.1  A primary cause of anemia in ESRD is iron 
deficiency, particularly among patients requiring hemodialysis (HD).  Iron deficiency can be 
classified into absolute iron deficiency and functional iron deficiency; their causes are 
multifactorial.3  Absolute iron deficiency, or depleted iron stores, is frequently a result of blood 
loss, reduced intake, and impaired intestinal absorption of dietary iron.3  Functional iron 
deficiency, or insufficient iron availability at the site of erythropoiesis despite adequate iron 
stores, can be caused by chronic inflammation associated with ESRD or elevated hepcidin 
levels.3  Overall, HD patients lose an average of 1 to 2 g of iron per year, and some as much as 4 
to 5 g per year.4  Management of iron deficiency to meet the need for erythropoiesis is thus 
essential for optimal management of anemia in ESRD patients.  
Intravenous (IV) iron is an effective way to supplement iron and optimize erythropoiesis.  
Existing randomized controlled trials (RCTs) showed that supplementing erythropoiesis-
stimulating agent (ESA) therapy with IV iron increases hemoglobin production and lowers ESA 
requirement.5-6  Consequently, co-administration of ESAs and IV iron has become the primary 
management strategy for anemia in HD patients.4  Subsequent to emerging evidence on the 
cardiovascular (CV) safety of ESAs7-9 and changes in the reimbursement policies in Medicare’s 
ESRD programs,10 the reliance on IV iron has increased, leading to reduction in ESA use and in 
potential risk of ESA-related adverse events.11-12  International guidelines correspondingly 
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recommended a wider use of iron.13-16  Altogether, these events led to significant, albeit transient, 
changes in clinical practice in recent years.  Mean IV iron dose increased sharply from 210 mg 
per month in 2009-2010 to 280 mg per month in 2011, then back to a stable 200 mg per month in 
2012-2013.17,18  During this time period, about 40% of HD patients had ferritin levels greater 
than 800 ng/mL.17  The persistently high levels of ferritin raised concerns about the safety of IV 
iron administration in HD patients. 
In contemporary clinical practice, IV iron is either provided intermittently via large doses 
over consecutive dialysis sessions (often termed “bolus dosing”) or via small doses provided 
every one to two weeks to maintain iron stores (often termed “maintenance dosing”). Decisions 
regarding when to use each dosing approach follow certain protocols adopted by dialysis clinics. 
A variety of dosing protocols exist in clinical practice, and they differ with respect to target 
levels of iron status parameters and dosing approach recommendations.19-21 
Several existing studies consistently demonstrated short-term benefits of bolus iron 
administration on hemoglobin levels and iron status compared to maintenance dosing.6,22 No 
difference in CV risks was associated with either dosing approach;23,24 however, a modestly 
increased risk of infection was associated with bolus dosing among patients with a history of 
infection and those with a central venous HD catheter.24,25 A recent observational study has 
reported an association between lower mortality risk and maintenance strategy relative to non-
maintenance strategies.26    
Compared to short-term effects, less is known about the long-term safety and 
effectiveness of different iron treatment protocols. Clinical trials assessing the long-term use of 
iron administration strategies are lacking; existing large observational studies have focused on 
the effect of cumulative iron exposure over a long period, which were not large enough to 
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resolve clinically meaningful effects of iron exposure on infection outcomes.20,27 The cumulative 
exposures do not align well with the treatment decisions that a physician needs to make 
regarding iron use in routine care.28  
Given the increased use of IV iron and data suggesting some risk, evaluating the long-
term safety of different IV iron dosing protocols is the overall goal of this thesis. This 
dissertation has two primary aims: 
1) Characterize IV iron treatment protocols in routine use among ESRD patients 
undergoing chronic hemodialysis; and  
2) Evaluate the comparative safety of continuous exposure to different commonly used 
IV iron treatment protocols.     
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CHAPTER 2: REVIEW OF THE LITERATURE 
2.1.  Overview of ESRD  
ESRD is the last stage of chronic kidney disease (CKD) where the renal function falls 
below 15% of normal.  The kidneys can no longer support the body’s needs by adequately 
removing nitrogenous waste or excess fluid from the body.  Renal replacement therapy, such as 
dialysis or kidney transplantation, is necessary for survival.  ESRD is a syndrome characterized 
by hypertension, anemia, renal/metabolic bone disease, nutritional impairment, neuropathy, 
impaired quality of life, and reduced life expectancy. 
As of 2012, 636,905 patients were receiving treatment for ESRD in the US, an increase 
of 1.3% in prevalence from 2011.29  Although slowing down, prevalent ESRD population 
continues to grow, and the counts are expected to reach 774,386 in 2020.30  The incidence of 
ESRD cases has been slowly decreasing since 2006 with 359 new cases per million population 
after adjusting for age, sex, and race.  This rate is still 11 cases above the targeted rate of Healthy 
People 2020.29  As shown in Table 2.1, the rate of incident ESRD is high among nonwhites, men 
or older people.  The incidence rates are almost as three times among Blacks/Africans and Native 
Hawaiians/Pacific Islanders compared to Whites and Asians. Hispanics also have higher 
incidence rate than non-Hispanics.  Males have a rate 59% higher than females, and this 
difference has increased by 17% from 2001.  The incidence rate increases with age and varies 
dramatically by geographic region.  The highest rates are in the South and Mississippi River 
valleys while the lowest rates are in the Northwest, New England, and some Rocky Mountain 
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states with the largest difference of 170 cases per million/year between ESRD Network 1 
(Maine, New Hampshire, and Rhode Island) and Network 14 (Texas).29   
Four primary causes of ESRD are diabetes, hypertension, glomerulonephritis, and cystic 
kidney disease. Most cases of ESRD are caused by diabetes or hypertension; their incidences had 
been increasing rapidly since 1980 but have been decreasing from 2010 to 2012.29 The number 
of cases with glomerulonephritis as the primary cause has declined since the 1990s while the 
number of cases with cystic kidney disease as the primary cause has been stable over the period 
from 1980 to 2012. New cases with diabetes have the highest rate among these four causes.  
Patients with ESRD require renal replacement therapy, either through dialysis or kidney 
transplantation. Dialysis is the mechanical process by which the blood is filtered to clean out 
excess water, minerals, and other metabolism products. There are two types of dialysis, 
hemodialysis (HD) and peritoneal dialysis (PD). HD is the most commonly used method to treat 
kidney failure and the focus of this thesis. Out of the 114,813 new ESRD patients in 2012, 89% 
started on HD, and 8% started on PD.29 In the process of HD, a patient’s blood flows through 
tubes into a dialyzer while a premixed dialysate solution flows into the dialyzer in the opposite 
direction. In the dialyzer, excess water, minerals, and wastes diffuse across a semi-permeable 
membrane that separates the blood and dialysate compartments. Cleaned blood then flows out of 
the dialyzer back into the patient through another tube. This process recurs during a typical 
dialysis session whereby blood volume several times greater than a patient’s innate amount flows 
through the dialysis circuit. Patients undergoing HD receive dialysis at a dialysis clinic three 
times a week generally, and each dialysis session lasts about three to four hours. 
The morbidity rates in ESRD patients are high. Among HD patients in 2012,29 the 
adjusted hospitalization rate was 1.73 admissions per patient year and 11.0 hospital days per 
6 
 
Table 2.1. Summary statistics on cases of ESRD in the US, by age, race, ethnicity, sex, and 
primary diagnosis 
  Incidence Prevalence 
  Count % Adj. rate Count % Adj. rate 
All 114,813 100 353.2 636,905 100 1,942.9 
Unadjusted     358.6     1,968.2 
Age             
0-19 1,163 1.0 13.1 7,545 1.2 83.1 
20-44 13,162 11.5 122.2 101,994 16.0 938.0 
45-64 45,069 39.3 570.2 283,021 44.4 3,550.1 
65-74 27,933 24.3 1,270.1 140,238 22.0 6,301.8 
75+ 27,486 23.9 1,618.4 104,107 16.3 6,261.1 
Race             
White 76,089 66.3 279.2 383,534 60.2 1,431.8 
Black/African American 31,398 27.3 908.0 200,797 31.5 5,670.5 
Native American 1,273 1.1 411.5 8,154 1.3 2,599.5 
Asian 5,840 5.1 378.9 35,878 5.6 2,271.8 
Other 50 0   5,860 0.9   
Unknown 163 0.1   2,682 0.4   
Hispanic 17,024 14.8 501.3 106,308 16.7 2,931.9 
Non-Hispanic 97,789 85.2 340.5 530,597 83.3 1,857.8 
Gender             
Male 65,842 57.3 446.0 363,497 57.1 2,396.7 
Female 48,971 42.7 278.0 273,312 42.9 1,558.4 
Unknown gender       96 0  
Cause             
Diabetes 50,534 44.0 154.3 239,837 37.7 731.0 
Hypertension 32,610 28.4 101.1 159,049 25.0 489.4 
Glomerulonephritis 9,115 7.9 28.3 106,012 16.6 325.8 
Cystic kidney disease 2,530 2.2 7.9 29,881 4.7 92.4 
Urologic disease 538 0.5 1.6 7,447 1.2 22.9 
Other known 12,281 10.7 38.2 59,714 9.4 184.7 
Unknown cause 3,506 3.1 10.8 25,977 4.1 78.2 
Missing cause 3,699 3.2 10.6 8,988 1.4 18.1 
a. Rates are per million population. Rates by age are adjusted for race and sex. Rates by sex are adjusted for race 
and age. Rates by race are adjusted for age and sex. Rates by disease group and total adjusted rates are adjusted for 
age, sex, and race. Adjusted rates do not include patients with other or unknown race. b. Statistics shown are for 
year 2012, adapted from Annual Data Report from the 2014 USRDS Annual Data Report On kidney disease. 29 
year. Although the overall hospitalization rate and average length of stay continued to decline, 
some cause-specific hospitalizations have been increasing. Among HD patients, hospitalization 
due to infection has increased by 34% since 1993 while hospitalization for cardiovascular (CV) 
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events has decreased by 12.7%. Patients aged 20-44 or 75 and older, females, Whites, 
Blacks/African Americans, and patients who have diabetes as their primary cause of ESRD have 
a higher risk of hospitalization.29 For HD patients, the rate of rehospitalization is also high. In 
2012, the overall all-cause rehospitalization rate was 35.2% while the CV- and infection-related 
hospitalization rates were 36.2% and 32.9%, respectively.29   
Patients with ESRD are very ill, and their mortality rates are high. In 2012, the mortality 
rate was 137.8 per 1,000 person years for all ESRD patients. Among HD patients, the mortality 
rate was 168.5 per 1,000 person years. Patients who are older, male, or White have higher rates. 
Mortality rates also increase with vintages in general, however, high rates also occur early in the 
first year among HD patients, especially in the second month on dialysis (all-cause mortality: 
421 per 1,000 patient years; CV mortality: 163 per 1,000 patient years; infection mortality: 35 
per 1,000 patient years).29  Compared to the general population, patients with ESRD have lower 
survival probabilities, and adjusted all-cause mortality rates are about 6.1 to 7.8 times higher. 
After adjusting for age, sex, race, Hispanic ethnicity, and primary diagnosis, only 54.2% of HD 
patients were alive 3 years after ESRD onset and 40.4% at 5 years after ESRD onset. They are 
expected to live less than one-third as long as people with similar characteristics but no ESRD 
(dialysis versus general population, 2010: 6.6 years versus 22.2 years).29   
The cost of ESRD is substantial. Although the total population of ESRD comprises less 
than 1% of the total Medicare population, the cost of ESRD accounts for about 6% of Medicare 
spending.29 In 2011, spending on HD patients accounts for about 85% of the total cost of ESRD 
and averaged $88,000 per person per year.31 In 2012, the second full year under the expanded, 
bundled Prospective Payment System (PPS), total spending increased by 3.5% from 2011 while 
inpatient spending was similar to 2011.   
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2.2. Anemia in the ESRD Population 
Patients with advanced kidney diseases such as ESRD often are anemic.32 The incidence 
of anemia increases as the GFR, a marker of kidney function, declines. Anemia, as defined by 
WHO, refers to lower than normal hemoglobin concentrations, with different cut-off values in 
different populations: below 13.0 g/dL in adult men and non-menstruating women, and below 
12.0 g/dL in menstruating women.33  
Factors contributing to anemia in the dialysis-dependent ESRD patients include (1) 
insufficient erythropoietin (EPO) production, (2) blood loss and iron deficiency, (3) acute and 
chronic inflammatory conditions, (4) severe hyperparathyroidism, (5) aluminum toxicity, (6) 
folate deficiency, and (7) decreased survival of red blood cells (RBCs).1,34 The kidneys produce 
about 90% of circulating EPO, an essential stimulus for bone marrow production of RBCs. The 
loss of EPO production in the setting of kidney failure is the primary mechanism responsible for 
anemia in these patients.  
Anemia has an adverse impact on health-related life as well as quality of life in ESRD 
patients. Clinical symptoms of anemia include fatigue, shortness of breath, skill pallor, 
palpitations, angina, decreased cognitive function, loss of libido, and decreased sense of well-
being.2,35-37 The goals of anemia management are to treat its underlying causes and reverse 
symptoms attributable to decreased hemoglobin.    
2.2.1. The Role of EPO and Iron in Erythropoiesis  
In the first stage of erythropoiesis process (Figure 2.1), the presence of decreased oxygen 
delivery due to hypoxemia or anemia leads to delayed spontaneous degradation of hypoxia 
inducible factor (HIF) produced by the kidneys and other tissues. The continuing presence of  
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Figure 2.1. Erythropoiesis in chronic kidney disease 
      Adapted from National Kidney Foundation’s Primer on Kidney Diseases34 
HIF promotes production of hormone EPO in the kidneys. EPO binds to receptors on erythroid 
progenitor cells, the burst-forming units (BFU-E), and colony-forming units (CFU-E) cells in the 
bone marrow, which then differentiate into erythroblasts. In the second stage, erythroblasts 
undergo rapid cell division and iron-dependent hemoglobinization to form reticulocytes that 
leave the bone marrow to circulation. The EPO-dependent first stage takes about 8 to 13 days 
and shortens as erythrocyte production increases. The second iron-dependent stage takes about 4 
days while iron-acquisition takes about 2 to 3 days. In the absence of EPO, the erythroid 
progenitor cells will undergo programmed death or apoptosis. In the absence of iron, hemoglobin 
formation in reticulocytes will stop, resulting in reduction of RBCs. Therefore, it is clear that 
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sufficient erythroblast production and adequate levels of iron are necessary for optimal RBCs or 
hemoglobin production in the treatment of anemia in ESRD patients.  
As shown in Figure 2.1, some other factors also play important roles in the production of 
RBCs, including proinflammatory cytokines such as interleukin 1 (IL-1), tumor necrosis factor-α 
(TNF- α), IL-6, interferon-γ (INF-γ), and hepcidin. They may be the basis for most of the anemia 
of chronic disease syndromes and contribute to the anemia in ESRD patients when inflammation 
and infection are present. However, for patients who are anemic without inflammation or 
infection, EPO deficiency and iron deficiency play a much greater role.    
2.2.2. Iron Deficiency   
Sufficient iron availability is necessary in erythropoiesis. Iron deficiency occurs in 
majority of ESRD patients on HD and can be classified into absolute or functional iron 
deficiency. Absolute iron deficiency reflects little or no iron stores.38 As defined by Weiss and 
Gordeuk,39 absolute iron deficiency refers to a concentration of serum ferritin <15 µg/L for men 
and <19 µg/L for women in general population. The cut-off values for patients with ESRD, 
however, are markedly higher. Because high serum ferritin levels may be a result of chronic 
inflammation, infection, malnutrition or malignancy and not necessarily reflect iron overload,40 
having serum ferritin >500 µg/L does not exclude iron deficiency in these patients. As a result, 
both serum ferritin levels and transferrin saturation (TSAT) are used for diagnosis, and 
concurrent low levels are thought to indicate absolute iron deficiency. Current evidence-based 
guidelines recommend a target serum ferritin level of ≥200 µg/L for dialysis patients,41 and 
serum ferritin as a marker for iron stores in the body should be measured every 3 months in 
patients undergoing ESA therapy and IV iron supplementation. No guidelines are available on 
the upper limit of serum ferritin at which iron treatment should be withheld.  
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Functional iron deficiency occurs when there is inadequate release of iron to support 
erythropoiesis although adequate amounts of iron stores are present.38 A common occurrence is 
in the presence of inflammation in patients undergoing ESA maintenance therapy. Functional 
iron deficiency is generally thought to be present when serum ferritin level is high but TSAT 
level is low. However, this view has been challenged by results from recent studies.38 TSAT, the 
ratio of serum iron to total serum iron binding capacity, is a measure of circulating iron available 
for delivery to the erythroid marrows. Patients with iron deficiency have TSAT levels <15% 
while the normal values lie between 16-40%. The level of TSAT fluctuates greatly with varying 
serum iron level while transferrin level is affected by the nutritional status. In the presence of 
inflammation, TSAT decreases, and a level <20% with normal or elevated serum ferritin levels 
indicates functional iron deficiency in patients with CKD. However, a TSAT level >20% and/or 
a serum ferritin level >100 µg/L does not exclude functional iron deficiency, because the 
specificity and sensitivity of these measures for iron deficiency are low.42 
It is hard to differentiate between absolute and functional iron deficiency without 
histological examination of the bone marrow.38 Common practice in clinical care has used the 
response to IV iron supplementation as a guide; it is thought that patients with absolute iron 
deficiency are generally more likely to respond to this therapy compared to those with functional 
iron deficiency. However, about 30% of patients with functional iron deficiency also respond to 
treatment.38 Nevertheless, both deficiencies contribute to iron-restricted erythropoiesis. It is 
recommended to use a trial of IV iron therapy to identify patients who need IV iron 
supplementation to optimize ESA therapy when hemoglobin (Hb) is below target levels or high 
ESA doses are used but iron status target levels are indefinite. A response to IV therapy with a 1 
to 2 g/dL increase in hemoglobin confirms iron deficiency.43   
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The cause of iron deficiency in ESRD patients on HD is also multifactorial.44 Absolute 
iron deficiency, or depleted iron stores, is frequently a result of blood loss, reduced intake, and 
impaired intestinal absorption of dietary iron. These patients undergo HD 3 times a week. Blood 
loss occurs due to clotted dialysis membranes and in the process of running through dialyzer, as 
well as frequent blood sampling. On average, a patient loses about 2-5 L of blood per year, 
which includes about 0.5-1.5 g of iron.45,46 Absorption of iron from food seems to vary inversely 
with ferritin levels, however, the amount absorbed from food is not sufficient enough to meet the 
need for erythropoiesis in these patients.44,47,48 Acquired gastrointestinal diseases such as 
autoimmune atrophic gastritis and Helicobacter pylori infection affect about 90% of HD 
patients, and the resulting use of gastric proton pump inhibitors and H2-antagonists contributes to 
the malabsorptive mechanism of iron deficiency anemia.49,50 Functional iron deficiency, caused 
by insufficient iron availability at the site of erythropoiesis despite adequate iron stores, can be a 
result of chronic inflammation associated with ESRD or elevated hepcidin levels.38,44 Hepcidin, a 
peptide hormone, regulates absorption of dietary iron and recycled iron from senescent RBCs in 
splenic and hepatic macrophages, and the release of iron from storage in hepatocytes. Hepcidin is 
cleared by the kidneys and therefore elevated in ESRD patients. Abnormal hepcidin synthesis 
thus results in increased hepcidin levels that lead to decrease in iron absorption, availability of 
recycled iron from macrophages, and then functional iron deficiency.34,44   
Iron deficiency has been linked with elevated risk for thromboembolic events and 
mortality in CKD patients on ESA treatment.44 It is also a cause of hyporesponsiveness to ESA 
therapy, which is potentially correctable with iron supplementation.41,44,47 Achieving adequate 
iron stores and availability is thus essential for optimal management of anemia in ESRD patients.         
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2.2.3. Consequence of Anemia 
The consequences of anemia are severe. Anemia in ESRD patients is associated with 
elevated morbidity, mortality, and healthcare costs.2,35-37 Left untreated, anemia can affect major 
organs such as heart and brain and contribute to CV morbidity and mortality outcomes, including 
an exacerbation of angina and left ventricular hypertrophy.36 While the incidence of ESRD is on 
the rise, affecting nearly 637,000 patients in the US as of December 31, 2012,29 anemia in ESRD 
patients remains an important public health problem. To minimize the potentially severe 
consequences of anemia in ESRD patients, adequate management of anemia is of great 
importance, and identifying optimal management strategies is essential.  
2.3. Management of Anemia in ESRD patients on HD 
Anemia, among the physiologic complications of advanced kidney disease, is probably 
the most responsive to treatment. Management of anemia in these patients has been evolving 
through time. Prior to 1990s, it was mainly through transfusions and IV iron supplementation, 
accompanying risk of transfusion reactions, immune sensitization, iron overload, and infection. 
The introduction of ESAs has decreased the use of transfusions.51 Treatment with concurrent use 
of ESAs and IV iron has become the standard therapy due to relative health benefits52-54 and 
cost-effectiveness11 compared to ESA alone. Recent studies7,8,55 showed evidence of harm 
associated with normalizing Hb with ESAs, contributing to a “black box” warning for ESAs and 
label change.56,57 Together with changes in CMS’s reimbursement program, the use of ESAs has 
been decreasing whereas reliance on IV iron has increased.58,59   
2.3.1. RBC Transfusions in HD Patients  
Before 1990s, anemia in HD patients required frequent RBC transfusions with an average 
of 6 times a year.45 During a RBC transfusion, a needle is used to insert an IV line into one of the 
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patient’s blood vessels, and healthy blood is given to the patient through this line. Transfusions 
raise the percentage of RBCs in the patient’s blood, increasing the amount of oxygen available to 
the body. Prior to the introduction of recombinant human erythropoietin (rHuEPO) in 1989, low 
hemoglobin levels of 5-7 g/dL were prevalent in HD patients.60 When iron and anabolic steroid 
treatments failed to improve the clinical symptoms of anemia, frequent blood transfusions were 
required.     
For ESRD patients, RBC transfusions are almost universally successful in increasing a 
patient’s blood volume and raising the hemoglobin level, and thus can help improve the patient’s 
symptoms and quality of life. They, however, do come with risks. Risks associated with RBC 
transfusions include both infectious and non-infectious reactions. Due to the advancements in 
viral and bacterial testing methodologies and extensive donor interviewing process, the incidence 
of transfusion-transmitted infections has reduced greatly.61 At the same time, reporting of non-
infectious complications of transfusion has increased, which will likely remain the leading cause 
of transfusion-related morbidity and mortality.  
The risk of transfusion-transmitted viral infections including HIV (risk 1 in 2.3 million), 
HBV (1 in 350,000) and HCV (1 in 1.8 million) infections is now greatly reduced, due to 
improved methods of donor history screening and laboratory testing.61 Bacterial and parasitic 
infections, in comparison, are rising concerns. Sepsis secondary to gram-negative bacteria carries 
a mortality rate as high as 60%;62 Babesia accounts for 30% of reported deaths due to RBC 
microbial infections with no currently available FDA-approved test to detect Babesia.61  
RBC transfusions can also cause a variety of non-infectious reactions, and the risks of 
their occurrence vary greatly as well as their impact on mortality. As reported to the FDA 
between 2005 and 2010, the top 3 causes of transfusion-related deaths were transfusion-related 
15 
 
acute lung injury (incidence 1 in 1,200-190,000 transfusions), hemolytic transfusion reactions, 
and transfusion-associated circulatory overload (<1 in 100 transfusions), accounting for 50%, 
25%, and 12% of the total events respectively. Serious allergic reactions, anaphylactic reactions 
(1 in 20,000-50,000 transfusions), accounted for 4% of total transfusion-related deaths, whereas 
mild allergic reactions such as mild urticarial reactions (incidence 1-3%) were less fatal.61  
Iron overload, another non-infectious risk of transfusion, was a common and potentially 
serious complication during the pre-EPO era.63 Because the amount of iron being released (~1 
mg iron per mL of RBCs) during transfusion dramatically exceeds what can be excreted (~1 mg 
per day), transferrin becomes saturated quickly after 10-15 units of RBCs. Excess iron 
accumulates in essential vital organs (reticuloendothelial system, liver, heart, spleen and 
endocrine organs), which may lead to liver failure and heart failure. 
Another common non-infectious reaction is alloimmunization, which can occur against 
RBC (incidence 6-10%) or Human Leukocyte antigens (HLA, incidence 2-25%).61 The 
incidences are much higher among patients receiving multiple transfusions. HLA 
alloimmunization is undesirable in ESRD patients because it is considered as a contraindication 
to transplantation. 
 With the introduction of EPO, the hemoglobin levels of patients on HD greatly improved, 
and the need for RBC transfusions dramatically decreased. However, RBC transfusions are still 
necessary for patients who need an immediate increase in oxygen carrying capacity.  
2.3.2. ESA Use in HD Patients 
The availability of rHuEPO in 1989 has revolutionized anemia management in patients 
with ESRD. The initial phase III trial showed elimination of the need for transfusions within 2 
months of initiation of ESA therapy, compared with 1,030 transfusions within the 6 months prior 
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to initiation.64 Because they dramatically reduced the need for frequent RBC transfusions and 
androgen as well as their associated adverse effects, ESA therapy became very appealing and 
widely used for anemia management in ESRD patients on HD.  
Exogenous ESAs are structurally and biologically similar to endogenous hormone EPO. 
They stimulate erythropoiesis via the same mechanism,34 inducing the body to create more RBCs 
and raise the hemoglobin level. ESAs also help mobilize iron stores, which is particularly helpful 
in ESRD patients with iron overload due to previous frequent transfusions.34,65,66  
ESAs in the US  
Two ESA agents are available for the treatment of anemia of CKD in the US: epoetin alfa 
(Epogen®/Procrit®) and darbepoetin alfa (Aranesp®). Approved by the FDA in 1989, epoetin alfa 
is the first agent in the ESA family and has been prescribed to 1.5 million Medicare patients on 
dialysis as of 2012.67,68 In 2001, the second-generation ESA darbepoetin alfa was approved.69 
Darbepoetin alfa differs from epoetin alfa in that it contains two more N-linked oligosaccharide 
chains, resulting in longer half-life than epoetin alfa. In November 2007, the third generation 
ESA methoxy polyethylene glycol-epoetin beta (Mircera®) was approved for the treatment of 
anemia associated with CKD in both patients on dialysis and not on dialysis.70 It is the only 
FDA-approved ESA to maintain stable hemoglobin levels with once-monthly or one-every-two-
week dosing in all CKD patients. Compared to the other ESAs, Mircera® has the longest half-
life, up to six times longer than darbepoetin alfa and up to 20 times longer than epoetin alfa. 
Mircera® has been available in Europe but not launched in the US due to a patent case. 
Indications and contraindications in HD patients 
Both epoetin alfa and darbepoetin alfa are indicated for the treatment of anemia due to 
CKD in most patients on HD who have a hemoglobin level of <10 g/dL.68,69 They are not 
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indicated to use in HD patients who have a history of stroke or malignancy, or active malignancy 
receiving treatments, unless also receiving concomitant myelosuppressive chemotherapy. ESAs 
cannot substitute for RBC transfusions in patients requiring immediate correction of anemia.68,69 
They are also contraindicated in patients with uncontrolled hypertension, pure red cell aplasia, 
and serious allergic reactions to ESA therapy.68,69   
ESA administration  
ESAs can be administered both intravenously and subcutaneously. Studies have shown 
that subcutaneous administration is 20% to 30% more efficient than a comparable intravenously 
administered dose.71 Nonetheless, ESAs are mostly administered intravenously for patients on 
HD in the US due to the convenience of IV administration and the potential risk of pure red cell 
aplasia subcutaneous administration carries. Initially, subcutaneous administration was more 
common in other countries.72 However, due to the association between cases of pure red cell 
aplasia and subcutaneous administration of epoetin alfa in Europe, IV administration of ESAs 
becomes more common. Recent guidelines suggest either administration route for HD patients.13  
Compared to long-acting darbepoetin alfa that requires injections once every one or two 
weeks, administration of epoetin alfa is more burdensome by requiring two or three injections 
per week.68 The difference of administration frequencies is due to the relatively shorter 
circulating half-time in plasma.74,75 In the US, epoetin alfa is the most frequently used ESAs.76 
Frequent monitoring, at least monthly, is recommended for patients who are receiving an 
ESA. Hemoglobin monitoring is performed prior to a mid-week HD session, aiming to minimize 
hemoglobin variability due to the longer inter-dialytic interval between the last treatment of one 
week and the first of the next. Hemoglobin testing should also be performed whenever clinically 
indicated, such as after a major surgical procedure, hospitalization, or bleeding episode.13 
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Efficacy and benefits of ESAs 
Data consistently demonstrated the ability of ESAs to raise the hemoglobin level in 
patients on HD. Ever since ESAs became the standard of care for anemia management in patients 
with advanced CKD, mean levels of hemoglobin and hematocrit (Hct) rose consistently.77 As of 
2006, the mean hemoglobin level was 12.0 g/dL while two thirds of them have a level between 
11.0-13.0 g/dL.72,78 The need for regular transfusions dropped by about 50% between 1999-2000 
and remained low since then, resulting in great reduction in complications including iron 
overload.30 Thanks to the ESA therapy, severe anemia is no longer a major cause of morbidity in 
HD patients. Improvements have been shown on the CV and hemodynamic abnormalities79,80 and 
non-hematologic symptomatic conditions81,82 with partial correction of severe anemia. Epoetin 
alfa and darbepoetin alfa are similarly effective in achieving and maintaining target hemoglobin 
levels; the main difference is that darbepoetin alfa is relatively long-acting.83-85  
Side effects of ESAs 
Since the introduction of ESAs, clinical practice guidelines for managing anemia in HD 
patients changed from transfusions to normalizing hemoglobin using ESAs. Despite the 
alleviation of anemia, emerging data suggested that ESAs are associated with increased mortality 
and morbidity starting 2003. Consequently, the FDA responded with package insert changes and 
a “black box” warning. Over the same period, Medicare underwent multiple changes to its 
reimbursement policy for ESAs, and anemia management guidelines were revised.    
Epidemiologic studies based upon data from the USRDS or Health Care Financing 
Administration (HCFA) database suggested that hemoglobin levels between 11-13 g/dL are 
associated with better outcomes compared to lower values.86-98 However, results from multiple 
RCTs, meta-analyses, and systematic reviews suggested that full correction of anemia with 
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hemoglobin approaching the normal range does not result in significant clinical benefit but is 
rather associated with elevated risk of adverse outcomes, compared with partial correction.99-104  
The pivotal RCTs (Table 2.2) raised concerns about ESAs, such as increased risks of 
arterial thrombotic events including stroke, venous thromboembolism, and exacerbation of 
cancer.7-9,55 The majority of meta-analyses performed showed similar results. In one recent meta-
analyses with 27 trials,104 compared with lower targets or placebo, higher hemoglobin targets 
were associated with an elevated risk for hypertension (risk ratio (RR) 1.67, 95% confidence 
interval (Cl), 1.31-2.12), stroke (RR 1.51, 1.03-2.21), and vascular thrombosis (RR 1.33, 1.16-
1.53). Although not statistically significant, higher risks were observed for mortality (RR 1.09, 
0.99-1.20) and serious CV events (RR 1.15, 0.98-1.33). The underlying mechanisms of these 
adverse effects are still unclear, which could be a direct effect of the higher hemoglobin level 
mediated by hemodynamic or rheological effects or indirect effects due to higher ESA doses.   
Examination of the effects of ESAs on quality of life returned inconsistent results. Some 
studies showed improvements,55,105-107 while others showed either no difference or not sustained 
effects.7-9 As evidence accumulates, they attracted the attention of the Congress, the FDA, the 
CMS, and the National Kidney Foundation (NKF) (Figure 2.2). The FDA responded by issuing a 
“black box” warning for ESAs that first recommended the minimum dose required to avoid the 
need for transfusion, and later changed to recommending a hemoglobin target of 10-12 g/dL.56,57 
The CMS responded by changing ESA reimbursement policy multiple times to a bundled 
composite pay rate system that includes services provided for dialysis including ESAs, iron, 
antibiotics, and laboratory tests related to the treatment of ESRD.10 The NKF followed with 
revisions to their KDOQI anemia guidelines in 2007 to recommend a target hemoglobin of 11-12 
g/dL in ESA-treated patients and to avoid hemoglobin >13 g/dL.109 
 Table 2.2. Large randomized studies of ESA in CKD patients with anemia 
Note: CKD=Chronic kidney disease, Hb= hemoglobin, Hct=Hematocrit, CV=Cardiovascular. Adapted from National Kidney Foundation’s Primer 
on Kidney Diseases34, and publication of these studies7-9 
Overall, evidence suggest that ESAs may increase risks of morbidity and mortality although they are effective at raising 
hemoglobin levels. The use of ESAs has gradually decreased, accompanying with gradually fallen target hemoglobin level for patients 
receiving ESAs and the lowest hemoglobin level for ESA initiation.110 Between 2009 and 2011, the mean hemoglobin level fell to 
10.96 g/dL, ESA doses dropped by 19.2%, while the use of IV iron has increased by 3.4% in the US. A slight increase in use of 
transfusions was noted.111,112    
  NHS CHOIR CREATE TREAT 
Year Published 1998 2006 2006 2009 
Location US,  
51 sites 
US,  
130 sites 
Europe,  
22 nations 94 sites 
International,  
24 nations 623 sites 
ESA Epoetin alfa Epoetin alfa Epoetin beta Darbepoetin alfa 
CKD Stage and 
Comorbidity 
Hd with cardiac disease Nondialysis Nondialysis Nondialysis with type 2 diabetes 
Sample Size 1,233 1,432 603 4,038 
Duration (year) 3+ (planned) Max 3  Max 4.25; Mean 3  Max 4; mean 2.42 
High Hb Target (g/dL) 14 (Hct 42) 13.5 13 to 15 13 
Low Hb Target (g/dL) 10 (Hct 30) 11.3 10.5 to 11.5 9 
CV Endpoints RR 1.3 (0.9 to 1.9) High in high Hb group No difference No difference except higher stroke 
in high Hb group 
Progression of CKD Not applicable No difference More in high Hb group No difference 
Cancer Deaths Not noted Not noted Not noted Higher in high Hb group among 
patients with previous cancer 
Quality of Life Better physical function 
in high Hb group 
No difference Better in high Hb group 
in the first year 
No difference except less fatigue in 
high Hb group 
2
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Figure 2.2. A timeline of the major events related to ESAs in the US that occurred between 1998 and 2012  
Regulatory actions and reimbursement changes are presented above the time line, and pivotal publications and clinical 
practice guidelines for anemia management in ESRD patients are presented below the time line. The adapted background 
graphs represent Amgen’s sales of Epogen® and Aranesp® from 1989 to 2010.108 Complete sales data for Procrit® were not 
available.  
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2.3.3.  IV Iron Use in HD Patients1 
A primary cause of anemia in ESRD is iron deficiency, particularly among patients 
requiring hemodialysis (HD).  Iron deficiency can be classified into absolute iron deficiency and 
functional iron deficiency, each with multifactorial causes.3  Absolute iron deficiency, or 
depleted iron stores, is frequently a result of blood loss, reduced intake, and impaired intestinal 
absorption of dietary iron.3  Functional iron deficiency, or insufficient iron availability at the site 
of erythropoiesis despite adequate iron stores, can be caused by chronic inflammation associated 
with ESRD or elevated hepcidin levels.3  Overall, HD patients lose an average of 1-2 g of iron 
per year, and some as much as 4-5 g per year.4  Management of iron deficiency to meet the need 
for erythropoiesis is thus essential for optimal management of anemia in ESRD patients.  
Intravenous (IV) iron is an effective way to supplement iron and optimize erythropoiesis.  
Existing randomized controlled trials (RCTs) showed that supplementing erythropoiesis-
stimulating agent (ESA) therapy with IV iron increases hemoglobin production and lowers ESA 
requirement.5-10  Consequently, co-administration of ESAs and IV iron has become the primary 
management strategy for anemia in HD patients.4  Subsequent to emerging evidence on the 
cardiovascular (CV) safety of ESAs7-9 and changes in the reimbursement policies in Medicare’s 
ESRD programs,10 hemoglobin targets have decreased, allowing providers to reduce ESA 
dosing, decreasing potential risks associated with ESAs.11-12  However, despite steadily falling 
hemoglobin levels, doses of IV iron rose from 210 mg per month in 2009-2010 to 280 mg per 
month in 2011, then back to a stable 200 mg per month in 2012-2013.17,18  Consequently, ferritin 
levels in dialysis patients have generally been elevated, with many greater than 800 ng/mL.17  
The persistently high levels of ferritin raised concerns about appropriate use of iron. 
                                                             
1 This section was submitted to Hemodialysis International.  
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Despite its established effectiveness, there have been concerns about safety of IV iron 
supplementation. Unlike oral iron supplements, IV iron bypasses various homeostatic 
mechanisms that keep iron tightly regulated.  Due to the association between labile iron and both 
induced oxidative stress and bacterial growth, elevated risks of CV events114-116 and infection117 
have been a concern related to IV iron use in HD patients.  Hypersensitivity reactions have also 
been linked to the use of some iron formulations.113  Unfortunately, the existing RCTs of IV iron 
are small and short-duration and therefore do not provide evidence on safety and long-term 
effects. Recent observational studies, primarily relying on cumulative iron exposure rather than 
clinical dosing patterns, have showed differing results.   
Five forms of IV iron preparations have been approved for use in the United States 
(Table 2.3).  These iron products are formulated with an iron oxyhydroxide core surrounded by a 
carbohydrate shell.118  The sizes of the core and its surrounding carbohydrate shell differ among 
iron formulations, leading to different amount of labile iron being released.  In contemporary 
clinical practice, IV iron is either provided intermittently via large doses over consecutive 
dialysis sessions (often termed “bolus dosing”) or via small doses provided every one to two 
weeks to maintain iron stores (often termed “maintenance dosing”). Decisions regarding when to 
use each dosing approach typically follow protocols established by dialysis clinics. These 
protocols provide treatment recommendations based on target levels of hemoglobin and observed 
iron status parameters - ferritin and transferrin saturation (TSAT).13,15 A variety of dosing 
protocols exist in clinical practice, and they differ with respect to target levels of iron status 
parameters and dosing approach recommendations.19,20 Optimal management strategies to 
administer IV iron have not been identified.  
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IV Iron and Hypersensitivity Reactions 
Hypersensitivity reactions have been a concerning complication of IV iron 
administration.  First, and foremost, an anaphylactic reaction can be life-threatening if not 
addressed with urgency. Second, the immediacy of the reaction that is experienced by the patient 
receiving the agent is traumatic for both patients and staff.  However, it appears that the absolute 
incidence of adverse hypersensitivity reactions is low, especially with the use of newer agents.  
Mechanism of Harm 
All IV iron preparations can lead to hypersensitivity reactions, including anaphylaxis.  
Historically, occurrences of anaphylaxis were observed with high-molecular-weight iron 
dextran,120 raising concerns regarding the safety of IV iron treatment.  This product was in turn 
replaced by low-molecular-weight iron dextran and other non-dextran products and is no longer 
commercially available.  Overall, anaphylactic reactions are rare in IV iron formulations other 
than high-molecular-weight iron dextran.  Using data from the US FDA MedWatch programme 
(2001-2003), Chertow et al examined the frequency of adverse drug events related to the four 
older preparations.  Compared to high-molecular-weight iron dextran, the rate of severe adverse 
reactions was much lower in low-molecular-weight iron dextran (3.3 versus 11.3 per million 
patients), or other non-dextran products (ferric gluconate: 0.9 per million patients; iron sucrose: 
0.6 per million patients).4  These rates were remarkably lower than those observed after their first 
release. 
The mechanism of anaphylaxis associated with IV iron administration remains unknown. 
Immunological IgE- and IgG-mediated responses associated with the dextran component may 
explain the relative higher occurrence of anaphylactic reactions associated with high-molecule-
weight iron dextran compared to other non-dextran preparations.4,121 Among the other 
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preparations, the activation of the complement system triggered by iron nanoparticles is likely to 
be involved.121 As a consequence of complement activation, activation of mast cells and 
basophils increases, resulting in secretion products that potentially lead to hypersensitivity 
reactions. 
Although the precise mechanism of hypersensitivity reactions to IV iron is unknown, the 
potential risk factors include asthma, mastocytosis, atopic status, and concurrent medications 
including beta blockers and angiotension-converting enzyme inhibitors.4  Given the inability to 
predict hypersensitivity in patients using a serological evaluation, careful monitoring is needed 
when administering any IV iron product.      
Epidemiologic Evidence 
Due to the rarity of occurrence, evaluation of the hypersensitivity risk associated with 
iron formulations is challenging in RCTs and prospective observational studies; impractically 
large sample size would be needed to reach adequate statistical power.  It is even more 
challenging to compare the risks among different iron formulations using these designs.  
Consequently, existing evidence base on IV iron and hypersensitivity reactions largely 
comprised of data from spontaneous reporting.122-126  Excluding high-molecular-weight iron 
dextran, the highest risk of anaphylaxis was observed in iron dextran, and no significant 
difference in risk was observed among other iron formulations including ferric gluconate, iron 
sucrose, and ferumoxytol.  However, caution needs to be exercised when interpreting these 
results because data from voluntary reporting is prone to reporting bias.127  Substantial under- or 
over-reporting and lack of verification makes them unfit for accurate estimation of incidence for 
a given adverse event. 
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Large observational studies can be used to examine the risk of such rare events.  In a 
large cohort of 688,183 Medicare beneficiaries from 2003-2010, Wang et al reported higher 
incidence rate of anaphylaxis associated with incident exposure to iron dextran compared to 
other iron products combined (68 versus 24 per 0.1 million patients).128  Following total iron 
repletion of 1 g administered within a 12-week period, the cumulative anaphylaxis risk was 
highest with iron dextran (82 per 0.1 million patients) and lowest with iron sucrose (21 per 0.1 
million patients). 
Despite the rarity of hypersensitivity events, physicians are required to inform patients 
about these risks before treatment,129 and management tips have been provided for these adverse 
reactions.4  A test dose is recommended for iron dextran.  For other non-dextran formations, 
administration with a relatively small dose and slower rate of infusion has been advised.130   
IV Iron and CV-related Risk 
Cardiovascular (CV) disease is the leading cause of death among HD patients.  There 
have been theoretical concerns that IV iron may increase the risk of CV-related outcomes 
through inducing increased oxidative stress.114-116  
Mechanism of Harm 
With IV administration, iron is directly released into plasma, resulting in transient 
concentrations of labile plasma iron and formation of highly reactive free radicals, damaging 
reactive oxygen species that attack membrane lipids and are associated with atherosclerosis.131  
Excess free radicals could change the redox balance state to increase oxidative stress or at least 
exacerbate the level of oxidative stress present in HD patients.131  Iron has been identified in 
atherosclerotic plaques, suggesting that IV iron may increase atherogenesis leading to CV deaths 
in HD patients.132  Cell culture models and animal models have shown IV iron formulations 
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induce oxidative stress and tissue inflammation.133-135  However, no definite link has been 
established between iron treatment, oxidative stress, and CV risk.  
Hepcidin, the important regulatory protein for iron, has also been hypothesized to 
mediate the effect of iron on CV-related risk by promoting iron accumulation in macrophages 
and subsequently atherosclerosis.136  However, animal studies have shown conflicting results 
regarding the association of hepcidin level and the atherosclerosis process.137-139  Recent clinical 
studies in HD patients found positive association between increased level of hepcidin and arterial 
stiffness140 and risk of CV events.141 
Epidemiologic Evidence 
Evidence from epidemiologic studies on IV iron and CV-related risk is inconclusive 
although early clinical studies indicated iron use with elevated risks of CV diseases139 and 
mortality142 in HD patients.  Susantitaphong et al reviewed and meta-analyzed 24 single-armed 
studies and 10 parallel-arm RCTs and found no association between high IV iron doses and CV 
mortality (Table 2.4).143  The completed studies were largely underpowered and generally 
evaluated outcomes that were not hard clinical end-points.  They also had relatively short 
duration for follow-up.  
A limited number of observational studies have evaluated the effect of IV iron on CV-
related events and mortality in HD patients (Table 2.4), and the results are inconsistent.  Iron 
doses greater than 400 mg/month144 and 300 mg/month145 were associated with higher CV 
mortality risk in two large cohort studies.  Higher cumulative iron doses were also linked with 
higher CV events in a Japanese prospective cohort study, which examined a product not 
currently used in the United States.146  Conversely, two recent retrospective studies of HD 
patients showed no association between large doses and short-term CV morbidity and 
28 
 
mortality.20,23  Similarly, no clear association has been established between IV iron and all-cause 
mortality.  Higher doses were associated with increased risk of death in some studies,144-146 but 
no association was found in others,145,146 with a few demonstrated reduced risks at certain levels 
of dosing.20,144,147  The conflicting data is partly due to the difficulty to separate the effect of iron 
overload from systemic inflammation on CV-related outcomes because serum ferritin level can 
be a marker for both conditions.  Residual confounding by indication is likely another factor 
contributing to the inconsistency, as patients receiving larger amounts of iron may be at higher 
underlying CV risk. 
Overall, despite theoretical concerns, it is unclear whether IV iron administration 
exacerbates atherosclerosis and leads to increased risk of CV diseases, the leading cause of death 
in the ESRD patients. Further research is needed to evaluate hard clinical end pints, including 
myocardial infarction, stroke, and mortality.  The potential mediating role of level of hepcidin 
and ferritin needs more thorough examination.  
IV Iron and Infection Risk 
Patients on HD frequently experience infectious complications leading to hospitalization 
and death.  There are concerns that IV iron may increase infection risk because of its effect on 
bacterial growth, host immunity, and clinical infection risk.  
Mechanism of Harm 
Iron is essential for bacterial growth.  In iron-rich environment, bacteria can acquire iron 
from the blood stream by producing iron chelating siderophores or obtain iron from transferrin 
directly via transferrin receptor and use it to grow.  Iron is also essential for proper host defense 
against infection.  Iron overload has been linked with impaired neutrophil and T-cell functions, 
and subsequent immune dysfunction and increased Gram-positive bacteria growth in vitro.148-150 
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Epidemiological Evidence 
As with CV risk, the few RCTs of IV iron were not large enough to evaluate infection 
risk.  The Dialysis Patients’ Response to Intravenous Iron with Elevated Ferritin (DRIVE) study 
randomized HD patients with TSAT ≤25% and ferritin 1,124-2,696 pmol/mL receiving high 
doses of epoetin alfa (>30,000 U per week) to ferric gluconate or no iron.  In these patients, 1 g 
of IV iron did not increase the risk of infection and actually reduced number of serious adverse 
events compared with patients who received no iron over the 3-month period.6  Another placebo-
controlled trial in patients with heart failure (but not on dialysis) found no elevated risks of 
infection, hospitalization or mortality in patients who received IV iron therapy.151 
Compared to oral iron supplements, IV iron showed increased risk of infection and CV 
events in a recent trial in non-dialysis patients with chronic kidney disease that had to be 
terminated early.152  The results were considerably different from that of the Ferinject® 
assessment in patients with Iron deficiency anaemia and Non-Dialysis-dependent Chronic 
Kidney Disease (FIND-CKD) study that found no difference in infection risk across all three 
arms.153  The discrepancy in the results may be partially caused by the single-center setting and 
greater loss to follow-up in the first study.  
Several systematic reviews and meta-analyses performed to date are inconclusive.  Early 
reviews published in 1999 found no evidence of an effect of iron and infection.154-156  As more 
data accumulated, an updated review conducted by Ishida and Johansen suggested a potential 
link between iron and elevated infection risk.157  Out of the 24 studies (published in and prior to 
2013) included in the review, 12 studies showed an association of usage, dose-dependent risk or 
frequency-dependent risk between iron and infection or infection-related mortality, whereas the 
rest showed no association.  Most of the 24 studies had small sample size and short follow-up 
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duration.  Many studies did not take into account of iron status parameters such as serum TSAT 
and ferritin levels, offering little information about the comparability of the patient groups across 
study groups.  More than half of the studies (15/24) were carried out in other countries or in 
older cohorts in the United States, limiting generalizability of these results.  
Two recent meta-analyses of RCTs also reported conflicting results.  With both HD 
patients and non-HD patients with CKD, Litton et al showed increased risk of infection 
comparing IV iron with either oral iron or no iron supplementation.158  The other meta-analysis 
evaluated the safety of IV iron in HD patients with functional iron deficiency reported no 
association of iron use with infection risk, but only two studies were included in the analyses for 
this outcome.143   
Cumulative Iron Exposure and Infection Risk 
To date, a number of observational studies examined the effect of IV iron administration 
and risk of infection; most of them focused on cumulative iron exposures over a long period.  
Current data, however, give mixed signals.  In the last five years, several observational studies 
with large population of HD patients have been published (Table 2.5). In a cohort of 14,078 
dialysis patients in the United States, Miskulin et al examined the accumulated IV iron dose over 
1-, 3-, and 6-month rolling windows and found large associations between cumulative dose and 
infection-related outcomes, but these associations were very imprecise and included the null 
effect in all case.20 Another study with 32,435 HD patients from 12 countries also reported non-
statistically significant difference across dosage groups.  However, infection-related mortality 
was elevated among patients receiving higher doses of IV iron over 4 months compared to 100-
199 mg/month.145  In another cohort of 9,544 incident HD patients, higher cumulative IV iron 
doses were not associated with infection-related hospitalizations.27  Inadequate statistical power 
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due to small sample sizes might have contributed to the inability to detect the difference in some 
of these studies.  
To identify patient subgroups at higher risk, the effect of IV iron on risk of infection has 
also been evaluated in several studies.  Catheters were found to be the leading risk factor of 
bacteremia in chronic HD patients.159  Higher iron dose was also associated in patients with 
catheter-related sepsis than in patient without.25  In recent work by our group comparing bolus 
dosing with maintenance dosing strategy in a large cohort of HD patients, highest risk of 
infection-related hospitalization was observed among patients with a catheter or history of recent 
infection.25   
Safety of Iron Protocols: Towards More Clinically-relevant Effects 
Much of the existing research on iron has studied long-term cumulative exposure or 
shorter-term dose effects – exposures that do not align with treatment decisions made by 
clinicians.  In contemporary clinical practice, IV iron is administered according to protocols, 
which recommend courses of treatment aimed at achieving target levels of hemoglobin and iron 
status parameters (ferritin and TSAT).  Following availability of levels of these parameters, 
physicians make decisions about the iron administration approach (e.g., bolus dosing or 
maintenance dosing) for the next treatment course.  A variety of dosing protocols exist in clinical 
practice, and they differ with respect to target levels of iron status parameters and administration 
approach recommendations.19-21  
Little evidence is available regarding the long-term safety and effectiveness of these 
dosing protocols in the literature.  Clinical trials assessing the use of IV iron dosing protocols are 
lacking; existing large observational studies have focused on the effect of cumulative iron 
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exposure over a long period, which do not align with the treatment decisions that physicians need 
to make regarding iron use.28  
Existing studies have compared the safety of exposure to different administration 
approaches. Several studies consistently demonstrated short-term benefits of bolus iron 
administration on hemoglobin levels and iron status compared to more conservative maintenance 
dosing22 or no iron.6  No difference in CV risks was associated with either administration 
approach.23,24  Elevated risk of infection was associated with bolus dosing approach. In a large 
cohort of 117,050 HD patients in the United States, our group compared bolus iron 
administration with maintenance dosing and found increased short-term risks of infection-related 
hospitalization or mortality (hazard ratio and 95% confidence interval: 1.08, 1.05-1.11).25  In 
another study of 12,969 HD patients in the United States, Michels et al reported lower mortality 
risk associated with maintenance dosing strategies compared with non-maintenance strategies.26  
It is worth noting that different definitions were used for administration strategies across these 
studies. 
Altogether, the evidence concerning IV iron dosing protocols is inconclusive.  The 
examination of cumulative exposures over a long time period offered little clinically meaningful 
information to physicians with regard to treatment decisions, which concern more about the 
dosage, frequency, and timing of IV iron.  Evaluation of different dosing protocols are needed to 
identify optimal strategies for iron treatment in HD patients. 
Summary 
Data have consistently demonstrated the effectiveness of IV iron treatment in 
management of anemia in the ESRD patients on HD. However, there remains considerable 
uncertainty about the best strategy for IV iron treatment of anemia management iron in ESRD 
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patients.  In particular, the dosage, frequency, and timing of IV iron use in HD patients are 
unknown. Given the increasing utilization of IV iron and data suggesting risk for some dosing 
practices in some patients, further research is needed to identify optimal dosing strategies that 
maximize the benefits of IV iron, while avoiding its potential risks.    
 Table 2.3. IV iron preparations available in the United States 
  
Generic Name 
Brand Name 
(Manufacturer) 
Approva
l Year 
Test Dose 
Needed  
Labeled Dosage for 
Iron Deficiency IV administration time Notes 
High-molecule-
weight iron 
dextran 
DexFerrum 
(American 
Regent) 
1954 Yes 1000 mg in 10 divided 
doses or total dose as 
a single IV infusion 
Undiluted at an infusion rate 
not to exceed 50 mg 
(1mL)/min 
Anaphylactic-type reactions and 
fatalities reported; resuscitation 
equipment and trained personnel 
necessary 
Low-molecule-
weight iron 
dextran 
InFed (Watson) 1992 Yes 1000 mg in 10 divided 
doses or total dose as 
a single IV infusion 
Undiluted at an infusion rate 
not to exceed 50 mg 
(1mL)/min 
Anaphylactic-type reactions and 
fatalities reported; resuscitation 
equipment and trained personnel 
necessary 
Ferric gluconate Ferrlecit             
(Sanofi-Aventis); 
Nulecit (Watson) 
1999 No 1000 mg in 8 divided 
doses (HD only) 
60 minutes diluted in saline; 
undiluted IV push at 12.5 
mg/min 
Reactions to benzyl alcohol ingredient 
Iron sucrose Venofer        
(American 
Regent) 
2000 No 1000 mg in 10 divided 
doses (HD); 1000 mg 
in 5 divided doses 
(NDD); 1000 mg in 2 
doses of 300 mg and 1 
dose of 400 mg (PD) 
2-5 minutes undiluted or 15 
minutes if diluted in saline 
(HD, NDD); 300 mg infused 
over 1.5 hours, 400 mg over 
2.5 hours 14 days later, 400 
mg infused over 2.5 hours 14 
days later (PD) 
7-day stability;                
anaphylactoid reactions 
Ferumoxytol Feraheme 
(AMAG) 
2009 No 510 mg × 2 doses 
separated  
by 3 or 8 days 
IV infusion diluted in saline 
or Dextrose Injection over 
15+ minutes 
MRI interaction for up to 3 mo; 
resuscitation equipment and trained 
personnel necessary. Anaphylactic-
type reactions presenting with 
cardiac/cardiorespiratory arrest, 
clinically significant hypotension, 
syncope, and unresponsiveness  
Ferric 
carboxymaltose  
Injectafer    
(American 
Reagent) 
2013 No 750 mg × 2 doses 
separated  
by at least 7 days 
(weighing ≥110 lb); 
15 mg/kg body weight 
separated by at least 7 
days (weighing <110 
lb) 
Undiluted IV push at 100 
(2mL) per minute, or diluted 
infusion over at least 15 
minutes 
Anaphylactic-type reactions 
presenting with shock, clinically 
significant hypotension, loss of 
consciousness, and/or collapse 
Note: IV= intravenous; HD=hemodialysis; NDD=Non-hemodialysis dependent; PD=peritoneal dialysis 
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 Table 2.4. Characteristics of epidemiological studies on IV iron and CV-related events among HD patients 
First Author 
Study 
Year Country Databases N 
Iron 
formulation Exposures Follow-up HR  (95% CI) CV riske 
Kalantar-Zedeh 
2005144  
2001-2003 US USRDS and 
DaVita 
58,058 ferric gluconate, 
iron sucrose, 
iron dextran 
<400  vs 0 mg/month 2 years 200-399: btw 0.5-0.6e – 
≥400 vs 0 mg/month       ≥400: btw 1.1-1.3 + 
Kuo  
2014146 
2004-2005 Taiwan Prospective study 
at Excelsior 
Renal Service Co 
1,239 ferric chloride 
hexahydrate 
40-800 vs 0 mg/6 months 12 months 1.7 (1.0-2.7) + 
840-1600 vs 0 mg/6 months                         3.5 (1.9-6.1) + 
1640-2400 vs 0 mg/6 
months 
5.1 (3.0-9.7) + 
Kshirsagar 
201323 
2004-2008 US USRDS and 
DaVita 
117,050 ferric gluconate, 
iron sucrose, 
iron dextran 
 bolus vs maintenance a  3 months 1.03 (0.99-1.07) * 
high vs low (> 200 vs ≤ 200 
mg/1 month) 
0.99 (0.96-1.03) * 
Miskulin 
201420 
2003-2008 US USRDS and 
Dialysis Clinic 
Inc 
14,078 all 
formulationsb 
      vs >0-150/1 month 
vs >0-450/3 months 
vs >0-900/6 months 
up to 4 years >350: 0.95 (0.70-1.29) 
>1050: 1.02 (0.74-1.41) 
>2100: 1.17 (0.76-1.79) 
* 
Susantitaphong 
2014143 
through 
Dec 2012 
multi-
country 
24 single-arm 
studies and 10 
parallel-arm 
RCTs 
2,658 Multiple 
formulationsc  
NA NA NA * 
Bailie           
2015145 
2002-2011 12 
countries 
DOPPS 32,435 Multiple 
formulationsd 
average dose over 4 months 
(mg/month): 0, 1-99, 100-
199 (reference), 200-299, 
300-399, 400+ 
Median (IQR): 
1.7 (1.0-2.4) 
years 
increased risks with 
≥300;                                                           
≥6 vs 1-2 mg/kg per 
month: 1.35 (1.12-1.62) 
+ 
Note: IV=intravenous; CV=cardiovascular; HD=hemodialysis; US=the United States; USRDS=the United States Renal Data System; IQR=interquartile range; CI=confidence interval; 
HR=hazard ratio; DOPPS=the Dialysis Outcomes and Practice Patterns Study 
aBolus dosing: consecutive doses ≥ 100 mg exceeding 600 mg during one month; maintenance: all other iron doses during the month;  
bNo further explanation provided in the article; 
cIron sucrose, ferric gluconate, iron dextran, iron saccharate, iron polymaltose,  iron oxide, ferrous colloid, ferumoxytol;  
dIron sucrose, ferric gluconate, iron dextran, iron saccharate, iron polymaltose, chondroitin sulfate iron complex, cideferron; 
eObtained from a figure in the article, the exact estimates were not available; 
fSymbol representation: + = increased risk; – = decreased risk; * = no difference 
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 Table 2.5. Characteristics of recent epidemiological studies on IV iron and infection among HD patients (2013-2016) 
Author/Year Study Year Country Databases N Population Exposures HR  (95% CI) 
Infection 
riskd 
Brookhart 
201325 
2004-2008 US USRDS and 
DaVita 
117,050 HD patients bolus vs maintenancea;     
high vs low (> 200 vs ≤ 
200 mg/1 month) 
1.08 (1.05–1.11) 
  1.05 (1.02–1.08) 
+ 
Miskulin         
201420 
2003-2008 US USRDS and 
Dialysis Clinic Inc. 
14,078 HD patients      vs >0-150/1 month 
vs >0-450/3 months 
vs >0-900/6 months 
>350: 1.26 (0.75-2.12) 
>1050: 1.69 (0.87-3.28) 
>2100: 1.59 (0.73-3.46) 
* 
Kuragano       
2014161 
2007-2009 Japan multicenter-
prospective 
1,086 HD patients cumulative weekly dose 
(vs no iron) 
  High: 5.22 (2.25–12.14); 
low: 1.78 (1.04–3.05) 
+ 
Zitt                
2014162 
2000-2007 Austria prospective 235 incident HD 
patients 
yes vs no 0.31 (0.09-1.04)b – 
Bailie            
2015145 
2002-2011 12 
countries 
DOPPS 32,435 HD patients average dose over 4 
months (mg/month): 0, 
1-99, 100-199 
(reference), 200-299, 
300-399, 400+ 
≥300: between 0.9-1.4c * 
Tangri            
201527 
2003-2008 US USRDS and 
Dialysis Clinic Inc. 
9,544 incident HD 
patients 
     vs >0-150/1 month 
vs >0-450/3 months 
vs >0-900/6 months 
>350: 0.91 (0.77-1.09) 
>1050: 1.08 (0.86-1.36) 
>2100: 1.26 (0.94-1.69) 
* 
 Note: IV=intravenous; HD=hemodialysis; US=the United States; USRDS=the United States Renal Data System; HR=hazard ratio; CI=confidence interval; DOPPS=the Dialysis  
Outcomes and Practice Patterns Study  
aBolus dosing: consecutive doses ≥ 100 mg exceeding 600 mg during one month; maintenance: all other iron doses during the month; 
bOutcome includes CV-related or sepsis-related mortality; 
cObtained from a figure in the article, the exact estimates were not available; 
dSymbol representation: + = increased risk; – = decreased risk; * = no difference 
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2.4. Comparing IV Iron Dosing Protocols 
IV iron dosing protocols are a type of dynamic treatment regimes. These protocols 
provide treatment recommendations based on patients’ evolving clinical history aimed at 
achieving target levels of hemoglobin and iron status parameters. To identify the best IV iron 
dosing protocols among a set of protocols in routine use, we need methods appropriate for 
estimating effect of dynamic treatment regimes.   
2.4.1. IV Iron Dosing Protocols as Dynamic Treatment Regimes 
Dynamic treatment regimes refer to treatment strategies involving decision rules to make 
treatment recommendations based on evolving clinical history.163  For patients with ESRD 
maintained on chronic HD, IV iron dosing protocols for anemia management are a type of 
dynamic treatment regimes. Patients receiving IV iron have laboratory tests evaluated on a 
regular basis to inform treatment titration. The current levels of hemoglobin and iron status 
parameters—TSAT and ferritin—inform the dosage level and frequency of IV iron 
administration for the next treatment course.13,15,109 Other examples of dynamic regimes include 
treatment of HIV/AIDs,164-166 management of type 2 diabetes,167 and cholesterol control.168  
Increasingly, clinical guidelines present recommendations in this dynamic format.164-168  
With a dynamic IV iron dosing protocol, levels of time-varying iron status parameters 
(𝑳𝑚) determine which dosing approach (𝐴𝑚) to use for the next treatment course; these levels 
are also affected by treatment (𝐴𝑚−1) in the previous course and associated with future survival 
(𝑌𝑚+1) (Figure 2.3). In this situation, current iron status tests are not only confounders for dosing 
approach and survival but also mediators for effect of previous treatment on survival. Thus, 
traditional regression-based statistical methods are not appropriate for evaluation of IV dosing 
protocols.   
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Figure 2.3. A schematic for an observational study involving dynamic treatment regimes  
The schematic represents a screenshot of two observational intervals during the follow-up: 
𝐴𝑚=treatment, 𝑳𝑚=time-dependent covariates, 𝑡𝑚=time of visit, 𝑌𝑚+1=outcome.  
2.4.2. Causal Inference with Dynamic Treatment Regimes 
Currently, a limited number of methods are available to directly estimate the effect of 
dynamic treatment regimes in observational studies. One approach is inverse probability 
weighted (IPW) estimation of Cox marginal structural models (MSMs). It was introduced by 
Robins to adjust for measured time-varying confounding and selection bias in observational 
studies.169-172 Hernán et al employed this method in comparison of two dynamic treatment 
regimes for the initiation of highly active antiretroviral therapy in HIV-infected patients.173 They 
described it as an approach to emulate RCTs with two dynamic treatment regimes using 
observational data. Using this approach, observation for subjects during follow-up are 
retrospectively examined to see if individual treatment was consistent with a particular regime of 
interest and are artificially censored at the first occurrence of a treatment that is not consistent 
with the regime initiated at baseline. Analyses are then carried out in uncensored individuals 
under regimes of interest by fitting an IPW Cox model with weights to adjust for potential 
selection bias introduced by this artificial informative censoring. The estimated effect from 
comparing two dynamic regimes can be interpreted as the difference in the outcome of interest if 
all the subjects always adhered to regime 1 versus regime 2.   
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Further studies generalized this method to compare multiple treatment regimes 
simultaneously.174-177 Orellana et al176 and Cain et al177,178 created an artificial data set in which 
each subject contributes observations for each regime they followed. Cotton and Heagerty 
proposed a data augmentation estimation approach179 and a weighted log-rank method180 to test 
for differences in survival among multiple dynamic regimes. Shortreed and Moodie used 
bootstrap method for inference.181 Under appropriate assumptions, IPW can appropriately adjust 
for measured time-varying confounding and selection bias in observational studies as well as in 
RCTs with imperfect compliance and loss to follow-up.  
The parametric g-formula is an alternative to IPW of MSMs to adjust for time-varying 
confounding when comparing dynamic treatment regimes. It was first introduced by Robins182 to 
estimate the causal effect of arsenic on heart disease and has been applied to compare the 
effectiveness of dynamic regimes involving lifestyle interventions.183,184 Young et al used this 
approach to estimate all-cause mortality risks of several dynamic regimes for combined 
antiretroviral therapy initiation.185 A g-estimation approach modeling the effect of the time-
varying treatment was also considered to find the optimal regime.174  
Under appropriate assumptions, these estimation methods can all provide consistent 
estimates of the counterfactual population parameters of interest. The identifying assumptions 
are the same, but each approach requires parametric assumptions on different components of the 
observed data.185 The parametric g-formula estimator is based on parametric maximum 
likelihood estimation while the IPW estimator is a semi-parametric estimator. Thus, under 
correct parametric assumptions, the parametric g-formula and g-estimation produce more 
efficient estimators (with smaller variance) than the IPW estimators but require more parametric 
modelling assumptions.  The parametric g-formula and g-estimation estimators are generally 
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more stable than the IPW estimators in the presence of near violations of the positivity 
assumption. However, due to the reliance on parametric assumptions, parametric g-formula and 
g-estimation estimators are more vulnerable to bias when the assumptions are violated. Correct 
specification is needed for the conditional probability of the outcome, the treatment, and the 
time-varying covariates in all follow-up intervals. In contrast, the validity of the IPW estimators 
requires correct specification of the treatment, the censoring indicator, and the MSM for the 
relation between a regime and the outcome of interest had all subjects followed this regime for 
all follow-up intervals. Parametric g-formula estimators are also subject to the “g-null paradox”, 
which will reject the causal null even when it is true in sufficiently large samples because it is 
impossible to correctly specify parametric models under the causal null hypothesis.  
 For this thesis work, we used IPW estimation of Cox MSMs to compare the effect of 
different IV iron dosing protocols.   
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CHAPTER 3: ANALYTICAL APPROACH  
3.1. Overall Study Design and Methods 
This thesis used an observational retrospective cohort study to address the two aims. 
First, I identified frequently used IV iron dosing protocols for anemia management among end-
stage renal disease (ESRD) patients undergoing chronic hemodialysis (HD). I then compared the 
effect of commonly used dosing protocols on all-cause mortality and infection-related outcomes. 
As a type of dynamic treatment regimes, the effect of long-term exposure to IV iron dosing 
protocols were compared using an inverse probability weighted (IPW) Cox marginal structural 
model (MSM). Under a set of assumptions, the results from Aim 2 allow for a causal 
interpretation of effect measure estimates. Aim 1 & 2 also demonstrated how to identify and 
evaluate dynamic treatment regimes in research studies for ESRD patients.     
3.1.1. Study Population 
This study used a cohort constructed using data derived from the clinical research 
database of a large dialysis provider in the United States (US), linked with the United States 
Renal Data System (USRDS). With over 2,042 dialysis centers located throughout the country, 
this dialysis provider manages services to approximately one third of all Americans with ESRD 
receiving dialysis.186 
I used the clinical research database to assess clinical detailed information relevant to 
dialysis and anemia management for HD patients, including IV iron and ESA use at each dialysis 
session, clinical laboratory values, current vascular access, and recent IV antibiotics use. As 
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usual clinical practice, such information is detailed into a patient’s record in clinical database. 
Due to ethics of clinical practice and financial reasons that the dialysis facilities are reimbursed 
for drugs administrated, the dialysis clinics must maintain accurate drug records and subject 
them to institutional quality control systems. The quality of the data was not a major concern. A 
study examined the medication records documenting medications administrated at the clinic 
including IV iron and erythropoiesis-stimulating agents (ESAs) and showed high accuracy,187 
minimizing the potential for error in exposure measurement and clinical covariate assessment for 
this study.  
I used the USRDS to assess demographic characteristics, comorbidities, healthcare 
system encounters, and specific outcomes of interest including death. Funded by the National 
Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), the USRDS is a national data 
system that collects, analyzes and distributes information about the treatment of ESRD.188 The 
data system includes data from the Medicare Enrollment database, the Medical Evidence Report 
Form, the ESRD Death Notification Form, and the standard analytic files containing final action 
claims data.  Thus, the USRDS contains detailed data on all patients in the Medicare’s ESRD 
system, including information collected at dialysis initiation detailing the primary cause of 
ESRD, clinical data, and certain laboratory measurements. The USRDS also contains Medicare 
Parts A and B claims that include information on diagnoses and procedures recorded for all 
outpatient office visits and hospitalizations. The quality and validity of the USRDS data have 
been evaluated by studies conducted by the USRDS. An average concordance rate of 90.6% was 
found for fifty variables under examination when comparing a sample of the USRDS data with 
patients’ medical chart.189,190   
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3.1.2. Cohort Identification 
The study population consisted of ESRD patients who were at least 65 years old and 
receiving center-based, outpatient HD in the US between January 1, 2004 and September 16, 2012 
and who had Medicare as their primary insurer.  
Patients were included in the cohort if they met the following criteria:  
1) started HD between January 1, 2004 and September 16, 2012 (so they had at least 3 months 
of HD and two-weeks of chronic anemia management);  
2) continued HD for at least 3 months after the start of HD; 
3) at least 65 years of age at the start of HD (to receive regular Medicare coverage because 
most HD patients who are younger than 65 do not have complete Medicare data until 3 
months after the start of HD); 
4) had continuous Medicare Part A and B coverage during the 3-month baseline period; 
5) had at least one claim before the first service date and at least 60 days covered by claims 
during the first 90 days of dialysis; 
6) had at least 9 dialysis sessions in the last month of baseline period (suggesting the 
individual was receiving regular center-based HD). 
Patients were excluded if they met the following criteria: 
1) had polycystic kidney disease (since many of these patients do not require ESAs and 
therefore may have different IV iron requirements); 
2) had missing values on baseline covariates or IV iron exposure.   
Study period 
The study period was from January 1, 2004 through December 31, 2012.  
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Baseline period  
The baseline period was the time period starting on 90 days before dialysis initiation and 
ending on the first TSAT laboratory test date (index TSAT) (Figure 3.4 & Figure 3.5). 
3.1.3. Study Variables 
Exposure 
The exposure of interest was IV iron dosing protocols for anemia management in ESRD 
patients on HD. Details for exposure assessment are listed separately for each aim under the 
Statistical Analysis section. 
Outcomes 
The outcomes for Aim 2 were the risks of all-cause mortality and infection-related 
hospitalization or mortality if all patients were persistent to the index IV iron dosing protocols. 
These endpoints were examined separately.   
Infection-related hospitalization outcomes included hospitalization due to sepsis, vascular 
access, and pneumonia. They were identified using Medicare Part A inpatient claims and 
definitions consisted of International Classification of Disease, Ninth Revision (ICD-9-CM) 
diagnosis codes. Infection-related death all-cause mortality outcomes were identified using the 
ESRD Death Notification File of the Medicare’s ESRD program and the specific cause of death. 
The detailed definitions were listed in Table 3.6.  
Follow-up period 
The follow-up period in Aim 2 started at the end of the first two-week exposure window 
(index exposure window) following index TSAT. Patients were followed up until occurrence of 
an event of interest, receipt of kidney transplantation, the time of switching modality (from 
center-based HD to peritoneal dialysis or home HD), loss to follow-up, disenrollment from this 
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dialysis provider, loss of Medicare coverage, 120 days since start of follow-up or administrative 
end of follow-up (which was December 31, 2012).  
Table 3.6. Definitions for study outcomes 
3.1.4. Covariate Assessment  
I collected covariates deemed important to the specific aims of this thesis by existing 
literature and the clinical expertise of the research team. They included demographic and clinical 
characteristics of the patients and dialysis facility. I evaluated both baseline covariates and time-
varying covariates. Baseline covariates were evaluated in the baseline period prior to the index 
date for first iron dosing protocol. Time-varying covariates were evaluated at fixed intervals 
following the start of follow-up.  
The clinical database, the USRDS, and Medicare Part A and B files were used for covariate 
assessment. Comorbidities were assessed using definitions consisting of ICD-9-CM diagnosis 
codes. Table 3.7 lists the detailed definitions for each condition and the data source of assessment.    
Table 3.7. Definition for covariates 
Covariate Definition Data Source 
Demographic 
Age Continuous variable USRDS 
Sex Male or female USRDS 
Race White, Black, Other (as reported on the Medial 
Evidence Form (CMS-2728) 
USRDS 
Medicaid eligibility Indicator for dual eligibility during any part of the 
baseline  
USRDS 
Census region Based on location of last dialysis center in baseline 
period: Northeast, South, Midwest, West 
USRDS 
Year of treatment 2004, 2005, 2006, 2007, 2008 Clinical Database 
Outcomes Definition Data Source 
Infection outcomes 
Hospitalized for infection Any ICD-9-CM diagnostic codes of 996.62 (vascular 
access), 481.xx (pneumonia), 038.xx (sepsis) 
Medicare Part A 
Infection-related death Primary cause of death: 33, 34, 45-58, 51, 52, 61-63, 70 Death Notification File 
All-cause mortality 
All-cause death Death as indicated in CMS file Death Notification File 
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Covariate Definition Data Source 
Clinical 
Vintage Time since start of renal replacement therapy, 
categorized as 0; 1-3; 4 or more years  
USRDS 
Cause of ESRD Diabetes, Glomerulonephritis, hypertension, other USRDS 
BMI As reported in the clinical database or the Medical 
Evidence Form ( CMS-2728), categorized as 
underweight, normal, overweight, obese 
Clinical Database & 
USRDS 
Serum creatinine, mg/dL Most proximal prior to index TSAT date Clinical Database 
IV antibiotics use Use of IV antibiotics (listed under infection definition) Clinical Database 
Anemia Management  
Access Most recent vascular access (catheter vs fistula/graft) 
prior to TSAT index date 
 Clinical Database 
EPO dose (baseline) Total EPO dose in the last month of baseline Clinical Database 
EPO dose (exposure) Total EPO dose in the 2-week exposure window Clinical Database  
Index TSAT, % Last TSAT at baseline  Clinical Database  
Iron dose, mg Total dose at last month of baseline. Clinical Database  
Hemoglobin, g/dL Most proximal Hb lab prior to index TSAT date Clinical Database  
Ferritin, ng/mL Most proximal serum ferritin prior to index TSAT date  Clinical Database  
Serum albumin, g/dL Most proximal prior to index TSAT date Clinical Database  
Comorbidities 
Hospital days in last month 
of baseline 
Total hospital days, continuous variable  USRDS, Medicare Part 
A Claims 
Infection in last month Any hospital admission in the last month with one of 
the following  ICD-9-CM diagnostic codes as the 
principal diagnostic code: 001–139, 254.1, 320–326, 
331.81, 372–372.39, 373.0–373.2, 382–382.4, 383.0, 
386.33, 386.35, 388.60, 390–393, 421–421.1, 422.0, 
422.91–422.93, 460–466, 472–474.0, 475–476.1, 
478.21–478.24, 478.29, 480–490, 491.1, 494, 510–
511, 513.0, 518.6, 519.01, 522.5, 522.7, 527.3, 528.3, 
540–542, 566–567.9, 569.5, 572–572.1, 573.1–573.3, 
575–575.12, 590–590.9, 595–595.4, 597–597.89, 598, 
599.0, 601–601.9, 604–604.9, 607.1, 607.2, 608.0, 
608.4, 611.0, 614–616.1, 616.3–616.4, 616.8, 670, 
680–686.9, 706.0, 711–711.9, 730–730.3, 730.8–
730.9, 790.7–790.8, 996.60–996.69, 997.62, 998.5, and 
999.3.  
 
Any claims with the following HCPCS codes for 
antibiotic use in last month of baseline: J3370, J0690, 
J0713, J0692, J0696, J1580, J3260, J0278, J1840, 
J1956. 
 
Any indication of the use of the following drugs: 
Amikin® (amikacin sulfate); ampicillin; Ancef®, 
Kefzol® (cefazolin); aztreonam; Cefizox® 
(ceftizoxime); Cefotan® (cefotetan); Fortaz®, 
Tazicef® (ceftazidime); Claforan® (cefotaxime); 
clindamycin; Cubicin® (daptomycin); ethambutol; 
gentamicin; Keflin® (cephalothin); Levaquin® 
(levofloxacin); Mefoxin® (cefoxitin); Merrem® 
(meropenem); nafcillin; Nebcin® (tobramycin); 
oxacillin; Penicillin G; Zosyn® (piperacillin and 
tazobactam); Primaxin® (imipenem and cilastatin); 
USRDS, Medicare Part 
A Claims 
 
 
 
 
 
 
 
 
 
 
 
 
USRDS, Medicare Part 
A & B Claims 
 
 
Clinical Database  
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Covariate Definition Data Source 
Rocephin® (ceftriaxone); streptomycin; Timentin® 
(ticarcillin and clavulanate potassium); Unasyn® 
(ampicillin and sulbactam); Vancocin® (vancomycin); 
Vibramycin® (doxycycline); Zinacef® (cefuroxime); 
Zyvox® (linezolid) 
Pneumonia Any ICD-9-CM diagnostic  code of 481.xx – 486.xx in 
baseline period 
USRDS, Medicare Part 
A & B Claims 
Vascular access infection Any ICD-9-CM diagnostic code of 996.62 in baseline 
period 
USRDS, Medicare Part 
A & B Claims 
Sepsis Any ICD diagnostic code 038.xx, 995.90, 995.91, 
995.92 in baseline period 
USRDS, Medicare Part 
A & B Claims 
Diabetes Any ICD-9-CM diagnostic code of 250.xx in baseline 
period 
USRDS, Medicare Part 
A & B Claims 
Ischemic stroke Any ICD-9-CM diagnostic code of 434.01, 434.11, 
434.91, 435, 436, 437, 438, V12.54 in baseline period 
USRDS, Medicare Part 
A & B Claims 
MI Any ICD-9-CM diagnostic code of 410.xx in baseline 
period 
USRDS, Medicare Part 
A & B Claims 
COPD Any ICD-9-CM diagnostic code of 490.xx-496.xx, 
505.xx, 506.4 in baseline period 
USRDS, Medicare Part 
A & B Claims 
Cancer Any ICD-9-CM diagnostic code of 173.3, 173.9, 
174.0-175.9, 179-195, 196-199, 232.9, 233.0, 233.1, 
300.29, 338.3, 789.51, 795.82, 799.4, V67.2, 200, 201, 
202.0-202.3, 202.50-203.01,203.8, 238.6, 273.3 in 
baseline period  
USRDS, Medicare Part 
A & B Claims 
GI bleeding Any ICD-9-CM diagnostic code of 578.xx in baseline 
period 
USRDS, Medicare Part 
A & B Claims 
Time-Varying Covariates 
Iron dose in previous month Total iron dose in the first month prior to the exposure 
period 
Clinical Database 
Iron dose in preceding two 
months 
Total iron dose in the second and third month prior to 
the exposure period 
Clinical Database 
Hospitalization for infection Any hospital admission in the last month with one of 
the following  ICD-9-CM diagnostic codes as the 
principal diagnostic code: 001–139, 254.1, 320–326, 
331.81, 372–372.39, 373.0–373.2, 382–382.4, 383.0, 
386.33, 386.35, 388.60, 390–393, 421–421.1, 422.0, 
422.91–422.93, 460–466, 472–474.0, 475–476.1, 
478.21–478.24, 478.29, 480–490, 491.1, 494, 510–
511, 513.0, 518.6, 519.01, 522.5, 522.7, 527.3, 528.3, 
540–542, 566–567.9, 569.5, 572–572.1, 573.1–573.3, 
575–575.12, 590–590.9, 595–595.4, 597–597.89, 598, 
599.0, 601–601.9, 604–604.9, 607.1, 607.2, 608.0, 
608.4, 611.0, 614–616.1, 616.3–616.4, 616.8, 670, 
680–686.9, 706.0, 711–711.9, 730–730.3, 730.8–
730.9, 790.7–790.8, 996.60–996.69, 997.62, 998.5, and 
999.3.  
USRDS, Medicare Part 
A Claims 
Vascular access Indicators representing most recent vascular access in 
the previous month (catheter, graft, fistula, or 
other/unknown) 
Clinical Database 
Hospital days Total hospital days in the previous month USRDS, Medicare Part 
A 
IV antibiotics Use of antibiotics during in last interval Clinical Database 
TSAT level, % Most proximal TSAT level in prior interval Clinical Database 
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Covariate Definition Data Source 
Ferritin level, ng/mL Most proximal ferritin level in prior interval Clinical Database 
Hemoglobin level, g/dL Most proximal hemoglobin level in prior interval Clinical Database 
EPO use Total EPO use in prior interval Clinical Database 
Serum albumin level, g/dL Most proximal albumin level in prior interval Clinical Database 
Serum creatinine, mg/dL Most proximal creatinine level in prior interval Clinical Database 
Pre-dialysis systolic blood 
pressure  
Median value in prior 2 weeks Clinical Database 
Ultrafiltration rate  Median calculated value in prior 2 weeks Clinical Database 
Pre-dialysis weight (kg) Median value in prior 2 weeks Clinical Database 
Dialysis session length Median value in prior 2 weeks Clinical Database 
Post-dialysis weight (kg)  Median value in prior 2 weeks Clinical Database 
 
3.2.  Statistical Analysis 
3.2.1. Aim 1 Protocol Identification  
Study population  
The study population for Aim 1 were ESRD patients who were at least 65 years old and 
who initiated center-based HD in the US between January 1, 2004 and September 16, 2012 and 
had Medicare as the primary insurer.  
Index interval 
The index interval was the interval anchored by the index TSAT and the subsequent 
TSAT.  
Dosing protocols 
IV iron dosing protocols specify a range of acceptable iron therapy values during an 
interval given a subject’s current time-varying laboratory test values for anemia management 
parameters. For example, one dosing protocol set a target range of ≤50% for TSAT, ≤1200 
ng/mL for ferritin, and 13.0 g/dL for hemoglobin. The strategy recommended bolus dosing (100 
mg of iron sucrose for 10 consecutive dialysis sessions) if TSAT fell below 20% and ferritin was 
below 200 ng/mL. The strategy recommended maintenance dosing (50 mg of iron sucrose 
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weekly) if TSAT was between 20-50% and ferritin was between 200-800 ng/mL. If any of the 
parameters were to be above the target range or if the patient was receiving IV antibiotics, the 
strategy recommended iron be withheld. 
Classification of dosing protocols was carried out in the index interval following index 
TSAT (Figure 3.4). The choice of anchoring on a TSAT measurement was because evaluation of 
IV iron administration typically occurs following the availability of iron status tests (TSAT and 
ferritin) in clinical practice.  
Figure 3.4. Schematic of study design for aim 1 
Methods  
The initiated dosing protocols D(δ, ρ)| 𝜃, γ, λ were characterized by a set of parameters 
(𝜃, γ, λ, δ, ρ), where 𝜃= TSAT level, γ= ferritin level, λ= having diagnoses of infection or use of 
IV antibiotics, hospitalization or blood transfusion, δ= iron dosage, and ρ= iron treatment 
frequency. Each protocol specified a range of acceptable treatment values for iron use depending 
on the value of iron status test level and status of infection or IV antibiotic use. I developed an 
identification approach for dosing protocols using an assessment window following the index 
TSAT. For each patient, the iron treatment experience in the assessment window was examined 
to see with which protocol(s) it was consistent.  
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The initiated protocols were summarized in a figure depicting how IV iron dosage, 
administration frequency, and iron status parameters relate in individual protocols. 
Characteristics of patients initiating different dosing protocols were described. The trend of 
protocol initiation was examined over the calendar years and region of residence during the study 
period.  
Logistic regression was used to estimate for each patient the probability of receiving a 
particular IV iron dosing protocol given observed characteristics and identify the most important 
baseline factors that contribute to the initiation of a particular protocol. Potential factors included 
demographic characteristics, comorbidities, medications, and healthcare use in the baseline 
period.  
Strengths 
 The detailed information on dialysis procedures, IV medication, and laboratory test 
values in the clinical research database offered a great opportunity to examine how IV 
iron is used for anemia management in HD patients. These patients receive dialysis 
treatment three times a week, and the clinical research database captured the amount of 
IV iron use, IV iron formulation, and EPO dose administered, as well as clinical values 
and laboratory values from each visit. The granularity of the clinical data helped us 
understand how IV iron was used and classify dosing protocols in everyday clinical 
practice. 
 The size and diversity of the population derived from the linked databases merging the 
USRDS and a clinical research database from a large dialysis provider allowed for 
examination of IV iron use for anemia management among general HD patients in the 
US.  
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Challenges 
 No data were available on IV medications administered during hospitalization. It was 
unclear if a patient was continuing the dosing protocol from the outpatient dialysis 
facility or using a different protocol when staying in the hospital. All candidate protocols 
were assigned to patients if they were hospitalized during the assessment window.  
 The prescribed dosing protocols were not available, thus it was challenging to evaluate 
the performance of the identification approach. I used knowingly previously implemented 
dosing protocols as a positive control. Their high prevalence of initiation speaks to the 
validity of the performance of the identification approach.  
3.2.2. Aim 2 Comparative Safety of Protocols 
I compared a set of commonly used IV iron dosing protocols with respect to the risks of 
all-cause mortality and infection-related hospitalization and mortality using inverse probability 
of censoring weighted estimation of MSMs.172,173  
Study population 
The study population included incident HD patients who initiated one of the commonly 
used IV iron dosing protocols for anemia management between January 1, 2009 and September 
16, 2012.  This cohort was a subset of the cohort in Aim 1 by restricting to patients who initiated 
the commonly used dosing protocols between 2009 and 2012.  
Exposure 
The exposure of interest was commonly used IV iron dosing protocols identified in Aim 
1. One of the most frequently initiated protocols was used as the reference protocol. Assessment 
of index dosing protocols were carried out in the first two weeks following the index TSAT. 
Although brief, the two-week window was representative of treatment experience in the interval. 
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Figure 3.5. Schematic of study design for aim 2 
 
Deviation 
During follow-up, the observation of an individual was discretized into intervals 
anchored by TSAT measurements. The two-week window following each TSAT lab was used to 
classify what dosing protocol this individual was following. An individual was classified as 
deviating from the index dosing protocol if the dosing protocol within the current interval was 
different from the index protocol. The date of deviation was the end of the two-week exposure 
window when the individual first deviated from the index protocol. Patients who deviated from 
their index protocols were artificially censored. Potential selection bias introduced by this 
informative censoring was adjusted for by inverse-probability weighting as described below.  
Outcome 
The outcomes were all-cause mortality and the composite outcome of infection-related 
hospitalization or mortality. Table 3.6 lists the detailed definitions for outcomes.  
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Methods  
Descriptive analyses described the characteristics of the subjects and their baseline 
comorbidities using percentages or medians and quartiles as appropriate.  
Survival time was measured from the IV iron dosing protocol initiation to outcome event 
of interest. Patients were administratively censored at December 31, 2012, or occurrence of one 
of the following: event of interest, 120 days since index date, receipt of kidney transplantation, 
the time of switching dialysis modality, loss to follow-up, disenrollment from this dialysis 
provider or loss of Medicare coverage.  Patients who deviated from the index dosing protocols 
during follow-up were artificially censored. Deviation from initial dosing protocol was assessed 
to identify important predictors for treatment deviation. Survival plots for compliance of index 
dosing protocols were created using Kaplan-Meier survival curves.191   
I estimated the cumulative risk of each outcome of interest using the complement of the 
Kaplan-Meier survival function191 for each dosing protocol and calculate cumulative incidence 
differences between each dosing protocol and the reference protocol during the follow-up period. 
One of the most frequently used dosing protocols was used as the reference protocol. The 95% 
confidence intervals for the cumulative incidence differences were estimated using a non-
parametric bootstrap procedure. I performed four different analyses.  
1) Crude intention-to-treat effect of treatment 
This approach summarized the effect of initiating one dosing protocol versus the 
reference protocol on each outcome of interest. Protocol deviation in the follow up was ignored. 
No adjustment was done to control for baseline confounding.  
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2) Crude effect of continuous compliance not adjusted for informative censoring 
Individual observation during follow-up was discretized into intervals anchored by TSAT 
laboratory tests. Patients who deviated from the index protocol were artificially censored. Once 
censored for deviation, patients could not reenter the study population. No adjustment was done 
for potential selection bias arising from such censoring or for baseline confounding control. 
3) Effect of continuous compliance not adjusted for informative censoring 
With the same setup as the second analysis, patients who deviated from their index 
protocol were artificially censored. I compared the effect of initiating and continuing each 
treatment protocol versus the reference group on each outcome of interests. Standardized 
mortality ratio weights (𝑆𝑊𝑖
𝑇) were estimated at the index date to adjust for baseline 
confounding by weighting initiators of each comparator protocol using the reference protocol 
initiator group as the standard.192,193 Weights were estimated using a logistic regression model 
that included baseline risk factors for outcome event of interest which also predicted protocol 
initiation. I used basic splines to flexibly model continuous variables. Potential selection bias 
introduced by artificial censoring due to protocol non-adherence was ignored.    
4) Effect of continuous compliance adjusted for informative censoring 
This approach used the same data structure in Analysis 3) described above. This analysis 
estimated the effect of continuing each dosing protocol versus the reference protocol on each 
outcome of interest adjusting for informative censoring due to protocol non-adherence using a 
product of standardized mortality ratio weights (𝑆𝑊𝑖
𝑇)192,193 for baseline confounding control and 
inverse probability of censoring weights for deviation (𝑆𝑊𝑖𝑗
𝐷) for selection bias.173,177,179  
We fitted censoring model to each protocol group separately to allow for different 
mechanisms that might have contributed to each group. For each interval anchored by TSAT 
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measurements, we estimated the probability of deviation given potential covariates associated 
with both deviation and outcomes using a Cox proportional hazards model. These covariates 
included baseline covariates and the most recent time-varying covariates in the interval prior to 
the 14-day assessment window in which deviation was thought to have occurred. Patients who 
experienced outcomes of interest were weighted inversely using the probability that the failure 
time was observed to account for potential informative censoring due to deviation. 
We first estimated the cumulative incidence of adverse outcomes in initiators of each 
dosing protocol separately. We then estimated the cumulative incidence differences between 
each protocol and the reference protocol during the follow-up period. The 95% confidence 
intervals (CI) for cumulative incidence differences were estimated using a non-parametric 
bootstrap procedure with 200 repetitions. We conducted sensitivity analyses by using different 
covariates for censoring weighting estimation.  
Assuming no unmeasured covariates that contributed to deviation from the index 
protocols and also to the outcomes of interest, this weighting approach adjusted for the time-
varying selection bias due to artificial censoring. This approach estimated the effect of continued 
compliance with initiated dosing protocols on the outcomes of interest.  
During the index assessment window, a patient’s treatment experience might be 
consistent with multiple administration strategies. I created k copies of the same patient for k 
strategies she was consistent with initially. Within each strategy group, the copy of the patient 
was followed up until she deviated from the respective index strategy.  As described previously, 
patients who deviated from index administrations strategy were artificially censored at the end of 
14-day assessment window. The remaining patients were weighted by the probability that they 
stayed on the index strategy to estimate the risks of all-cause mortality and infection-related 
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hospitalization or mortality. These patients were also censored for reasons other than deviation as 
described previously, but the cohorts were not reweighted to account for possible dependent 
censoring related to these additional events.   
Strengths  
 Most previous observational studies on IV iron evaluated cumulative iron doses over a period 
of time, which could classify two different dosing protocols, one with smaller doses and 
more frequent treatments and another with larger doses and infrequent treatments, into the 
same category based solely on the aggregated dose. This made it difficult to understand the 
safety of IV iron use in HD patients without differentiating the effectiveness and safety of 
different IV iron dosing strategies. To my knowledge, this thesis is the first to compare 
different dosing protocols and examine their safety profile of longer-term effects, providing 
evidence to help identify optimal treatment protocols for anemia management in HD patients. 
 The weighted survival curves provide an easy presentation of the outcome risks over the 
entire follow-up period and estimation of cumulative incidence risks that are clinically 
relevant and interpretable.   
Challenges 
 As the study population were patients on HD from a single dialysis managing company, 
results from this study may not be completely generalizable to patients who receive HD from 
other dialysis providers. However, this company is one of the largest dialysis providers in the 
US and provides services to approximately one third of all Americans with ESRD receiving 
dialysis. Selected from their large clinical database with few exclusion criteria, the study 
population had characteristics similar to a general ESRD patients receiving dialysis in the 
US.  
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 There is potential for unknown confounders not included in the model for protocol initiation 
or model for protocol non-adherence and hence the effect estimates are subject to residual 
confounding and selection bias. However, the clinical research database and the USRDS 
database contain rich, frequently measured clinical, laboratory, treatment, and demographic 
variables that reduce the chance of strong residual confounding. Additional investigation is 
needed to explore the extent of residual confounding. 
 It is possible but unlikely that patients excluded from the study had a different distribution of 
factors associated with deviation compared to patients included in the study, so the amount of 
selection bias was small.   
 The outcomes based on claims-based algorithms are subject to some measurement error. 
However, the potential for measurement error of mortality outcome was low as the ESRD 
Death Notification form identifies more than 99% of HD patient deaths.188  
3.3. Human Subjects 
 This research project used de-identified data from existing databases and involved no 
direct contact with the patients in this study or access to personal identifying information, 
incurring no direct physical or psychological risks to these patients. The full database as well as 
all interim and analytic datasets were stored on a secure Pharmacoepidemiology server located at 
the Cecil G. Sheps Center for Health Services Research, University of North Carolina at Chapel 
Hill, North Carolina. Access to the data on the server was via password-protected secure remote 
connections and was limited to project personnel. Copies of the data were not made or 
transmitted outside of these guidelines. This study was approved by the Non-Biomedical 
Institutional Review Board (IRB) at University of North Carolina at Chapel Hill.  
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CHAPTER 4: IDENTIFICATION OF DYNAMIC TREATMENT REGIMES IN 
COMPLEX LONGITUDINAL DATA1 
4.1. Introduction 
Clinical management of patients with chronic disease frequently involves sequences of 
treatment decisions regarding treatment, dose adjustments, testing, and use of add-on therapies.  
For example, almost all end-stage renal disease (ESRD) patients maintained on chronic 
hemodialysis receive intravenous (IV) iron therapy to help manage anemia by correcting iron 
deficiency. Patients receiving IV iron for anemia management have laboratory tests evaluated on 
a regular basis. The levels of hemoglobin and iron status parameters—transferrin saturation 
(TSAT) and ferritin—inform the dosage level and frequency of IV iron administration for the 
next treatment course.13,15,109 Treatment strategies involving decision rules to make treatment 
recommendations based on evolving clinical history are termed “dynamic treatment regimes”.163 
Other examples of dynamic treatment regimes include treatment of HIV/AIDs,164-166 
management of type 2 diabetes,167 and cholesterol control.168  Increasingly clinical guidelines 
present recommendations in this dynamic format.164-168  
Dynamic treatment regimes can be evaluated directly in randomized controlled trials in 
which patients are randomized to one of a set of different regimes that specify how treatments 
and tests are to be used given a patient’s evolving clinical history. Additionally, designs such as 
sequential, multiple assignment, randomized trial (SMART) allow construction and comparison 
of dynamic treatment regimes to identify the optimal regime.195,196  However, in the settings of 
                                                             
1 This section was submitted to Epidemiology.  
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multiple candidate regimes with differing therapy options and management goals, trials would 
likely be prohibitively expensive and impractical. Consequently, in practice, trials of dynamic 
treatment regimes tend to compare a few limited options. For example, currently completed trials 
for IV iron in hemodialysis patients have only evaluated static regimes such as “125 mg ferric 
gluconate with eight consecutive dialysis sessions”.6  Static regimes, in contrast to dynamic 
regimes, specify a fixed treatment strategy at the start of treatment and stay unchanged during the 
course of treatment, making them suboptimal for patients with changing response to treatment 
and evolving clinical needs. Consequently, despite the completion of several randomized trials, 
there still remains considerable uncertainty in the best practice for IV iron administration for 
anemia management in hemodialysis patients.11,22,23,25,197 As anemia affects almost all 
hemodialysis patients with ESRD, comparative effectiveness research of different iron 
administration strategies is needed to identify the optimal treatment approaches to iron treatment.  
Currently, epidemiologic and statistical methods exist that can be used to estimate the 
effect of dynamic treatment regimes using observational data.173-185,198. However, these methods 
require accurate assessment of the treatment decisions being made by the physician as well as the 
clinical and laboratory variables that guide such treatment decisions. Increasingly available large 
healthcare databases containing rich, granular patient-level information may make such 
approaches more feasible.  For example, for ESRD patients on chronic hemodialysis, linked 
clinical and administrative research databases exist that contain detailed longitudinal information 
on patients, including medication treatment, routine laboratory tests, and healthcare encounters.  
These data arguably provide all relevant information needed to assess the effectiveness of 
different IV iron administration strategies in hemodialysis patients. Yet even with suitable data, 
one can only estimate the effectiveness of treatments and treatment regimes that actually occur in 
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practice.  In other words, if certain sequences of treatment decisions are never made, the data 
will not be informative about the effects of protocols that would dictate such treatment decisions. 
In this study, we aimed to develop a process to identify treatment regimes that could be 
evaluated given a particular data source. We considered regimes that prescribe a range of 
treatment values based on multiple time-varying covariates by using IV iron administration 
strategies for anemia management in hemodialysis patients as an example.  
 
4.2. Methods 
Data source, study design, and study population 
We constructed our study cohort using data derived from the clinical research database of 
a large dialysis provider in the United States, linked with the United States Renal Data System 
(USRDS) (2004-2012).188,199 With over 2,042 dialysis centers located throughout the country, 
this company provides services to approximately one third of all Americans with ESRD 
receiving dialysis.186 We obtained detailed clinical information regarding patients’ dialysis 
treatments, vascular access, routine laboratory tests, IV medications, and anemia management 
using the clinical research database. We obtained patient information regarding their 
demographic characteristics, comorbidities, and healthcare system encounters from the USRDS. 
The study was approved by the University of North Carolina at Chapel Hill Institutional Review 
Board, Chapel Hill, NC, USA. 
We used a cohort design with the index date for IV iron administration strategy defined 
as the first time a TSAT test result became available within 90-136 days after dialysis initiation. 
The choice of anchoring on a TSAT measurement was because evaluation of IV iron 
administration strategy typically occurs following the availability of iron status tests (TSAT and 
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ferritin) in clinical practice. Results of iron status tests are typically interpreted together with 
hemoglobin levels and ESA doses to guide iron therapy including the dose and duration.13,15,109 
We defined the TSAT measurement on the index date as the index TSAT. We assessed the levels 
of ferritin and hemoglobin on the same day. If ferritin and hemoglobin values were not available 
on the index date, values were obtained from their previous measurements in the baseline period. 
The baseline period was defined as the period starting 90 days prior to dialysis initiation and 
ending on the day before the index date. We defined the interval between index TSAT and its 
subsequent TSAT measurement as the index interval, where the strategy that guided IV iron 
administration was the focus of this article (Figure 4.6).  
Our study population comprised outpatient hemodialysis patients who initiated in-center 
hemodialysis between 1 January, 2004 and 16 September, 2012. Patients included were aged 65 
and older and who had Medicare as their primary insurer, continued hemodialysis for at least 90 
days, and had complete information on baseline covariates and IV iron exposure. To ensure 
patients were receiving regular in-center hemodialysis and anemia management, we excluded 
patients who had fewer than nine dialysis sessions in the last month of baseline period or no 
TSAT measurement during the 120 days following dialysis initiation. We also excluded patients 
if they had polycystic kidney disease because their management strategies of IV iron could differ 
(see Appendix A).  
Strategy identification process 
The identification was an iterative process that consists of four major steps: 1. 
Development of candidate administration strategies; 2. Determination of assessment window; 3. 
Identification of administration strategies; 4. Fine-tuning of identification process.  
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We defined an administration strategy as a dosing protocol or dosing strategy that a 
clinician uses to make treatment decisions. A strategy consisted of a set of decision rules with 
laboratory test values and corresponding dosage patterns. In this IV iron example, dosage 
patterns referred to the iron therapy patients received, including the dosage level for each session 
and therapy frequency in a period of treatment.  
Step 1- Development of candidate administration strategies  
We considered IV iron administration strategies that specified a range of acceptable iron 
therapy values during an interval given a subject’s current time-varying laboratory test values for 
anemia management parameters. For example, this example administration strategy (see 
Appendix B) set a target range of ≤50% for TSAT, ≤1200 ng/mL for ferritin, and 13.0 g/dL for 
hemoglobin. The strategy recommended bolus dosing (100 mg of iron sucrose for 10 consecutive 
dialysis sessions) if TSAT fell below 20% and ferritin was below 200 ng/mL. The strategy 
recommended maintenance dosing (50 mg of iron sucrose weekly) if TSAT was between 20-
50% and ferritin was between 200-800 ng/mL. If any of the parameters were to be above the 
target range or if the patient was receiving IV antibiotics, the strategy recommended iron be 
withheld. 
We developed administration strategies from existing dosing protocols in routine clinical 
use and modified them through consultations with experts. Two sets of administration strategies 
were considered, one set with hemoglobin as a deciding factor, and another set without 
hemoglobin restriction. Definitions of the strategies are listed in Appendix C. The strategies 
varied in terms of cut-off laboratory test levels and corresponding iron dosage pattern choices. 
The strategy definitions were updated by incorporating the choice of assessment window and the 
distribution of dosage levels in the data in Step 2. We examined the influence of three laboratory 
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tests on the decision for iron therapy by assessing the distribution of a particular laboratory test 
across different iron dosage patterns. The results presented in this article focused on the set of 
administration strategies with influential laboratory tests.   
Step 2- Determination of assessment window  
We developed a data visualization tool using ggplot2 package in the R statistical package 
to examine patient-level data, including laboratory test values, clinical data, treatment 
information, and healthcare system encounters.200 The visualization tool depicted the patient 
journey with treatment and her clinical condition evolution across time using two panels 
(Appendix D). The top panel illustrated the changes in anemia management parameters, while 
the bottom panel presents the IV iron dosage level received at each dialysis session, occurrence 
of hospitalization, skilled nursing facility stay, hospice use, and IV antibiotic use (a marker for 
active infection).  
To inform the length of assessment window and classification of iron dosage patterns, we 
examined the patient journey of a random sample of eligible patients in the cohort using this data 
visualization tool. The length of assessment window was chosen so that it maximized the 
representativeness of treatment experience in the window for the treatment experience in the 
interval while minimizing the days required for the assessment window to maximize follow-up 
time for subsequent studies evaluating effect of strategies on health outcomes. The dosage 
patterns in the assessment window were classified into groups by prorating iron dosage levels for 
different dosage patterns specified in the candidate strategies over the chosen assessment 
window. These dosage patterns were then incorporated into the candidate administration 
strategies. 
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Step 3- Identification of administration strategies    
We identified IV iron administration strategies that were consistent with treatment 
patterns in the assessment window for index interval. For each patient, we compared three 
laboratory test levels (TSAT, ferritin, and hemoglobin) on the index date together with the 
dosage pattern in the assessment window with the candidate administration strategies to identify 
consistent strategies. The consistent strategies were then assigned as the index administration 
strategy for that patient. Because considered strategies contained overlapping target ranges for 
anemia management parameters and same treatment patterns for some ranges of laboratory 
value, multiple strategies could be consistent with a patient’s treatment history and be assigned 
for that patient.  
Step 4- Fine-tuning the identification process 
Strategy identification drew information from a patient’s treatment history in the 
assessment window. Insufficient information could have been resulted from hospitalization, use 
of IV antibiotics during active infection, or use of blood transfusion during the strategy 
assessment window. For patients with insufficient information in the assessment window, all 
candidate administration strategies were assigned to their index intervals.  
Evaluation of strategy initiation 
We examined the distribution of initiated administration strategies in the study period 
2004-2012. Important predictors for strategy initiation were identified by assessing their 
standardized mean differences between patients who initiated a strategy and those who initiated 
other strategies. Potential predictors included patient demographic characteristics, clinical 
characteristics, and comorbidities. We also examined the trend of initiation across calendar year 
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and region of residence. All analyses were performed in R, version 3.3.1 (R Foundation for 
Statistical Computing, Vienna, Austria) or SAS 9.4 (SAS Institute, Inc., Cary, North Carolina). 
For dosage patterns that could not be matched with the candidate strategies, we detected 
interaction using classification and regression trees (CART).201 The objective was to identify 
baseline predictors for the use of different dosage patterns in the assessment window and 
summarize these unique practice patterns. Potential predictors included measures of 
demographics (race/ethnicity, age, gender), infection, transfusion, days in the hospital, type of 
access, iron status tests, and hemoglobin). Trees were built by recursive portioning, and cross-
validation was used to prune the tree. The importance of factors for initiation of these unique 
practice patterns was evaluated using random forest.202 
 
4.3. Results 
Identification process 
We focused on administration strategies initiated in the index interval defined by the first 
two consecutive TSAT laboratory tests after the baseline period. As informed by explorative 
analysis with the data visualization tool (Appendix D), treatment patterns in the two-week 
window following the index TSAT measurement was representative of the treatment experience 
in the interval. We used the two-week window starting from the index date as assessment 
window for identification of IV iron administration strategies in the index interval.  
Between 2004 and 2012, 43,166 patients met the eligibility criteria for study entry and 
were included in the cohort (Appendix A). Table 4.8 presents their baseline demographic and 
clinical characteristics. Overall, about half of the cohort were female, and a quarter of them were 
black. The mean age was 75.8 years. The length of index interval has a median of 28 days 
66 
 
(interquartile range [IQR]: 28-35 days), with 995 (2.3%) shorter than 14 days and 429 (1.0%) 
longer than 120 days.  
The IV iron dosage pattern in the two-week assessment window was categorized into five 
levels: bolus dosing (> 500 mg), half bolus dosing (201-500 mg), maintenance dosing (101-200 
mg), low maintenance dosing (1-100 mg), and none (0 mg) (Appendix E). More than half of the 
patients initiated dosage patterns with lower doses or no iron in the index interval. The most 
frequently initiated pattern was low maintenance dosing (32.9%, median (IQR) of iron dose: 100 
(50-100) mg). About 7.5% of patients were treated with bolus dosing (median (IQR): 600 (600-
600) mg). The distribution of the iron status tests on the index date, TSAT and ferritin, were 
different among patients initiated with different dosage patterns (Appendix E and Figure 4.7). 
The levels of these tests were inversely associated with the dosage pattern initiated. In 
comparison, the distribution of hemoglobin levels was similar among these dosage patterns, and 
the proportion of dosage patterns did not change much across hemoglobin levels (results not 
shown), suggesting that hemoglobin was not playing a huge role in the decision for 
administration strategies during this study period.    
Figure 4.8 shows how dosage pattern initiation was related to levels of TSAT and ferritin 
simultaneously. For patients with TSAT greater than approximately 50% or ferritin greater than 
800 ng/mL, no IV iron was given. For intervals with TSAT levels below 50% and ferritin levels 
below 800 ng/mL, there was considerable heterogeneity in dosage patterns, suggesting different 
strategies were guiding treatment decisions and we could exploit this variation to compare effect 
of various IV iron dosing strategies.   
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Results of administration strategies 
Explorative analyses showed little influence of hemoglobin levels on initiation of dosage 
patterns, so we focused on the strategies without hemoglobin restrictions in the following 
sections. Appendix C listed definition of all candidate strategies.  
Between 2004 and 2012, 79.1% of 43,166 patients had treatment experience consistent 
with one or more candidate administration strategies, and 20.9% of them were not matched to 
considered strategies. Among the eight strategies without hemoglobin restriction, the three most 
frequently initiated were strategy 2 (54.8%), strategy 3 (52.3%), and strategy 1 (52.2%) (Table 
4.9); the least frequently initiated strategy was strategy 5 (34.2%).   
Year and regional trend of protocol initiation   
Figure 4.9 shows the trend of strategy initiation persisted across calendar years, with the 
first three strategies more frequently initiated. However, the proportion of patients initiating 
these three strategies increased sharply in 2011 and 2012, whereas the proportion of patients 
initiating other strategies stayed constant. Consequently, the prevalence of treatment patterns that 
could not be matched dropped dramatically from 25.0% in 2004 to 11.6% in 2011 and to 9.3% in 
2012. There was not much variation in the initiation of strategies across regions (Appendix F).  
Characteristics of patients initiating different protocols  
Baseline characteristics of patients initiating candidate strategies were similar, suggesting 
little confounding by indication at baseline (Figure 4.10). The distribution of initiation 
throughout calendar year was different for strategy 1, strategy 2, and treatment patterns not 
matched. Compared to patients who were matched with candidate strategies, patients who could 
not be matched had different laboratory test values (lower TSAT and ferritin levels and higher 
hemoglobin level) and prevalence of comorbidities, specifically lower infection risks in the last 
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month of the baseline period. They also spent fewer days in the hospital and received fewer 
transfusions in the baseline period.       
Characteristics of treatment patterns that could not be matched 
These practices were collapsed into 10 different exception rules (Figure 4.11).  The 
important factors that predicted which pattern to initiate were TSAT, ferritin, total Epoetin 
received, post-dialysis weight in the last two weeks, creatinine, pre-treatment systolic blood 
pressure in the last two weeks, hemoglobin, age, and albumin level. 
4.4. Discussion 
We developed an identification process for dynamic treatment regimes in complex 
longitudinal, observational data when it is not known what regimes may be in use in a given 
population. We aimed to systematically construct cohorts of patients initiating treatment 
strategies under consideration for comparative effectiveness research studies.  This identification 
approach matches treatment pattern and current laboratory test values with candidate strategies 
by consistency; whereas candidate strategies are constructed using expert’s knowledge and 
examination of patient-level data using visualization techniques. This approach allows pragmatic 
classification of dynamic treatment regimes for causal inference using rich observational data.  
We applied this identification process in an empirical example of IV iron administration 
strategies for anemia management in ESRD patients undergoing chronic hemodialysis. Between 
2004 and 2012, 79% of patients were matched with one or more strategies under consideration. 
The prevalence of match increased sharply starting in 2010 to 91% in 2012. The increasing trend 
of matches across calendar years was consistent with the fact that the installation of 
administration strategies occurred in recent years in dialysis clinics.20,21,180 The baseline 
characteristics of patients initiating different strategies were very similar, indicating little 
69 
 
confounding by indication at baseline, which improves our ability to compare these strategies 
with respect to their effects on outcomes.  
The identification process fits well with the need for estimation of the effect of dynamic 
treatment regimes in non-experimental settings. Time-varying confounding is a pertinent 
problem in evaluating complex medical decisions that change with patients’ evolving clinical 
needs, but has not been sufficiently investigated. Cumulative exposures are often examined in 
the literature using marginal structure models. However, our data visualization tool revealed that 
aggregated cumulative exposures over a long period could mask the substantial heterogeneity 
among patients’ experience. Moreover, studies of cumulative exposures do not align with 
decisions made by clinicians.  For example, clinicians treating dialysis patients do not make 
decision about how much cumulative iron to provide a patient over an extended time period, 
although contemporary dosing schedules have an upper limit of cumulative dose over 3 or 6 
months.  Instead, they want to know when to provide a course of iron and how to provide it. 
Comparative effectiveness research of dynamic treatment regimes is clearly needed in many 
contexts.   
Without the information on the exact regime a patient was treated under, there was no 
direct way to evaluate the performance of this identification process. However, positive controls 
such as knowingly implemented strategies in routine clinical care could help gauge the 
performance of classification. In this empirical example, we considered three strategies that were 
adapted from known pre-existing dosing protocols. These strategies were more highly initiated 
and adhered to relative to the other strategies, and the trend of the rapid uptake in recent years 
was also consistent with their installation in clinical practice around 2010, confirming the 
performance of the identification approach.  
70 
 
This identification approach could assign multiple strategies to a single patient at a point 
of time, if the strategies under consideration are not entirely distinct, which is common in 
practice. When two strategies prescribe same treatment in certain ranges of laboratory test 
values, the treatment experience of a patient receiving that treatment would be consistent with 
both strategies. Well-developed statistical methods exist to help us make valid inference on the 
effect of these regimes on outcome of interest.173,176-180 
This identification process can be easily adapted for other dynamic treatment regimes, 
but adaptation needs to be evaluated on a study-by-study basis. It can also be extended for more 
complex strategies. In addition to hemoglobin, iron status tests, and infection status, some 
guidelines recommended incorporation of erythropoiesis-stimulating agent (ESA) doses and 
trend of iron status tests.13-15,109  Although we did not consider ESA doses and the trend of iron 
status because the knowingly implemented strategies did not consider these factors, the role of 
these additional factors on IV iron administration could be explored in future studies.  
Data visualization was a helpful tool that provided insight into the data structure and 
informed strategy identification. Extensive examination of patient-level data with complex data 
visualization revealed that aggregated cumulative iron exposure over a long time period would 
mask heterogeneity across patients. Patients with same total or average iron doses over a fixed 
time period could have different treatment and clinical experience with respect to iron treatment 
frequency, treatment intensity, and healthcare encounters. The data visualization tool helped 
determine the assessment window for strategy identification. It also illustrated that a longitudinal 
treatment decision design with intervals anchored by the TSAT laboratory tests had advantages 
over the fixed-length interval design for this current study (results not shown). Using this tool, it 
is easy to view the whole patient journal across time in a fast manner, including outcomes of 
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interest. However, caution needs to be exercised to not condition the study or cohort construction 
on the outcome status when using this tool.  
 
4.5. Conclusion 
With the increasing availability of detailed healthcare data and sophistication of methods, 
we have a great opportunity to improve the clinical management of complex patient care using 
existing data. We illustrated the use of an approach to identify dynamic treatment regimes that 
could be evaluated in a large observational database. Furthermore, we demonstrated the use of 
data visualization that provided insights into the complexity of data structure and helped us 
identify appropriate exposure assessment, study design, and analytical approaches for study 
questions of interest. 
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Table 4.8. Baseline characteristics for eligible patients included in the cohort, 2004-2012  
  
Overall (N = 43,166) 
N % 
Age, year     
   Mean (SD) 75.8 (6.8) 
   Median (IQR) 75 (70-81) 
   65-74 19,959 46.2 
   75-84 18,150 42.0 
   85-94 4,951 11.5 
   95- 106 0.2 
Sex of patient     
   Male 22,249 51.5 
   Female 20,914 48.5 
   Unknown <11 0.0 
Race     
   White 31,080 72.0 
   Black 10,109 23.4 
   Other 1,977 4.6 
Region     
   Midwest 9,510 22.0 
   Northeast 6,380 14.8 
   South 19,035 44.1 
   West 8,234 19.1 
   Others <11 0.0 
Primary cause of ESRD     
   Diabetes 19,447 45.1 
   Glomerulonephritis 2,267 5.3 
   Hypertension 15,756 36.5 
   Other reason 5,633 13.0 
   Missing 63 0.1 
Year of protocol start     
2004 3,724 8.6 
2005 5,287 12.2 
2006 5,118 11.9 
2007 5,182 12.0 
2008 5,053 11.7 
2009 5,397 12.5 
2010 5,290 12.3 
2011 4,191 9.7 
2012 3,924 9.1 
Time on dialysis     
0 43,166 100 
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Comorbidities     
Vascular access infection, baseline last month 534 1.2 
Pneumonia, baseline last month 868 2.0 
Sepsis, baseline last month 846 2.0 
Infection, ADR definition, baseline last month 1,238 2.9 
Antibiotic use, baseline last month 6,716 15.5 
IV antibiotics in clinic, baseline last month 4,600 10.6 
Infection (broad definition) baseline last month 8,910 20.6 
Diabetes 29,203 67.5 
Hypertensive disease 41,738 96.5 
Congestive heart failure 27,528 63.7 
Myocardial infarction, acute 4,297 9.9 
Angina 3,726 8.6 
Coronary artery disease/atherosclerosis 24,601 56.9 
Ischemic stroke 3,429 7.9 
Intracerebral hemorrhage 120 0.3 
Subarachnoid hemorrhage 46 0.1 
Hemorrhagic stroke 287 0.7 
Cerebrovascular disease 9,164 21.2 
Chronic obstructive pulmonary disease & 
asthma 
14,134 
32.7 
Hyperlipidemia 23,359 54.0 
Cancer 8,601 19.9 
Liver disease 1,661 3.8 
Gastrointestinal bleeding & ulcer 1,206 2.8 
Peripheral vascular disease 11,483 26.6 
Rheumatic heart disease 2,871 6.6 
Psychiatric disorder 2,233 5.2 
Substance abuse 2,386 5.5 
Autoimmune disorder 1,755 4.1 
Blood loss anemia 2,481 5.7 
Other neurological disorders 4,645 10.7 
Hyperparathyroidism 1,678 3.9 
Chronic heart disease procedures 2,519 5.8 
Blood transfusion 14,163 32.7 
Rheumatoid arthritis/collagen vascular disease 1,130 2.6 
Neuropathy 8,335 19.3 
Osteoarthritis 7,522 17.4 
Osteoporosis 1,555 3.6 
History of fall 1,603 3.7 
Anemia Management in last month of baseline period 
Access     
    Catheter                   27,410  63.5 
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    Fistula                   10,033  23.2 
    Graft                     5,331  12.4 
    Missing                       392  0.9 
Pre-treatment SBP, mmHg 143.0 (129.0-158.5) 144.2 (22.2) 
Post-treatment weight, kg 71.8 (61.0-84.2) 73.9 (18.2) 
Hospital days 0 (0-0) 0.6 (1.9) 
Anemia Management at last month of baseline perioda 
Total EPO dose, 1000 units/month 60.5 (24.2-118.8) 85.1 (84.2) 
Total iron dose, mg 200 (75-500) 337 (357) 
TSAT, % 22 (17-29) 24.4 (11.9) 
Ferritin, ng/mL 292 (155-520) 398.5 (402.4) 
Hemoglobin, g/dL 12.1 (11.1-13.2) 12.1 (1.6) 
Albumin, g/dL 3.6 (3.3-3.9) 3.6 (0.5) 
Creatinine, mg/dL 5.0 (3.8-6.4) 5.2 (2.0) 
Anemia Management on index dateb 
TSAT, % 25 (18-33) 27.5 (13.6) 
Ferritin, ng/mL 341 (184-582) 440.2 (405.4) 
Hemoglobin, g/dL 12.3 (11.3-13.3) 12.3 (1.5) 
Albumin, g/dL 3.7 (3.4-3.9) 3.6 (0.4) 
Creatinine, mg/dL 5.20 (3.92-6.61) 5.4 (2.1) 
SD=Standard deviation; IQR=interquartile range; ESRD=end stage renal disease; ADR=annual 
data report; TSAT=transferrin saturation; EPO=Epoetin 
aIf laboratory tests in the last month of baseline were missing, the previous test values were used; 
bIf a laboratory test was missing on index date, the last non-missing test values were used. 
For all continuous variables, the first column is median (IQR), and the second column is mean 
(SD). 
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Table 4.9. Identified IV iron administration strategies in 2004-2012   
Number 
Number of consistent strategies   
Strategy 
Prevalence of initiation 
N %a   N %b 
0 9,023 20.9   strategy 1 22,532 52.2 
1 5,188 12.0   strategy 2 23,663 54.8 
2 5,731 13.3   strategy 3 22,570 52.3 
3 5,901 13.7   strategy 4 18,100 41.9 
4 2,394 5.5   strategy 5 14,782 34.2 
5 1,728 4.0   strategy 6 16,146 37.4 
6 621 1.4   strategy 7 18,900 43.8 
7 1,162 2.7   strategy 8 19,080 44.2 
8 11,418 26.5   Other 9,023 20.9 
aThese percentages describe the proportion of 43,166 patients were consistent with a specific number of 
strategies, so they sum up to 100%. 
bThese percentages describe the proportion of 43,166 patients were consistent with a specific strategy. 
Because multiple strategies could be consistent to one patient’s treatment history, so these percentages do 
not sum up to 100%. 
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Figure 4.6. The scheme of study design describes the index date and index interval in relation to 
hemodialysis initiation and iron management parameters  
HD=hemodialysis IV=intravenous; TSAT=transferrin saturation.  
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Figure 4.7. Distribution of laboratory tests across dosage patterns in the assessment window 
B=bolus dosing (> 500 mg); HB=half bolus dosing (201-500 mg); M=maintenance dosing (101-
200 mg), LM=low maintenance dosing (1-100 mg); N=none (0 mg). 
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Figure 4.8. The joint density of dosage patterns across levels of TSAT and ferritin  
B=bolus dosing (> 500 mg); HB=half bolus dosing (201-500 mg); M=maintenance dosing (101-
200 mg), LM=low maintenance dosing (1-100 mg); N=none (0 mg). 
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Figure 4.9. Trend of matched IV iron administration strategies across calendar year in the study 
period 2004-2012 
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Figure 4.10. Absolute standardized mean difference (SMD) for baseline predictors of initiation 
comparing patients initiating one strategy versus patients initiating other strategies 
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Figure 4.11. Decision tree for dosage patterns among patients who could not be matched with 
strategies under consideration 
B=bolus dosing (> 500 mg); HB=half bolus dosing (201-500 mg); M=maintenance dosing (101-
200 mg), LM=low maintenance dosing (1-100 mg); N=none (0 mg). 
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CHAPTER 5: COMPARATIVE EFFECTIVENESS OF INTRAVENOUS IRON 
ADMINISTRATION STRATEGIES IN HEMODIALYSIS PATIENTS 
5.1. Introduction 
Anemia, a common complication of end stage renal disease (ESRD),1 is associated with 
elevated morbidity, mortality, and healthcare costs.2  A primary cause of anemia in ESRD is iron 
deficiency, particularly among patients requiring hemodialysis.  Iron deficiency can be classified 
into absolute iron deficiency and functional iron deficiency; their causes are multifactorial.3  
Absolute iron deficiency, depleted iron stores, is frequently a result of blood loss, reduced intake, 
and impaired intestinal absorption of dietary iron.3  Functional iron deficiency, insufficient iron 
availability at the site of erythropoiesis despite adequate iron stores, can be caused by chronic 
inflammation associated with ESRD or elevated hepcidin levels.3  Overall, hemodialysis patients 
lose an average of 1-2 g of iron per year, and some as much as 4-5 g per year.4  Management of 
iron deficiency to meet the need for erythropoiesis is thus essential for optimal management of 
anemia in ESRD patients.   
In contemporary clinical practice, intravenous (IV) iron is either provided intermittently 
via large doses over consecutive dialysis sessions (often termed “bolus dosing”) or via small 
doses provided every one to two weeks (often termed “maintenance dosing”).  Administration of 
IV iron is always anchored on regular laboratory tests of iron status parameters - ferritin and 
transferrin saturation (TSAT).13-15  Decisions regarding dose, frequency, and duration of IV iron 
(i.e., maintenance dosing, bolus dosing, or other variation) are specified by protocols adopted by 
dialysis clinics.  Surprising variation exists in dosing protocols used in clinical practice with 
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respect to IV iron administration.19-21 For example, one (intense) protocol may specify 100 mg of 
IV iron administered over 10 consecutive dialysis sessions for TSAT <30% and ferritin <1200 
ng/mL while another (conservative) protocol would hold iron for any ferritin >500 ng/mL 
regardless of TSAT.  
Several existing studies consistently demonstrated short-term benefits of bolus iron 
administration on hemoglobin levels and iron status compared to more conservative maintenance 
dosing.6,22 No difference in cardiovascular risks was associated with either dosing approach; 23,24 
however, a modestly increased risk of infection was associated with bolus dosing among patients 
with a history of infection and those with a central venous hemodialysis catheter.24,25 A recent 
observational study has reported association between lower mortality risk and maintenance 
strategy relative to non-maintenance strategies.26    
Compared to short-term effects, less is known about the long-term safety and 
effectiveness of different iron protocols. Clinical trials assessing the long-term use of iron 
administration strategies are lacking; existing large observational studies have focused on the 
effect of cumulative iron exposure over a long period, which were not large enough to resolve 
clinically meaningful effects of iron exposure on infection outcomes.20,27 The cumulative 
exposures do not align well with the treatment decisions that a physician needs to make 
regarding iron use in routine care.28  
Given the growing use of IV iron for anemia management and data suggesting some risk, 
it is of great interest to examine the long-term effectiveness and safety of different IV iron dosing 
protocols and to identify optimal treatment strategies for hemodialysis patients that can 
maximize the known benefits of IV iron, while avoiding its potential risks.  In this study, we 
identified a set of commonly used IV iron administration strategies in a contemporary cohort of 
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hemodialysis patients.  We then compared their effect on risks of mortality and infection-related 
morbidity and mortality.  
 
5.2. Results 
Between 2009 and 2012, 18,697 patients met our study entry criteria (Figure 4.6 & 
Appendix G). Among them, 15,481 (82.8%) patients were matched with at least one IV iron 
administration strategy, and 13,249 (70.9%) patients initiated one of the five most commonly 
used strategies. At strategy initiation, the average age was 76.0 years (standard deviation (SD) 
6.9 years). About half of the cohort were female, and 22.7% were African American. The most 
commonly initiated strategy was strategy 2, and the least commonly initiated strategy was 
strategy 5. Strategies 4 and 5 recommended more aggressive iron therapy in much broader 
ranges of TSAT and ferritin levels. For example, strategy 5 recommended bolus dosing patterns 
(100 mg IV iron sucrose for 10 consecutive dialysis sessions) if TSAT fell below 30% and 
ferritin was not greater than 1200 ng/mL. The strategy recommended half bolus dosing (100 mg 
for 5 consecutive dialysis sessions) if TSAT was between 30-40% and 100 mg weekly if TSAT 
was between 40-50%. The definitions of the administration strategies are listed in Table 5.10. 
Table 5.11 presents patients’ baseline characteristics stratified by strategy. Baseline 
characteristics were similar among initiators of strategies 1, 2, and 3. Compared to these patients, 
initiators of strategies 4 and 5 were more likely to initiate in early years and used a catheter. 
Recent history of infections and comorbidities were more common in strategy 5 initiators, 
including congestive heart failure, ischemic stroke, chronic obstruction pulmonic disease, and 
cancer. Strategy 5 initiators were also more likely to have had a gastrointestinal bleed or received 
blood transfusion during the baseline period. During the last month of baseline period, the 
strategy 5 initiators received higher doses of epoetin and IV iron and spent more days in the 
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hospital. Levels of index TSAT and ferritin tests were also higher among initiators of strategy 5 
compared to other patients.   
During follow-up, patients deviated from their index administration strategy quickly. The 
median time to deviation was shortest in the strategy 5 group and longest in the strategy 2 group 
with 49 days (95% confidence interval (CI): 42, 54 days) and 131 days (95% CI: 126, 147 days), 
respectively. Between 40-80% of patients deviated from their index strategy by the end of 4 
months. Factors that increased probability of deviation included vascular access-related infection 
in the last month of baseline, use of a catheter, higher albumin level, fewer dialysis sessions, and 
higher EPO doses in the previous treatment interval. In contrast, having blood transfusions and 
more days of hospitalization in the previous treatment interval reduced the probability of 
deviation.   
The estimated cumulative incidence differences and their 95% CIs of all-cause mortality 
among strategy groups in the 4 months of treatment are presented in Figure 5.13 and Table 5.12. 
Compared with initiators of strategy 1, initiators of strategies 2 and 3 showed reduced but non-
statistically significant mortality risks; strategy 4 showed increased risks, and the risk differences 
(RD) and 95% CIs at 2 months and 4 months were 0.6% (0.3, 1.1%) and 1.5% (0.1, 3.1%), 
respectively. The highest risks were seen among the strategy 5 group and the RDs at 2 months 
and 4 months were 1.3% (0.8, 2.1%) and 3.1% (1.0, 5.6%), respectively.  
A similar trend was observed for the composite outcome of infection-related 
hospitalization or mortality at 2 months and 4 months (Figure 5.14 and Table 5.12). Compared to 
the strategy 1 group, users of strategy 4 and strategy 5 had increased risks, while strategy 2 and 
strategy 3 users had little difference. At 2 months, RDs for strategy 4 and strategy 5 users were 
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0.8% (0.3, 1.3%) and 1.8% (1.2, 2.6%), respectively. At 4 months, RDs for these two groups 
were 1.7% (0.4, 2.9%) and 4.3 (2.2, 6.8%).  
Appendix H & Appendix I show the estimated cumulative incidence differences and 95% 
CIs of both outcomes among strategy groups in sensitivity analyses. Models with different sets 
of covariates were used to estimate the censoring weights for strategy deviation. Little difference 
was seen among the estimates except the intercept-only model that did not consider any 
covariates.  
 
5.3. Discussion 
In a large contemporary cohort of hemodialysis patients, we compared a set of five 
commonly initiated IV iron administration strategies to assess their risks of mortality and 
infection-related events over 4 months.  Increased risks of these outcomes were observed among 
strategies 4 and 5 that recommended aggressive dosing approaches at higher levels of TSAT and 
ferritin.  Compared with strategy 1, strategy 5 may result in an additional 13 deaths or 18 
infection-related events per 2 months per 1000 patients treated.  Increased risks were also 
observed with strategy 4 but with a slightly smaller magnitude.   
To our knowledge, this study is one of the first to assess the longer-term safety profile of 
IV iron administration strategies that align with clinical practice patterns among hemodialysis 
patients.  In routine care, the treatment decision for IV iron use is dynamic.  Physicians make 
frequent adjustments to treatment based on the evolving clinical characteristics of patients.  
Following the availability of iron status test results, treatment decisions occur, and physicians 
make recommendations on how much iron to provide and how frequent to provide according a 
certain treatment protocol.13-15  We designed our study by mimicking this dynamic treatment 
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decision process in routine care and aligning our exposure assessment with points of possible 
treatment decisions.203  The multidimensional strategies we compared in this study were adopted 
from complex protocols that actually occur in clinical practice.  The comparative analyses of 
these strategies provided evidence that could be directly used to inform clinical decisions.  
Our findings–that more intense strategies were associated with higher risks of infection–
confirm and complement findings from prior studies.  In a large cohort of hemodialysis patients, 
increased risk of infection-related hospitalizations or deaths was observed with more aggressive 
bolus dosing strategy compared with maintenance dosing.25 The bolus dosing was defined as 
having at least two consecutive dialysis sessions of ≥100 mg iron or two or more administrations 
of >100 mg iron with the potential to exceed 600 mg in a month.  Yet, the magnitude of the 
current results were relatively larger.  The observed difference may be due to the difference in 
age and strategy definition.  Our study cohort included hemodialysis patients who were at least 
65 years old at dialysis initiation.  Eligible patients averaged around 76 years old, which was 16 
years older than that of the previous study.  Another recent cohort study also showed higher 
mortality risk associated with non-maintenance strategies of IV iron compared with maintenance 
strategies.26  No direct comparisons could be done for the estimates of effects as their definitions 
of the strategies were substantially different from ours.  They defined maintenance strategy as 
having IV iron in a regular schedule and non-maintenance strategy as having any other iron 
administrations practice.    
Among the commonly used administration strategies, the main difference is the level of 
ferritin at which iron treatment needs to be held. Among strategies 1-3, the TSAT levels 
indicating a particular dosage pattern were the same, but the ferritin levels for stopping iron 
decreased from 1200 ng/mL in strategy 1 to 500 ng/mL in strategy 3. Although not statistically 
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significant, the risks for all-cause mortality were modestly lower associated with strategies 2 and 
3 that had lower stopping ferritin levels compared with strategy 1. The findings suggest that 
aggressive iron treatment with high ferritin level could have contributed to the increased risk. 
Compared with the first three strategies, strategies 4 and 5 made more intensive treatment 
recommendations. The TSAT levels for indicating a particular dosage pattern are much higher 
with these two strategies. For example, both strategies recommended bolus dosing when TSAT 
<30% while the other strategies would not recommend bolus dosing until TSAT <20%. In 
addition, the ferritin levels for holding iron were >1200 ng/mL, and the dosage pattern at high 
ferritin levels were either bolus in strategy 5 or at least half bolus in strategy 4. Increased risks of 
both mortality and infection-related events associated with these two strategies could potentially 
be explained by the aggressive treatment at high levels of ferritin. These results suggest that level 
of ferritin should be routinely evaluated in determining iron administration, calling into question 
the common practice of checking ferritin every 3 months rather than monthly.    
Our analyses were subject to possible bias from unmeasured confounding or residual 
selection bias. Residual confounding bias would occur if unknown confounders for strategy 
initiation and outcomes were not included in the treatment model for estimation of standardized 
mortality ratio (SMR) weights. Residual confounding could also occur if initiators of more 
aggressive strategies were inherently different from initiators of other strategies and they were 
treated more aggressively for a reason. We did not have access to individual’s indication for the 
use of a certain dosage approach. If the indication were a risk factor for the outcome, then the 
observed effect would be subject to bias. Residual selection bias would occur if there were 
unmeasured risk factors for both strategy deviation and adverse outcomes. The clinical research 
database and the USRDS database contain rich, frequently measured clinical, laboratory, 
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treatment, and demographic variables. We examined the impact of different sets of covariates on 
the estimated effects in sensitivity analyses. The results were robust to changes in the models, 
suggesting the possibility that the association between strategy deviation and the outcomes 
studied may not be strongly confounded by the measured covariates. However, there might exist 
some unmeasured variables for deviation adjustment of which would potentially attenuate the 
effect estimates.     
In conclusion, administration strategies that recommended more aggressive treatment at 
higher levels of ferritin and TSAT were associated with increased risks of all-cause mortality and 
infection-related hospitalization or mortality. Our findings suggest iron may need to be used 
more sparingly in patients with elevated ferritin levels, but further exploration is needed to assess 
the extent of potential residual confounding and selection bias.   
 
5.4. Concise Methods 
Data sources  
We constructed our study cohort using data derived from the clinical research database of 
a large dialysis provider in the United States, linked with the United States Renal Data System 
(USRDS) (2009-2012). We obtained detailed clinical information regarding patients’ dialysis 
treatments, vascular access, routine laboratory tests, IV medications, and anemia management 
using the clinical research database. We obtained information regarding their demographic 
characteristics, comorbidities, healthcare system encounters, and outcomes of interest including 
death from the USRDS. The study was approved by the University of North Carolina at Chapel 
Hill Institutional Review Board, Chapel Hill, North Carolina, USA.  
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Study design and study population 
Detailed methods for cohort construction have been described elsewhere (Chapter 4). 
Briefly, we used a retrospective cohort design with the index date for IV iron administration 
strategy defined as the first time a TSAT test result became available within 90-136 days after 
dialysis initiation. The TSAT measurement on the index date was defined as the index TSAT. 
We used the 14-day window following the index TSAT as the index strategy assessment window 
to assess the IV iron administration strategy a patient was initiated on. We defined the baseline 
period as the period starting 90 days prior to dialysis initiation and ending on the day before the 
index date. Eligible patients were followed for outcomes of interest starting on day 15 following 
the index strategy assessment window (Figure 4.6).   
 Our study population comprised outpatient hemodialysis patients who initiated in-center 
hemodialysis between 1 January, 2009 and 16 September, 2012.  We included patients who had 
Medicare as their primary insurer, continued hemodialysis for at least 90 days, and had complete 
information on baseline covariates. To ensure patients were receiving regular in-center 
hemodialysis and anemia management, we excluded patients who had fewer than nine dialysis 
sessions in the last month of baseline period or no TSAT measurement during the 136 days 
following dialysis initiation. We also excluded patients if they had polycystic kidney disease 
because their administration strategies of IV iron could differ. The cohort construction is outlined 
in Appendix G.    
IV iron administration strategies  
 We identified the IV iron administration strategies initiated by eligible patients in the 
index assessment window using an approach outlined in Chapter 4. As the set of commonly used 
strategies were not known a priori, this identification approach matched a patient’s treatment 
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pattern in the 14-day assessment window and current laboratory test values with candidate 
strategies by consistency. The length of assessment window was chosen so that it maximized the 
representativeness of treatment experience in the assessment window for the treatment 
experience in the entire treatment course while minimizing the days required for the assessment 
window to maximize follow-up time for outcomes. Each candidate strategy consisted of a set of 
decision rules that specified a range of acceptable iron therapy values (including dosage and 
frequency) during a treatment course given a patient’s current laboratory test values.  
To evaluate the effect of long-term exposure, we assessed whether a patient deviated 
from her index strategy during follow-up. We discretized the observation of an individual into 
intervals anchored by dates of TSAT laboratory tests. At each measurement of TSAT, we 
evaluated the treatment pattern in the 14-day assessment window, updated iron status laboratory 
test values against the index strategy for consistency and censored patients for deviation if they 
were not consistent. The date of deviation was the end of the 14-day assessment window when 
the individual first deviated from the index strategy. Patients were not censored for deviation if 
insufficient information was available for exposure assessment in the assessment window (e.g., 
the gap between two consecutive TSAT tests was shorter than 14 days, or the patient was 
hospitalized or had active infection in the assessment period, during which the anemia 
management strategy was unknown). Potential bias introduced by this artificial censoring was 
adjusted for by inverse-probability censoring weighting as described in the statistical analysis 
section below.  
Outcomes 
Two adverse outcomes were examined: all-cause mortality and a composite outcome of 
infection-related hospitalization or death. These events were identified using the Medicare 
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inpatient and outpatient claims and death notification data. For analyses of all-cause mortality, 
patients were followed up until death, receipt of kidney transplantation, the time of switching 
modality, loss to follow-up, disenrollment from the dialysis provider, loss of Medicare coverage, 
120 days after the index exposure window, or the administrative end of follow-up (December 31, 
2012). For analyses of infection-related events, patients were followed up until death attributed 
to reasons other than infection. For both analyses, patients were also censored by deviation from 
index strategy. Infection-related hospitalization included sepsis, vascular access infection, or 
pneumonia. The detailed definitions for the outcomes are listed in Table 3.6. 
Covariates 
We evaluated both baseline and time-varying covariates using Medicare claims and the 
clinical research database. Baseline covariates included demographic characteristics (e.g. age, 
sex, race, region of residence, year of strategy initiation), clinical characteristics (e.g., cause of 
ESRD, body mass index), and a list of comorbidities. Time-varying covariates included time-
varying laboratory values (TSAT, ferritin, hemoglobin, albumin, creatinine), clinical 
characteristics (e.g., type of vascular access, number of dialysis sessions, median post-treatment 
systolic blood pressure), and comorbidity measures (e.g., days of hospitalization, receipt of blood 
transfusion). Comorbidities were assessed using definitions consisting of International 
Classification of Disease, Ninth Revision diagnosis codes (Table 3.7). 
Statistical analysis 
We compared different IV iron administration strategies with respect to risk of all-cause 
mortality and risk of infection-related hospitalization or mortality using inverse probability of 
weighted estimation of Cox marginal structural models.172 We chose one frequently used 
strategy as the referent strategy. Standardized mortality ratio weighting was used to adjust for 
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potential baseline confounders. Inverse probability of censoring weighting was used to adjust for 
potential selection bias introduced by artificially censoring patients who deviated from index 
administrations strategy. Variables included in the censoring model included time-dependent 
prognostic factors both for outcomes of interest and for censoring (lengths of hospital stay, total 
Epoetin doses received, number of dialysis sessions, type of vascular access, current iron status 
tests in the treatment course before deviation, and etc), and time-independent factors (gender, 
cause of ESRD, comorbidities, and etc). We estimated the cumulative incidence differences 
between each strategy and the referent strategy during the follow-up period. The 95% confidence 
intervals (CI) for cumulative incidence differences were estimated using a non-parametric 
bootstrap procedure with 200 repetitions. We conducted sensitivity analyses by using different 
covariates for censoring weighting estimation. We also conducted three additional analyses to 
estimate different effects of administration strategy exposure. Detailed methods and results are 
described in Supplemental Material. All statistical analyses were conducted using the R 
Statistical Software version 3.3.1 (R Foundation for Statistical Computing, Vienna, Austria) and 
SAS version 9.4 (SAS Institute Inc., Cary, North Carolina, USA). 
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5.5. Detailed Methods 
Data sources  
We constructed our study cohort using data derived from the clinical research database of 
a large dialysis provider in the United States, linked with the United States Renal Data System 
(USRDS) (2009-2012). With over 2,042 dialysis centers located throughout the country, this 
dialysis provider manages services to approximately one third of all Americans with ESRD 
receiving dialysis. We obtained detailed clinical information regarding patients’ dialysis 
treatments, vascular access, routine laboratory tests, IV medications, and anemia management 
using the clinical research database. We obtained information regarding their demographic 
characteristics, comorbidities, healthcare system encounters, and outcomes of interest including 
death from the USRDS. The study was approved by the University of North Carolina at Chapel 
Hill Institutional Review Board, Chapel Hill, North Carolina, USA.  
Study design and study population 
Detailed methods for cohort construction have been described elsewhere (Chapter 4). 
Briefly, we used a retrospective cohort design with the index date for IV iron administration 
strategy defined as the first time a TSAT test result became available within 90-136 days after 
dialysis initiation. The TSAT measurement on the index date was defined as the index TSAT. 
We used the 14-day window following the index TSAT as the index strategy assessment window 
to assess the IV iron administration strategy a patient was initiated on. We defined the baseline 
period as the period starting 90 days prior to dialysis initiation and ending on the day before the 
index date. Eligible patients were followed for outcomes of interest starting on day 15 following 
the index strategy assessment window (Figure 4.6).   
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 Our study population comprised outpatient hemodialysis patients who initiated in-center 
hemodialysis between 1 January, 2009 and 16 September, 2012. We included patients who had 
Medicare as their primary insurer, continued hemodialysis for at least 90 days, and had complete 
information on baseline covariates. To ensure patients were receiving regular in-center 
hemodialysis and anemia management, we excluded patients who had fewer than nine dialysis 
sessions in the last month of baseline period or no TSAT measurement during the 136 days 
following dialysis initiation. We also excluded patients if they had polycystic kidney disease 
because their administration strategies of IV iron could differ. The cohort construction is outlined 
in Appendix G.    
IV iron administration strategies  
 We identified the IV iron administration strategies initiated by eligible patients in the 
index assessment window using an approach outlined in (Li unpublished). As the set of 
commonly used strategies were not known a priori, this identification approach matched a 
patient’s treatment pattern in the 14-day assessment window and current laboratory test values 
with candidate strategies by consistency. The length of assessment window was chosen so that it 
maximized the representativeness of treatment experience in the assessment window for the 
treatment experience in the entire treatment course while minimizing the days required for the 
assessment window to maximize follow-up time for outcomes. Each candidate strategy consisted 
of a set of decision rules that specified a range of acceptable iron therapy values (including 
dosage and frequency) during a treatment course given a patient’s current laboratory test values.  
To evaluate the effect of long-term exposure, we assessed whether a patient deviated 
from her index strategy during follow-up. We discretized the observation of an individual into 
intervals anchored by dates of TSAT laboratory tests. At each measurement of TSAT, we 
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evaluated the treatment pattern in the 14-day assessment window and updated iron status 
laboratory test values against the index strategy for consistency and censored patients for 
deviation if they were not consistent. The date of deviation was the end of the 14-day assessment 
window when the individual first deviated from the index strategy. Patients were not censored 
for deviation if insufficient information was available for exposure assessment in the assessment 
window (e.g., the gap between two consecutive TSAT tests was shorter than 14 days, or the 
patient was hospitalized or had active infection in the assessment period, during which the 
anemia management strategy was unknown). Potential selection bias introduced by this artificial 
censoring was adjusted for by inverse-probability censoring weighting as described in the 
statistical analysis section below.  
Outcomes 
Two adverse outcomes were examined: all-cause mortality and a composite outcome of 
infection-related hospitalization or death. These events were identified using the Medicare 
inpatient and outpatient claims and death notification data. For analyses of all-cause mortality, 
patients were followed up until death, receipt of kidney transplantation, the time of switching 
modality, loss to follow-up, disenrollment from this dialysis privder, loss of Medicare coverage, 
120 days after the index exposure window, or the administrative end of follow-up (December 31, 
2012). For analyses of infection-related events, patients were followed up until death attributed 
to reasons other than infection. For both analyses, patients were also censored by deviation from 
index strategy. Infection-related hospitalization included sepsis, vascular access infection, or 
pneumonia. The detailed definitions for the outcomes are listed in Table 3.6. 
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Covariates 
We evaluated both baseline and time-varying covariates using Medicare claims and the 
clinical research database. Baseline covariates included demographic characteristics (e.g. age, 
sex, race, region of residence, year of strategy initiation), clinical characteristics (e.g., cause of 
ESRD, body mass index), and a list of comorbidities. Time-varying covariates included time-
varying laboratory values (TSAT, ferritin, hemoglobin, albumin, creatinine), clinical 
characteristics (e.g., type of vascular access, number of dialysis sessions, median post-treatment 
systolic blood pressure), and comorbidity measures (e.g., days of hospitalization, receipt of blood 
transfusion). Comorbidities were assessed using definitions consisting of International 
Classification of Disease, Ninth Revision diagnosis codes (Table 3.7). 
Statistical analysis 
We compared different IV iron administration strategies with respect to risk of all-cause 
mortality and risk of infection-related hospitalization or mortality using inverse probability of 
weighted estimation of Cox marginal structural models. We chose one frequently used strategy 
as the referent strategy.  
Four main analyses were carried out. We first estimated an unadjusted analysis. Similar 
to an intention-to-treat analysis, this estimate ignored any treatment changes occurred during 
follow up and estimated the effect of initiating one administration strategy versus the referent 
strategy on outcomes of interest. No adjustment was done for baseline confounding between 
initiation of strategies.  
The second analysis estimated the effect of continuous treatment by artificially censoring 
patients for strategy deviation. No adjustment was done to adjust for potential selection bias 
arising from such censoring. No adjustment was done for baseline confounding control either. 
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 The third analysis used standardized mortality ratio (SMR) weights at the index date to 
adjust for baseline confounding. This analysis used the same structure as the analysis by 
censoring patients when they deviated from index strategy. No adjustment was done for the 
potential selection bias introduced by artificial censoring. 
The final analysis compared the effect of continuing a strategy on each outcome of 
interest adjusted for informative censoring due to regimen non-adherence using a product of  
SMR weights (𝑆𝑊𝑖
𝑇) for baseline confounding control and inverse probability of censoring 
weights (IPCW) for deviation (𝑆𝑊𝑖𝑗
𝐷) for selection bias. 
During the index assessment window, a patient’s treatment experience might be 
consistent with multiple administration strategies. We created k copies of the same patient for k 
strategies she was consistent with initially. Within each strategy group, the copy of the patient 
was followed up until she deviated from the respective index strategy.  As described previously, 
patients who deviated from index administrations strategy were artificially censored at the end of 
14-day assessment window. The remaining patients were weighted by the probability that they 
stayed on the index strategy to estimate the risks of all-cause mortality and infection-related 
hospitalization or mortality. These patients were also censored for reasons other than deviation as 
described previously, but the cohorts were not reweighted to account for possible dependent 
censoring related to these additional events.   
We fit censoring model to each strategy group separately to allow for different 
mechanisms that might have contributed to each strategy group. For each interval anchored by 
TSAT measurements, we estimated the probability of deviation given potential covariates 
associated with both deviation and outcomes using a Cox proportional hazards model. These 
covariates included baseline covariates and the most recent time-varying covariates in the 
99 
 
interval prior to the 14-day assessment window in which deviation was thought to have occurred. 
Patients who experienced outcomes of interest were weighted inversely using the probability that 
the failure time was observed to account for potential informative censoring due to deviation. 
We first estimated the cumulative incidence of adverse outcomes in initiators of each 
administration strategy separately. We then estimated the cumulative incidence differences 
between each strategy and the referent strategy during the follow-up period. The 95% confidence 
intervals (CI) for cumulative incidence differences were estimated using a non-parametric 
bootstrap procedure with 200 repetitions. We conducted sensitivity analyses by using different 
covariates for censoring weighting estimation. All statistical analyses were conducted using the 
R Statistical Software version 3.3.1 (R Foundation for Statistical Computing, Vienna, Austria) 
and SAS version 9.4 (SAS Institute Inc., Cary, North Carolina, USA).
 Table 5.10. Definitions of IV iron administration strategies 
A. Strategies without hemoglobin restriction B. Dose pattern definition
Strategy 1
<200 >1200 2-Week Monthly equivalence
<20 B N Bolus (B) >500 100 mg × 10 consecutive sessions
20-50 M N Half bolus (HB) 201-500 100 mg × 5 consecutive sessions
>50 N N Maintenance (M) 101-200 100 mg weekly
Low maintenance (LM) 1-100 25 or 50 mg weekly
Strategy 2 None (N) 0 0 mg
<200 >800
<20 B N
20-50 M N
>50 N N
Strategy 3
<200 >500
<20 B N
20-50 M N
>50 N N
Strategy 4
800-1200 >1200
<30 HB N
30-50 LM N
>50 N N
Strategy 5
≥1200
<30 N
30-40 N
41-49 N
≥50 N
Note:TSAT = transferrin saturation; Hgb = hemoglobin 
Dose Pattern
Iron Dosage Level
T
S
A
T
, 
%
B
HB
M
N
Ferritin, ng/mL
<1200
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A
T
, 
% B
LM
N
Ferritin, ng/mL
<800
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S
A
T
, 
% LM
LM
N
Ferritin, ng/mL
200-500
T
S
A
T
, 
% LM
LM
N
Ferritin, ng/mL
200-1200
Ferritin, ng/mL
200-800
T
S
A
T
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% LM
LM
N
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Table 5.11. Baseline characteristics of hemodialysis patients by initiated IV iron administration strategy, 2009-2012 
Characteristics  Overall Strategy 1 Strategy 2 Strategy 3 Strategy 4 Strategy 5 
N 13,249 10,882 11,293 10,397 8,089 6,305 
  Age, Mean (SD) 75.97 (6.92) 75.91 (6.94) 75.95 (6.94) 75.92 (6.93) 75.94 (6.95) 75.89 (6.97) 
Female, % 49.4 49.4 49.5 49.3 48.9 49.4 
Race, %             
Black 22.7 22.4 22.5 22.2 21.9 22.5 
White 72.0 72.5 72.3 72.6 73.1 72.8 
Other 5.3 5.1 5.2 5.2 5.0 4.7 
Medicaid, % 29.3 29.3 29.3 29.2 29.3 29.8 
Lower income subsidy, % 34.4 34.5 34.5 34.4 34.8 35.2 
Region, %             
Midwest 23.0 23.3 23.3 23.5 23.0 23.1 
Northeast 14.0 14.0 13.7 13.8 13.8 13.5 
Other 0.0 0.0 0.0 0.0 0.0 0.0 
South 42.1 41.3 41.5 41.8 42.7 43.3 
West 21.0 21.3 21.5 20.9 20.4 20.0 
Cause of ESRD, %             
Diabetes 44.7 45.0 44.7 45.0 44.5 43.9 
   Glomerulonephritis 5.1 4.9 4.9 4.9 5.1 5.0 
Hypertension 36.3 36.1 36.2 35.7 36.3 35.9 
Missing 0.3 0.4 0.4 0.4 0.4 0.4 
Other 13.5 13.6 13.8 14.0 13.8 14.8 
Index year, %             
2009 25.0 23.1 23.6 25.2 26.9 28.6 
2010 24.8 23.0 23.5 25.4 26.3 28.1 
2011 25.5 27.3 27.1 26.0 24.1 22.4 
2012 24.7 26.5 25.8 23.4 22.8 20.9 
Comorbidities, %             
Vascular access infectiona 1.1 1.2 1.2 1.3 1.6 2.0 
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Pneumoniaa 2.2 2.4 2.3 2.4 2.7 3.3 
Sepsisa 2.3 2.5 2.5 2.6 3.1 3.8 
Infection (ADR definition)a 3.6 4.0 3.9 4.1 4.9 6.0 
Antibiotic usea 19.5 21.1 20.7 21.2 23.9 27.6 
IV antibiotics (dialysis center)a 11.1 12.1 11.9 12.5 14.4 17.3 
Infection (broad definition)a 24.3 26.1 25.7 26.3 29.4 34.1 
Diabetes 69.3 69.6 69.4 69.6 69.3 69.8 
Hypertensive disease 95.6 95.3 95.4 95.8 96.2 96.6 
Congestive heart failure 62.4 62.5 62.7 63.4 64.0 66.3 
Myocardial infarction, acute 9.7 9.6 9.7 9.9 9.6 9.8 
Angina 6.9 6.9 7.0 7.1 6.9 7.2 
Coronary artery disease/atherosclerosis 56.1 56.3 56.3 56.9 57.5 59.1 
Ischemic stroke 7.5 7.7 7.7 7.7 7.9 8.6 
Intracerebral hemorrhage 0.3 0.3 0.3 0.3 0.3 0.3 
Subarachnoid hemorrhage 0.1 0.1 0.1 0.1 0.1 0.1 
Hemorrhagic stroke 0.7 0.7 0.7 0.7 0.8 0.8 
Cerebrovascular disease 23.8 24.1 24.1 24.2 24.4 25.4 
Chronic obstructive pulmonary disease & 
asthma 33.0 33.4 33.4 33.9 34.5 36.2 
Hyperlipidemia 60.5 60.5 60.4 60.6 60.5 60.3 
Cancer 21.4 21.6 21.7 21.7 22.2 23.2 
Liver disease 4.2 4.2 4.2 4.3 4.4 4.8 
GI bleeding & ulcer 2.7 2.8 2.8 2.8 3.1 3.4 
Blood transfusion 36.2 36.1 36.4 37.1 38.0 40.5 
Blood loss anemia 5.2 5.1 5.2 5.3 5.6 5.8 
Peripheral vascular disease 26.4 26.7 26.5 27.0 27.0 28.1 
Rheumatic heart disease 6.1 6.1 6.1 6.1 6.3 6.7 
Psychiatric disorder 5.9 6.0 6.0 6.0 6.0 6.7 
Substance abuse 6.3 6.5 6.4 6.5 6.8 7.1 
Autoimmune disorder 4.8 4.8 4.8 4.7 4.9 4.9 
Other neurological disorders 13.5 13.7 13.7 14.3 14.6 16.1 
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Hyperparathyroidism 3.7 3.7 3.6 3.6 3.8 3.7 
Chronic heart disease procedures 5.5 5.5 5.6 5.7 5.5 5.9 
Rheumatoid arthritis 2.8 2.7 2.7 2.7 2.7 2.8 
Neuropathy 20.8 21.3 21.2 21.4 21.4 21.7 
Osteoarthritis 19.8 20.2 20.2 19.9 20.1 20.6 
Osteoporosis 4.6 4.6 4.7 4.6 4.6 4.6 
History of fall 5.5 5.5 5.5 5.5 5.7 5.9 
Last month of baseline period, Mean (SD)b            
Total EPO dose, 1000 units/month 68.46 (73.30) 68.26 (73.02) 68.22 (72.91) 70.65 (74.57) 72.99 (79.39) 83.32 (83.03) 
Total iron dose, mg 299.04 (310.93) 292.50 (295.98) 287.87 (299.13) 289.11 (307.68) 310.18 (321.75) 334.24 (342.57) 
TSAT, % 24.99 (12.41) 24.90 (12.34) 25.02 (12.50) 25.06 (12.72) 25.48 (13.26) 24.67 (13.75) 
Ferritin, ng/mL 489.93 (435.28) 470.50 (437.11) 486.75 (445.72) 484.10 (462.63) 487.68 (481.96) 510.90 (525.13) 
Hemoglobin, g/dL 11.47 (1.43) 11.43 (1.42) 11.45 (1.43) 11.47 (1.45) 11.49 (1.49) 11.38 (1.53) 
Albumin, g/dL 3.57 (0.45) 3.57 (0.46) 3.57 (0.46) 3.57 (0.46) 3.55 (0.47) 3.51 (0.47) 
Creatinine, mg/dL 5.07 (1.91) 5.07 (1.91) 5.07 (1.90) 5.06 (1.91) 5.06 (1.92) 5.01 (1.94) 
Pre-treatment SBP, mmHg 143.03 (22.15) 142.87 (22.08) 142.84 (22.16) 142.90 (22.26) 142.41 (22.13) 141.87 (22.40) 
Post-treatment weight, kg 74.40 (18.49) 74.66 (18.65) 74.49 (18.63) 74.60 (18.72) 74.52 (18.61) 74.39 (18.76) 
Hospital days 0.71 (1.97) 0.75 (2.03) 0.74 (2.02) 0.77 (2.06) 0.87 (2.18) 1.03 (2.34) 
Number of transfusions 0.03 (0.20) 0.03 (0.22) 0.03 (0.21) 0.03 (0.22) 0.04 (0.25) 0.05 (0.27) 
Access, %             
   Catheter 62.8 63.4 63.7 64.7 65.9 70.1 
   Fistula 26.6 26.1 25.9 24.9 24.1 20.7 
   Graft 10.6 10.4 10.5 10.4 10 9.2 
Index date, Mean (SD)c            
Index TSAT, % 28.43 (13.90) 28.56 (14.48) 28.58 (14.37) 28.69 (14.74) 30.65 (16.11) 29.12 (17.74) 
Index Ferritin, ng/mL 546.02 (463.50) 526.22 (488.18) 542.53 (486.91) 535.54 (506.28) 559.52 (548.57) 583.85 (607.72) 
Index Hemoglobin, g/dL 11.57 (1.31) 11.52 (1.30) 11.54 (1.30) 11.58 (1.32) 11.55 (1.36) 11.51 (1.42) 
Index Albumin, g/dL 3.61 (0.45) 3.60 (0.46) 3.60 (0.45) 3.60 (0.46) 3.57 (0.47) 3.53 (0.47) 
Index Creatine, mg/dL 5.24 (1.98) 5.24 (1.99) 5.24 (1.98) 5.23 (1.98) 5.23 (2.01) 5.18 (2.01) 
SD=Standard deviation; IQR=interquartile range; ESRD=end stage renal disease; ADR=annual data report; TSAT=transferrin saturation; EPO=Epoetin 
aPrevalence during the last month of baseline period; 
bIf laboratory tests in the last month of baseline were missing, the previous test values were used; 
cIf a laboratory test was missing on index date, the last non-missing test values were used. 
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Table 5.12. Adjusted cumulative incidence differences and 95% confidence intervals at 2 months 
and 4 months 
Strategy 
  Death 
Infection-related hospitalization 
or death 
Total 2-month 4-month 2-month 4-month 
1   10,882  referent referent referent referent 
2 11,293 -0.2 (-0.4, 0.0) -0.7 (-1.2, 0.0) 0.1 (-0.1, 0.3) -0.2 (-0.5, 0.3) 
3 10,397 -0.1 (-0.4, 0.2) -0.6 (-1.6, 0.7) 0.2 (-0.1, 0.5) 0.2 (-0.6, 1.0) 
4 8,089 0.6 (0.3. 1.1) 1.5 (0.1, 3.1) 0.8 (0.3. 1.3) 1.7 (0.4, 2.9) 
5 6,305 1.3 (0.8, 2.1) 3.1 (1.0, 5.6) 1.8 (1.2, 2.6) 4.3 (2.2, 6.8) 
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Figure 5.12. Study design for assessing the effect of initiating and staying on a particular IV iron 
administration strategy  
Patients are followed starting on the end of the 1st 14-day iron exposure window for all-cause 
mortality. Those deviated from the index strategy are artificially censored.  
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Figure 5.13. Estimated 4-month cumulative incidence differences and 95% confidence intervals 
of mortality, 2009-2012  
The observed cumulative incidence difference represents elevated risks of all-cause mortality 
comparing new users of an IV iron administration strategy with that of strategy 1.  
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Figure 5.14. Estimated 4-month cumulative incidence differences and 95% confidence intervals 
of infection-related hospitalization or mortality, 2009-2012  
Users of IV iron administration strategy 1 were used as the referent group.  
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CHAPTER 6: DISCUSSION 
6.1. Summary of Findings 
The primary objective of this first specific aim was to develop an approach to 
systematically identify dynamic treatment regimes in secondary databases for comparative 
effectiveness and safety studies when a priori regimes are not available. We developed an 
approach that identifies regimes using treatment experience in an assessment window and current 
laboratory tests at a point of treatment decision. Candidate regimes under consideration were 
assigned to a patient if they were consistent with treatment experience in the assessment window. 
We exploited data visualization of patient-level data to inform regime construction and 
identification. We applied this identification process in an empirical example of IV iron dosing 
protocols for anemia management in hemodialysis patients, using measurements of iron status 
tests and iron treatment experience in a two-week assessment window. Among 43,166 patients 
initiated hemodialysis in 2004-2012, 79.1% of them were matched with candidate protocols. The 
prevalence of protocol matches increased from 75.0% in 2004 to 90.7% in 2012. Due to the 
unavailability of exact protocols that were used, we could not evaluate the performance of the 
identification approach; however, higher prevalence of knowingly implemented protocols 
confirmed the performance of this identification approach. 
The primary objective of the second specific aim was to evaluate the comparative safety 
of continuous exposure to different commonly used IV iron treatment protocols.  We estimated 
the effect of continuous exposure to the five most commonly initiated protocols in 2009-2012 on 
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risks of mortality and infection-related events. Two less commonly initiated protocols were more 
aggressive, recommending a large amount of iron at higher iron status levels; their initiators were 
sicker at baseline. Compared with the protocol that recommended less intensive treatment at 
lower ferritin levels, protocols that indicated a large amount of iron at higher levels of iron status 
tests were at elevated risk of all-cause mortality. We observed similar trends in elevated risks for 
a composite outcome of infection-related hospitalization and death among more aggressive 
protocols. Protocols that recommend less intensive use of iron at high levels of ferritin and TSAT 
may lower risks of mortality and infection-related events, but further exploration is needed to 
address potential residual confounding and selection bias.  
 
6.2. Public Health Implications 
This dissertation project aimed to find evidence to inform IV iron use for anemia 
management in ESRD patients maintained on hemodialysis. The important question regarding IV 
iron is not whether we should use IV iron. Data have consistently shown the benefit of IV iron 
use relative to no use.5,6 Instead, the important question is on how best to provide IV iron, and 
identifying optimal management strategies is essential. Our study is one of the first to assess 
longer-term safety of commonly used IV iron administration protocols. We used a study design 
that mimics the dynamic treatment decision regarding IV iron use in routine care and compared 
multidimensional protocols that commonly used in clinical practice. Doing so, we were able to 
obtain clinically-relevant evidence that could be directly used to inform clinical decisions. 
We observed that certain protocols that recommend aggressive use of iron at high iron 
status levels were at elevated risk of adverse outcomes in the longer term. This finding suggests 
that thorough examination is needed on the initiating levels of iron status tests for various iron 
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dosing approaches, which is urgently important in current practice with increasing reliance on IV 
iron. In the U.S, there were more than 468,000 hemodialysis patients, and 69% of more than 
hemodialysis patients were receiving IV iron in April 2014.204 Inappropriate IV iron treatment 
could potentially cause harm to a large number of patients.  
 
6.3. Future Research 
In the second aim, our analyses suggested that protocols that recommend intensive iron 
therapy at high levels of iron status tests are associated with elevated risks of infection-related 
outcomes, compared to protocols that recommend less intensive strategies. The differences in the 
baseline clinical characteristics among their initiators, however, casts some doubt on potential 
residual confounding bias and selection bias. Although the differences in distributions of 
observed covariates diminished after adjustment with SMR weighting, it is possible that we did 
not have access to some important risk factors for the outcome that also had contributed to the 
initiation of these aggressive protocols. Further investigation should examine the extent of 
potential unmeasured confounding and selection bias.   
As a leading cause of death for ESRD patients, cardiovascular outcomes are another big 
concern. Prior studies have not established a difference in cardiovascular risks between 
maintenance and bolus dosing administration, but they remain a constant concern. We observed 
elevated risks of infection-related outcomes in protocols that recommend intensive iron therapy 
at high levels of iron status tests. It would be important to examine the effect of these protocols 
on risks of cardiovascular outcomes.  
Within these two aims, we set up a working framework to compare the safety of dynamic 
treatment regimes using complex longitudinal data using causal inference methods. In the first 
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aim, we developed an approach to identify commonly used regimes. In the second aim, we 
established the longitudinal treatment decision design for evaluation of comparative safety of the 
regimes. This framework could be easily generalized to assess the comparative effectiveness of 
the regimes. For this example of IV iron in hemodialysis patients, it is equally important to know 
which protocols can achieve better anemia management goals including hemoglobin response 
and ESA dose requirement reduction. More aggressive IV iron treatment protocols may lead to 
better anemia response.  
This study identified a number of commonly used dosing protocols. Pragmatic trials 
could be carried out within dialysis clinics to directly compare these protocols and evaluate their 
real-world effectiveness and safety. 
 
6.4. Conclusions 
Starting around 2009, more and more IV iron treatment patterns in ESRD patients on 
hemodialysis were matched with IV iron dosing protocols. These dosing protocols differed in IV 
iron administration approaches and their corresponding levels of iron status tests. Protocols that 
recommend less intensive use of iron at high levels of iron status tests may lower risks of 
mortality and infection-related events, but further exploration is needed to address potential 
residual confounding and selection bias.  
Increasingly available large healthcare databases containing rich, granular patient-level 
information can make estimation of effect of dynamic treatment regimes more feasible.  With 
appropriate study design and statistical methods, we can compare the regimes in comparative 
effectiveness and safety research to provide evidence to assist decision-making in clinical 
practice. 
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APPENDIX A: FLOW DIAGRAM OF STUDY POPULATION FOR CHAPTER 4 
Figure A.1: Flow diagram of study population for Chapter 4  
 
 
 
 
 
 
 
Excluded if no TSAT in last 90 days of 
baseline period (N= 12,427); 
No pre-dialysis claims or insufficient claims 
in last 90 days of baseline (N= 3,565); 
<9 dialysis sessions in last 30 days of 
baseline period (N= 5,749) 
 
Excluded if polycystic kidney disease     
(N= 469) 
Excluded if no TSAT after 90 days on 
dialysis/no index TSAT (N= 47,523); 
Not on Medicare Parts A & B for entire 
baseline period (N= 47,447); 
Not on hemodialysis for last 90 days of 
baseline period (N= 8,246) 
 
    Patients aged 65 or older with their 
first ESRD service date between 
01/01/2004 and 09/02/2012 
       N= 172,719 
    Patients with center-based hemodialysis 
patients receiving anemia management 
       N= 47,293 
Final eligible patients 
N= 43,166 
Excluded if index TSAT occurred after 136 
days since first dialysis date (N= 4,046) 
Excluded if no follow up days (N= 81) 
113 
 
APPENDIX B: IV IRON DOSING PROTOCOL EXAMPLE 
Figure B.1: Example intravenous iron dosing strategy for end-stage renal failure patients on 
chronic hemodialysis 
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APPENDIX C: DEFINITIONS OF CANDIDATE ADMINISTRATION STRATEGIES  
A. Strategies without hemoglobin restriction B. Strategies with hemoglobin restriction
Strategy 1 Strategy 1 If hgb > 13 g/dL then N; else do:
<200 >1200 <200 >1200
<20 B N <20 B N
20-50 M N 20-50 M N
>50 N N >50 N N
Strategy 2 Strategy 2 If hgb > 13 g/dL then N; else do:
<200 >800 <200 >800
<20 B N <20 B N
20-50 M N 20-50 M N
>50 N N >50 N N
Strategy 3 Strategy 3 If hgb > 13 g/dL then N; else do:
<200 >500 <200 >500
<20 B N <20 B N
20-50 M N 20-50 M N
>50 N N >50 N N
Strategy 4 Strategy 4 If hgb > 13 g/dL then N; else do:
800-1200 >1200 800-1200 >1200
<30 HB N <30 HB N
30-50 LM N 30-50 LM N
>50 N N >50 N N
Strategy 5 Strategy 5 If hgb > 13 g/dL then N; else do:
≥1200 ≥1200
<30 N <30 N
30-40 N 30-40 N
41-49 N 41-50 N
>=50 N >50 N
Strategy 6 Strategy 6 If hgb > 13 g/dL then N; else do:
<200 200-<800 800-<1200 ≥1200 <200 200-<800 800-1200 >1200
<20 B B HB N <20 B B HB N
20-29 B HB M N 20-30 B HB M N
30-39 HB M LM N 30-40 HB M LM N
40-49 M M LM N 40-50 M M LM N
>=50 N N N N >50 N N N N
Strategy 7 Strategy 7 If hgb > 13 g/dL then N; else do:
≥1200 ≥1200
<20 N <20 N
20-40 N 20-40 N
41-49 N 40<-50 N
>=50 N >50 N
Strategy 8 Strategy 8 If hgb > 13 g/dL then N; else do:
≥1200 ≥1200
<20 N <20 N
20-40 N 20-40 N
41-49 N 40<-50 N
>=50 N >50 N
T
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 APPENDIX D: PATIENT JOURNEY – A VISUALIZATION TOOL 
Figure D.1: Patient journey, a data visualization tool that depicts the patient journey with treatment and her clinical condition 
evolution across time using two panels. The top panel illustrated the changes in anemia management parameters, while the bottom 
panel presents the IV iron dosage level received at each dialysis session, healthcare system encounters and outcome information. 
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 APPENDIX E: DISTRIBUTION OF IRON DOSAGE PATTERNS 
Table E.1: Distribution of iron dosage pattern 
Dose pattern 
Definition         
Iron dose,                         
mg 
TSAT,   
% 
Ferritin, 
ng/mL 
Hgb,    
g/dL 
2-week Monthly equivalence N % 
Median 
(IQR) Mean (SD) Median (IQR) 
Bolus >500 
100 mg × 10 
consecutive sessions    3,218  7.5 
600     
(600-600) 627.6 (279.9) 
17         
(13-20) 
192         
(101-360.8) 
12.1    
(11.2-13.1) 
Half bolus 201-500 
100 mg × 5 
consecutive sessions    4,853  11.2 
400      
(300-500) 393.3 (88.5) 
18       
(14-23) 
226         
(116-415) 
12.2   
(11.2-13.2) 
Maintenance 101-200 100 mg weekly    7,902  18.3 
200     
(200-200) 189.2 (23.8) 
24        
(19-31) 
299         
(174-480) 
12.5    
(11.5-13.4) 
Low maintenance 1-100 25 or 50 mg weekly  14,182  32.9 
100       
(50-100) 83.9 (24.3) 
26        
(21-34) 
358        
(224-543) 
12.2   
(11.3-13.1) 
None 0 0 mg  13,011  30.1 
0             
(0-0) 0 (0) 
29        
(21-41) 
492      
(227.3-884) 
12.4   
(11.3-13.4) 
Note: IQR = interquartile range; SD = standard deviation; TSAT = transferrin saturation; Hgb = hemoglobin  
 
 
 
 
 
 
1
1
6
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APPENDIX F: REGIONAL TREND OF MATCHED IV IRON ADMINISTRATION 
STRATEGIES 
Figure F.1: Distribution of matched IV iron administration strategies was similar among 
residential regions in 2004-2012. 
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APPENDIX G: FLOW DIAGRAM OF STUDY POPULATION FOR CHAPTER 5 
Figure G.1: Flow diagram of study population for Chapter 5, 2009-2012 
Excluded if no TSAT in last 90 days of baseline 
period (N= 12,427); 
No pre-dialysis claims or insufficient claims in last 
90 days of baseline (N= 3,565); 
<9 dialysis sessions in last 30 days of baseline 
period (N= 5,749) 
  
Excluded if polycystic kidney disease (N= 469) 
Excluded if no TSAT after 90 days on dialysis/no 
index TSAT (N= 47,523); 
Not on Medicare Parts A & B for entire baseline 
period (N= 47,447); 
Not on hemodialysis for last 90 days of baseline 
period (N= 8,246) 
    Patients aged 65 or older with their first 
ESRD service date between 01/01/2004 
and 09/02/2012 
       N= 172,719 
    Patients with center-based hemodialysis 
patients receiving anemia management 
       N= 47,762 
Eligible patients in 2004-2012 
N= 42,439 
Excluded if index TSAT occurred after 136 days 
since first dialysis date (N= 4,046) 
Excluded if no follow up days (N= 81) 
Excluded if missing baseline covariates (N= 727) 
Index date on or after 01/01/2009 
N= 18,697 
 APPENDIX H: SENSITIVITY ANALYSIS VARYING MODELS FOR DEVIATION – ALL CAUSE MORTALITY 
Figure H.1: Cumulative risk difference curves for all-cause mortality varying models for deviation (a) simplified full model; (b) full 
model with time-fixed and time-varying covariates; (c) time-varying covariates only model; (d) intercept-only model 
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 APPENDIX I: SENSITIVITY ANALYSIS VARYING MODELS FOR DEVIATION – INFECTION-RELATED EVENTS 
Figure I.1: Cumulative risk difference curves for all-cause mortality varying models for deviation (a) simplified full model; (b) full 
model with time-fixed and time-varying covariates; (c) time-varying covariates only model; (d) intercept-only model 
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 APPENDIX J: FOUR DIFFERENT ESTIMATION MODELS – ALL-CAUSE MORTALITY 
Figure J.1: Cumulative risk difference curves for all-cause mortality varying estimation models (a) crude-intention-to-treat; (b) crude-
as treated; (c) SMRW-as treated; (d) SMRW-IPCW 
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 APPENDIX K: FOUR DIFFERENT ESTIMATION MODELS – INFECTION-RELATED EVENTS 
Figure K.1: Cumulative risk difference curves for infection-related events varying estimation models (a) crude-intention-to-treat; (b) 
crude-as treated; (c) SMRW-as treated; (d) SMRW-IPCW 
  
  
a) b) 
c) d) 
1
2
2
 
123 
 
REFERENCES 
1. Eschbach JW, Adamson JW. Anemia of end-stage renal disease. Kidney Int. 1985;28:1–
5. 
 
2. Collins AJ, Li S, St Peter W, et al. Death, hospitalization, and economic associations 
among incident hemodialysis patients with hematocrit values of 36 to 39%. J Am Soc 
Nephrol. 2001;12:2465–2473. 
 
3. Gaweda AE, Ginzburg YZ, Chait Y, et al. Iron dosing in kidney disease: inconsistency of 
evidence and clinical practice. Nephrol Dial Transplant. 2015;30:187–196. 
 
4. Macdougall IC, Bircher AJ, Eckardt K, et al. Iron management in chronic kidney disease: 
conclusions from a “Kidney Disease: Improving Global Outcomes” (KDIGO) 
Controversies Conference. Kidney Int. 2016;89:28–39. 
 
5. Kapoian T, O’Mara NB, Singh AK, et al. Ferric gluconate reduces epoetin requirements 
in hemodialysis patients with elevated ferritin. J Am Soc Nephrol. 2008;19(2):372–379. 
 
6. Coyne DW, Kapoian T, Suki W, et al. Ferric gluconate is highly efficacious in anemic 
hemodialysis patients with high serum ferritin and low transferrin saturation: results of 
the Dialysis Patients’ Response to IV Iron with Elevated Ferritin (DRIVE) Study. J Am 
Soc Nephrol. 2007;18(3):975–984. 
 
7. Singh AK, Szczech L, Tang KL, et al; CHOIR Investigators: Correction of anemia with 
epoetin alfa in chronic kidney disease. N Engl J Med. 2006;355:2085–2098. 
 
8. Drüeke TB, Locatelli F, Clyne N, et al; CREATE Investigators: Normalization of 
hemoglobin level in patients with chronic kidney disease and anemia. N Engl J Med. 
2006;355:2071–2084. 
 
9. Pfeffer MA, Burdmann EA, Chen CY, et al; TREAT Investigators: A trial of darbepoetin 
alfa in type 2 diabetes and chronic kidney disease. N Engl J Med. 2009;361:2019–2032. 
 
10. Centers for Medicare & Medicaid Services, HHS: Medicare Program; end-stage renal 
disease prospective payment system. Final rule. Fed Regist. 2010;75:49029–49214. 
 
11. Freburger JK, Ng LJ, Bradbury BD, et al: Changing patterns of anemia management in 
US hemodialysis patients. Am J Med. 2012;125:906.e9–914.e9. 
 
12. Miskulin DC, Zhou J, Tangri N, et al. Trends in anemia management in US hemodialysis 
patients 2004-2010. BMC Nephrology. 2013;14:264. 
 
13. Kidney Disease: Improving Global Outcomes Anemia Work Group. KDIGO clinical 
practice guideline for anemia in chronic kidney disease. Kidney Int Suppl. 2012;2:279–
335. 
124 
 
14. Locatelli F, Bárány P, Covic A, et al. Kidney Disease: Improving Global Outcomes 
guidelines on anaemia management in chronic kidney disease: a European Renal Best 
Practice position statement. Nephrol Dial Transplant. 2013;28:1346–1359. 
 
15. Kliger AS, Foley RN, Goldfarb DS, et al. KDOQI US commentary on the 2012 KDIGO 
Clinical Practice Guideline for Anemia in CKD. Am J Kidney Dis. 2013;62:849–859. 
 
16. Moist LM, Troyanov S, White CT, et al. Canadian Society of Nephrology commentary 
on the 2012 KDIGO Clinical Practice Guideline for Anemia in CKD. Am J Kidney Dis. 
2013;62:860–873. 
 
17. Fuller DS, Pisoni RL, Bieber BA, et al. The DOPPS practice monitor for U.S. dialysis 
care: update on trends in anemia management 2 years into the bundle. Am J Kidney Dis. 
2013;62:1213–1216. 
 
18. Karaboyas A, Zee J, Morgenstern H, et al. Understanding the recent increase in ferritin 
levels in United States dialysis patients: potential impact of changes in intravenous iron 
and erythropoiesis-stimulating agent dosing. Clin J Am Soc Nephrol. 2015;10:1814–
1821. 
 
19. Krishnan M, Weldon J, Wilson S, et al. Effect of Maintenance Iron Protocols on ESA 
Dosing and Anemia Outcomes [Abstract 153]. Am J Kidney Dis. 2011;57(4):A55. 
 
20. Miskulin DC, Tangri N, Bandeen-Roche K, et al; Developing Evidence to Inform 
Decisions about Effectiveness (DEcIDE) Network Patient Outcomes in End Stage Renal 
Disease Study Investigators: Intravenous iron exposure and mortality in hemodialysis 
patients. Clin J Am Soc Nephrol. 2014;9(11):1930–1939. 
 
21. Implementing an IV iron administration protocol within a dialysis organization. 
http://www.nephrologynews.com/implementing-an-iv-iron-administration-protocol-
within-a-dialysis-organization/. [Accessed 22 March 2015] 
 
22. Kshirsagar AV, Freburger JK, Ellis AR, et al. The comparative short-term effectiveness 
of iron dosing and formulations in US hemodialysis patients. Am J Med. 2013;126(6): 
541. 
 
23. Kshirsagar AV, Freburger JK, Ellis AR, et al. Intravenous iron supplementation practices 
and short-term risk of cardiovascular events in hemodialysis patients. PLoS ONE. 
2013;8(11):e78930. 
 
24. Freburger JK, Ellis AR, Kshirsagar AV, et al. Comparative short-term safety of bolus 
versus maintenance iron dosing in hemodialysis patients: a replication study. BMC 
Nephrology. 2014;15:154. 
 
125 
 
25. Brookhart MA, Freburger JK, Ellis AR, et al. Infection risk with bolus versus 
maintenance iron supplementation in hemodialysis patients. J Am Soc Nephrol. 2013;24: 
1151–1158. 
 
26. Michels WM, Jaar BG, Ephraim PL, et al; DEcIDE Network Patient Outcomes in End 
Stage Renal Disease Study Investigators: Intravenous iron administration strategies and 
anemia management in hemodialysis patients. Nephrol Dial Transplant. 2016;0:1–9.  
 
27. Tangri N, Miskulin DC, Zhou J, et al. Effect of intravenous iron use on hospitalizations 
in patients undergoing hemodialysis: a comparative effectiveness analysis from the 
DEcIDE-ESRD study. Nephrol Dial Transplant. 2015;30(4):667–675. 
 
28. Brookhart MA, Li X, Kshirsagar AV. What are the considerations in balancing benefits 
and risks in Iron treatment? Semin Dial. 2016;30:25–27. 
 
29. U.S. Renal Data System, USRDS 2014 Annual Data Report: Epidemiology of Kidney 
Disease in the United States. National Institutes of Health, National Institute of Diabetes 
and Digestive and Kidney Diseases, Bethesda, MD, 2014. 
 
30. U.S. Renal Data System, USRDS 2009 Annual Data Report: Atlas of Chronic Kidney 
Disease and End-Stage Renal Disease in the United States, National Institutes of Health, 
National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, MD, 2009. 
 
31. U.S. Renal Data System, USRDS 2013 Annual Data Report: Atlas of Chronic Kidney 
Disease and End-Stage Renal Disease in the United States, National Institutes of Health, 
National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, MD, 2013. 
 
32. Brugnara C, Eckardt KU. Hematologic aspects of kidney disease. In: Taal MW, ed. 
Brenner and Rector’s The Kidney. 9th ed. Philadelphia: Saunders; 2011:2081–2120. 
 
33. Iron deficiency anemia: assessment, prevention, and control. A guide for programme 
managers. Geneva, World Health Organization, 2001 (WHO/NHD/01.3).  
 
34. Primer on Kidney Diseases Sixth edition. National Kidney Foundation. Gilbert SJ, 
Weiner DE, Gipson DS, Perazella mA, & Tonelli M. (Eds).  Philadelphia, PA: Elsevier 
Saunders; 2013.  
 
35. Farag YM, Keithi-Reddy Sr, Mittal BV, et al. Anemia, inflammation and health-related 
quality of life in chronic kidney disease patients. Clin Nephrol. 2011;75(6):524–533. 
 
36. Levin A, Singer J, Thompson CR, et al. Prevalent left ventricular hypertrophy in the 
predialysis population: identifying opportunities for intervention. Am J Kidney Dis. 
1996;27(3):347–354. 
 
37. Foley RN, Parfrey PS, Harnett JD, et al. The impact of anemia on cardiomyopathy, 
morbidity, and mortality in end-stage renal disease. Am J Kidney Dis. 1996;28(1):53–61. 
126 
 
38. Besarab A, Coyne DW. Iron supplementation to treat anemia in patients with chronic 
kidney disease. Nat Rev Nephrol. 2010;6:699–710. 
 
39. Weiss G, Gordeuk VR. Benefits and risks of iron therapy for chronic anaemias. Eur J 
Clin Invest. 2005;35[Suppl 3]:36–45. 
 
40. Kalantar-Zadeh K, Rodriguez RA, Humphreys MH. Association between serum ferritin 
and measures of inflammation, nutrition and iron in haemodialysis patients. Nephrol Dial 
Transplant. 2004;19:141–149. 
 
41. KDOQI; National Kidney Foundation. KDOQI clinical practice guidelines and clinical 
practice recommendations for anemia in chronic kidney disease. Am J Kidney Dis. 
2006;47(5 Suppl 3):S11–S145. 
 
42. Wish JB. Assessing iron status: Beyond serum ferritin and transferrin saturation. Clin J 
Am Soc. Nephrol 2006;1[Suppl]:S4–S8. 
 
43. Cavill I, Macdougall IC. Erythropoiesis and iron supply in patients treated with 
erythropoietin. Erythropoiesis. 1992;3:50–55. 
 
44. Gaweda AE, Ginzburg YZ, Chait Y, et al. Iron dosing in kidney disease: inconsistency of 
evidence and clinical practice. Nephrol Dial Transplant 2015;30;187–196. 
 
45. Sargent JA, Acchiardo SR. Iron requirements in hemodialysis. Blood Purif. 2004; 
22:112–123. 
 
46. Horl WH. Clinical aspects of iron use in the anemia of kidney disease. J Am Soc 
Nephrol. 2007;18:382–393. 
 
47. Eschbach JW, Cook JD, Scribner BH, et al. Iron balance in hemodialysis patients. Ann 
Int Med. 1977;87:710–713. 
 
48. Eschbach JW, Cook JD, Finch CA. Iron absorption in chronic renal disease. Clin Sci. 
1970;38:191–201. 
 
49. Al-Mueilo SH. Gastroduodenal lesions and Helicobacter pylori infection in hemodialysis 
patients. Saudi Med J. 2004;25:1010–1014. 
 
50. Hershko C, Skikne B. Pathogenesis and management of iron deficiency anemia: 
emerging role of celiac disease, Helicobacter pylori, and autoimmune gastritis. Semin. 
Hematol. 2009;46:339–350. 
 
51. Eschbach JW, Egrie JC, Downing MR, et al. Correction of the anemia of end-stage renal 
disease with recombinant human erythropoietin. Results of a combined phase I and II 
clinical trial. N Engl J Med. 1987;316:73–78. 
127 
 
52. Szczech LA, Barnhart HX, Inrig JK, et al. Secondary analysis of the CHOIR trial 
epoetin-alpha dose and achieved hemoglobin outcomes. Kidney Int. 2008;74:791–798. 
 
53. Provenzano R, Schiller B, Rao M, et al. Ferumoxytol as an intravenous iron replacement 
therapy in hemodialysis patients. Clin J Am Soc Nephrol. 2009;4:386–393. 
 
54. Rozen-Zvi B, Gafter-Gvili A, Paul M, et al. Intravenous versus oral iron supplementation 
for the treatment of anemia in CKD: Systematic review and meta analysis. Am J Kidney 
Dis. 2008;52:897–906. 
 
55. Besarab A, Bolton WK, Browne JK, et al. The effects of normal as compared with low 
hematocrit values in patients with cardiac disease who are receiving hemodialysis and 
epoetin. N Engl J Med. 1998;339:584–590. 
 
56. Epogen Package Insert Revised April 2009. http://www.epogen.com/pdf/epogen_pi.pdf. 
[Accessed February 10, 2014] 
 
57. US Food and Drug Administration. FDA public health advisory: erythropoiesis-
stimulating agents (ESAs). 
http://www.accessdata.fda.gov/drugsatfda_docs/label/2007/103234s5122lbl.pdf. 
[Accessed February 10, 2014] 
 
58. Ibrahim HN, Foley RN, Zhang R, et al. Parenteral iron use: possible contribution to 
exceeding target hemoglobin in hemodialysis patients. Clin J Am Soc Nephrol. 
2009;4(3):623–629. 
 
59. St Peter WL, Obrador GT, Roberts TL, et al. Trends in intravenous iron use among 
dialysis patients in the United States (1994-2002). Am J Kidney Dis. 2005;46(4):650–
660. 
 
60. Kliger AS, Fishbane S, Finkelstein FO. Erythropoietic Stimulating Agents and Quality of 
a Patient’s Life: Individualizing Anemia Treatment. Clin J Am Soc Nephrol. 
2012;7(2):354–357. 
 
61. Tanhehco YC, Berns JS. Red blood cell transfusion risks in patients with end-stage renal 
disease. Semin Dial. 2012;25(5);539–544.  
 
62. Reading FC, Brecher ME. Transfusion-related bacterial sepsis. Curr Opin Hematol. 
2001;8:380–386. 
 
63. Hendrickson JE, Hillyer CD. Noninfectious serious hazards of transfusion. Anesth Analg. 
2009;108:759–769. 
 
64. Eschbach JW, Abdulhadi MH, Browne JK, et al. Recombinant human erythropoietin in 
anemic patients with end-stage renal disease: results of a phase III multicenter clinical 
trial. Ann Intern Med. 1989;111:992–1000. 
128 
 
65. Macdougall IC. Novel erythropoiesis stimulating protein. Semin Nephrol. 
2000;20(4):375–381. 
 
66. Tong EM, Nissenson AR. Erythropoietin and anemia. Semin Nephrol. 2001;21(2):190–
203. 
 
67. Epogen. http://www.epogen.com/patient/about-epogen/what-is-epogen.html [Accessed 
February 20, 2014] 
 
68. United States Food and Drug Administration. Epogen® (epoetin alfa) injection, for 
intravenous or subcutaneous use. 
http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/103234Orig1s5166_103234O
rig1s5266lbl.pdf [Accessed February 20, 2014] 
 
69. United States Food and Drug Administration. Aranesp® (darbepoetin alfa) injection, for 
intravenous or subcutaneous use. 
http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/103951Orig1s5173_103951O
rig1s5258lbl.pdf [Accessed February 20, 2014] 
 
70. United States Food and Drug Administration. Mircera® (methoxy polyethylene glycol-
epoetin Beta) injection. 
http://www.accessdata.fda.gov/drugsatfda_docs/nda/2007/125164toc.cfm [Accessed 
February 20, 2014] 
 
71. Besarab A, Reyes CM, Hornberger J. Meta-analysis of subcutaneous versus intravenous 
epoetin in maintenance treatment of anemia in hemodialysis patients. Am J Kidney Dis. 
2002;40:439–446. 
 
72. Centers for Medicare and Medicaid Services, Kinney R. 2005 Annual Report: ESRD 
Clinical Performance Measures Project. Am J Kidney Dis. 2006;48:S1–106. 
 
73. Pisoni RL. Erythropoietin therapy in Europe: Results from the DOPPS. Contrib Nephrol. 
2002;137:396–402. 
 
74. Macdougall IC, Roberts DE, Coles GA, et al. Clinical pharmacokinetics of epoetin 
(recombinant human erythropoietin). Clin Pharmacokinet. 1991;20(2):99–113. 
 
75. Macdougall IC, Padhi D, Jang G. Pharmacology of darbepoetin alfa. Nephrol Dial 
Transplant. 2007;22 Suppl 4:iv2-iv9. 
 
76. Brookhart MA, Schneeweiss S, Avorn J, et al. Comparative mortality risk of anemia 
management practices in incident hemodialysis patients. JAMA. 2010;303(9):857–864. 
 
77. Obrador GT, Roberts T, St Peter WL, et al. Trends in anemia at initiation of dialysis in 
the United States. Kidney Int. 2001;60:1875–1884. 
 
129 
 
78. Hariharan S, Yang H. Introduction. Am J Kidney Dis. 2006; 47(4 Suppl 2):S1. 
 
79. Harnett JD, Kent GM, Foley RN, et al. Cardiac function and hematocrit level. Am J 
Kidney Dis. 1995;25:S3–7. 
 
80. Zehnder C, Zuber M, Sulzer M, et al. Influence of long-term amelioration of anemia and 
blood pressure control on left ventricular hypertrophy in hemodialyzed patients. Nephron 
1992;61:21–25. 
 
81. Benz RL, Pressman MR, Hovick ET, et al. A preliminary study of the effects of 
correction of anemia with recombinant human erythropoietin therapy on sleep, sleep 
disorders, and daytime sleepiness in hemodialysis patients (The SLEEPO study). Am J 
Kidney Dis. 1999;34:1089–1095. 
 
82. Pickett JL, Theberge DC, Brown WS, et al. Normalizing hematocrit in dialysis patients 
improves brain function. Am J Kidney Dis. 1999;33:1122–1130. 
 
83. Nissenson AR, Swan SK, Lindberg JS, et al. Randomized, controlled trial of darbepoetin 
alfa for the treatment of anemia in hemodialysis patients. Am J Kidney Dis. 
2002;40:110–118. 
 
84. Vanrenterghem Y, Bárány P, Mann JF, et al. Randomized trial of darbepoetin alfa for 
treatment of renal anemia at a reduced dose frequency compared with rHuEPO in dialysis 
patients. Kidney Int. 2002;62:2167–2175. 
 
85. Tolman C, Richardson D, Bartlett C, Will E. Structured conversion from thrice weekly to 
weekly erythropoietic regimens using a computerized decision-support system: a 
randomized clinical study. J Am Soc Nephrol. 2005;16:1463–1470. 
 
86. Ma JZ, Ebben J, Xia H, Collins AJ. Hematocrit level and associated mortality in 
hemodialysis patients. J Am Soc Nephrol. 1999;10:610–619. 
 
87. Xia H, Ebben J, Ma JZ, Collins AJ. Hematocrit levels and hospitalization risks in 
hemodialysis patients. J Am Soc Nephrol. 1999;10:1309–1316.  
 
88. Ofsthun N, Labrecque J, Lacson E, et al. The effects of higher hemoglobin levels on 
mortality and hospitalization in hemodialysis patients. Kidney Int. 2003;63:1908–1914. 
 
89. Li S, Collins AJ. Association of hematocrit value with cardiovascular morbidity and 
mortality in incident hemodialysis patients. Kidney Int. 2004;65:626–633. 
 
90. Li S, Foley RN, Collins AJ. Anemia, hospitalization, and mortality in patients receiving 
peritoneal dialysis in the United States. Kidney Int. 2004; 65:1864–1969.  
 
130 
 
91. Locatelli F, Pisoni RL, Combe C, et al. Anaemia in haemodialysis patients of five 
European countries: association with morbidity and mortality in the Dialysis Outcomes 
and Practice Patterns Study (DOPPS). Nephrol Dial Transplant. 2004;19:121–132. 
 
92. Pisoni RL, Bragg-Gresham JL, Young EW, et al. Anemia management and outcomes 
from 12 countries in the Dialysis Outcomes and Practice Patterns Study (DOPPS). Am J 
Kidney Dis. 2004;44:94–111. 
 
93. Lu WX, Jones-Burton C, Zhan M, et al. Survival benefit of recombinant human 
erythropoietin administration prior to onset of end-stage renal disease: variations across 
surrogates for quality of care and time. Nephron Clin Pract. 2005;101:c79–c86. 
 
94. Robinson BM, Joffe MM, Berns JS, et al. Anemia and mortality in hemodialysis patients: 
accounting for morbidity and treatment variables updated over time. Kidney Int. 
2005;68:2323–2330. 
 
95. Wolfe RA, Hulbert-Shearon TE, Ashby VB, et al. Improvements in dialysis patient 
mortality are associated with improvements in urea reduction ratio and hematocrit, 1999 
to 2002. Am J Kidney Dis. 2005;45:127–135. 
 
96. Regidor DL, Kopple JD, Kovesdy CP, et al. Associations between changes in 
hemoglobin and administered erythropoiesis-stimulating agent and survival in 
hemodialysis patients. J Am Soc Nephrol. 2006;17:1181–1191. 
 
97. Gilbertson DT, Ebben JP, Foley RN, et al. Hemoglobin level variability: associations 
with mortality. Clin J Am Soc Nephrol. 2008;3:133–138. 
 
98. Messana JM, Chuang CC, Turenne M, et al. Association of quarterly average achieved 
hematocrit with mortality in dialysis patients: a time-dependent comorbidity-adjusted 
model. Am J Kidney Dis. 2009;53:503–512. 
 
99. Strippoli GF, Craig JC, Manno C, Schena FP. Hemoglobin targets for the anemia of 
chronic kidney disease: a meta-analysis of randomized, controlled trials. J Am Soc 
Nephrol. 2004;15:3154–3165. 
 
100. Volkova N, Arab L. Evidence-based systematic literature review of 
hemoglobin/hematocrit and all-cause mortality in dialysis patients. Am J Kidney Dis. 
2006;47:24–36. 
 
101. Parfrey PS. Target hemoglobin level for EPO therapy in CKD. Am J Kidney Dis. 2006; 
47:171. 
 
102. Phrommintikul A, Haas SJ, Elsik M, Krum H. Mortality and target haemoglobin 
concentrations in anaemic patients with chronic kidney disease treated with 
erythropoietin: a meta-analysis. Lancet 2007;369:381–388. 
 
131 
 
103. Clement FM, Klarenbach S, Tonelli M, et al. The impact of selecting a high hemoglobin 
target level on health-related quality of life for patients with chronic kidney disease: a 
systematic review and meta-analysis. Arch Intern Med. 2009;169:1104–1112. 
 
104. Palmer SC, Navaneethan SD, Craig JC, et al. Meta-analysis: erythropoiesis-stimulating 
agents in patients with chronic kidney disease. Ann Intern Med. 2010;153:23–33. 
 
105. Johansen KL, Finkelstein FO, Revicki DA, et al. Systematic review and meta-analysis of 
exercise tolerance and physical functioning in dialysis patients treated with 
erythropoiesis-stimulating agents. Am J Kidney Dis. 2010;55:535–548. 
 
106. Gandra SR, Finkelstein FO, Bennett AV, et al. Impact of erythropoiesis-stimulating 
agents on energy and physical function in nondialysis CKD patients with anemia: a 
systematic review. Am J Kidney Dis. 2010;55:519–534. 
 
107. Lewis EF, Pfeffer MA, Feng A, et al. Darbepoetin alfa impact on health status in diabetes 
patients with kidney disease: a randomized trial. Clin J Am Soc Nephrol 2011;6:845–855. 
 
108. The rise and fall of a billion-dollar drug. Washingpost. 
http://www.washingtonpost.com/wp-srv/business/amgen-anemia-drugs/index.html. 
[Accessed May 17, 2015] 
 
109. KDOQI. KDOQI Clinical Practice Guideline and Clinical Practice Recommendations for 
anemia in chronic kidney disease: 2007 update of hemoglobin target. Am J Kidney Dis. 
2007;50:471–530. 
 
110. McFarlane PA, Pisoni RL, Eichleay MA, et al. International trends in erythropoietin use 
and hemoglobin levels in hemodialysis patients. Kidney Int. 2010;78(2):215–223. 
 
111. Collins AJ. ESRD payment policy changes: the new “bundled” dialysis prospective 
payment system (PPS) in the United States, National Kidney Foundation Spring Clinical 
Meeting Presentation 2012; 2012. 
 
112. Robinson BM, et al. The impact of bundling on clinical practice: Changes in practice 
pattern & laboratory values, National Kidney Foundation Spring Clinical Meeting 
Presentation 2012; 2012. 
 
113. Chertow GM, Mason PD, Vaage-Nilsen O, Ahlmen J. On the relative safety of parenteral 
iron formulations. Nephrol Dial Transplant. 2004;19(6):1571–1575. 
 
114. Agarwal R, Vasavada N, Sachs NG, et al. Oxidative stress and renal injury with 
intravenous iron in patients with chronic kidney disease. Kidney Int. 2004;65:2279–2289. 
 
115. Brewster UC. Intravenous iron therapy in end-stage renal disease. Semin Dial. 
2006;19:285–290. 
 
132 
 
116. Himmelfarb J, Stenvinkel P, Ikizler TA, Hakim RM. The elephant in uremia: oxidant 
stress as a unifying concept of cardiovascular disease in uremia. Kidney Int. 
2002;62(5):1524–1538. 
 
117. Maynor L, Brophy DF. Risk of infection with intravenous iron therapy. Ann 
Pharmacother 2007;41:1476–1480. 
 
118. Duncan R, Gaspar R. Nanomedicine(s) under the microscope. Mol Pharm. 2011;8:2101–
2141. 
 
119. Charytan DM, Pai AB, Chan CT, et al. Considerations and challenges in defining optimal 
iron utilization in hemodialysis. J Am Soc Nephrol. 2015;26(6):1328–1347. 
 
120. Hamstra RD, Block MH, Schocket AL. Intravenous iron dextran in clinical medicine. 
JAMA 1980;243:1726–1731. 
 
121. Rampton D, Folkersen J, Fishbane S, et al. Hypersensitivity reactions to intravenous iron: 
guidance for risk minimization and management. Haematologica 2014;99:1671–1676. 
 
122. Michael B, Coyne DW, Fishbane S, et al; Ferrlecit Publication Committee: Sodium ferric 
gluconate complex in hemodialysis patients: Adverse reactions compared to placebo and 
iron dextran. Kidney Int. 2002;61:1830–1839. 
 
123. Aronoff GR, Bennett WM, Blumenthal S, et al; United States Iron Sucrose (Venofer) 
Clinical Trials Group: Iron sucrose in hemodialysis patients: Safety of replacement and 
maintenance regimens. Kidney Int. 2004;66:1193–1198. 
 
124. Moniem KA, Bhandari S. Tolerability and efficacy of parenteral iron therapy in 
haemodialysis patients: a comparison of preparations. Transfus Altern Transfus Med. 
2007;1:1–7. 
 
125. Sav T, Tokgoz B, Sipahioglu MH. Is there a difference between allergic potencies of the 
iron sucrose and low molecular weight iron dextran? Ren Fail. 2007;29:423–426. 
 
126. Wysowski DK, Swartz L, Borders-Hemphill BV, et al. Use of parenteral iron products 
and serious anaphylactic-type reactions. Am J Hematol. 2010;85:650–654. 
 
127. Vecchio LD, Longhi S, Locatelli F. Safety concerns about intravenous iron therapy in 
patients with chronic kidney disease. Clin Kidney J. 2016;9:260–267. 
 
128. Wang C, Graham DJ, Kane RC, et al. Comparative risk of anaphylactic reactions 
associated with intravenous iron products. JAMA 2015;314:2062–2068. 
 
129. http://www.ema.europa.eu/ema/index.jsp?curl=pages/news_and_events/news/2013/06/ne
ws_detail_001833.jsp&mid=WC0b01ac058004d5c1 [Accessed 15 December 2016] 
133 
 
130. FDA strengthens warnings and changes prescribing instructions to decrease the risk of 
serious allergic reactions with anemia drug Feraheme (ferumoxytol). US Food and Drug 
Administration, Drug Safety Communications. Available at: 
http://www.fda.gov/downloads/Drugs/DrugSafety/UCM440336.pdf. [Accessed 11 May 
2015] 
 
131. Bishu K, Agarwal R. Acute injury with intravenous iron and concerns regarding long-
term safety. J Am Soc Nephrol. 2006;1 (Suppl 1):S19–S23. 
 
132. Stadler N, Lindner RA, Davies MJ. Direct detection and quantification of transition metal 
ions in human atherosclerotic plaques: evidence for the presence of elevated levels of 
iron and copper. Arterioscler Thromb Vasc Biol 2004;24:949–954. 
 
133. Zager RA, Johnson AC, Hanson SY, et al. Parenteral iron formulations: A comparative 
toxicologic analysis and mechanisms of cell injury. Am J Kidney Dis. 2002;40:90–103. 
 
134. Toblli JE, Cao G, Oliveri L, et al. Assessment of the extent of oxidative stress induced by 
intravenous ferumoxytol, ferric carboxymaltose, iron sucrose and iron dextran in a 
nonclinical model. Arzneimittelforschung. 2011;61:399–410. 
 
135. Lim CS, Vaziri ND. The effects of iron dextran on the oxidative stress in cardiovascular 
tissues of rats with chronic renal failure. Kidney Int. 2004;65:1802–1809. 
 
136. Sullivan JL. Do hemochromatosis mutations protect against iron-mediated atherogenesis? 
Circ Cardiovasc Genet. 2009; 2:652–657. 
 
137. Li JJ, Meng X, Si HP, et al. Hepcidin destabilizes atherosclerotic plaque via 
overactivating macrophages after erythrophagocytosis. Arterioscler Thromb Vasc Biol. 
2012;32:1158–1166. 
 
138. Kautz L, Gabayan V, Wang X, et al. Testing the iron hypothesis in a mouse model of 
atherosclerosis. Cell Rep. 2013;5:1436–1442. 
 
139. Reis KA, Guz G, Ozdemir H, et al. Intravenous iron therapy as a possible risk factor for 
atherosclerosis in end-stage renal disease. Int Heart J. 2005;46:255–264. 
 
140. Drueke T, Witko-Sarsat V, Massy Z, et al. Iron therapy, advanced oxidation protein 
products, and carotid artery intima-media thickness in end-stage renal disease. 
Circulation. 2002;106:2212–2217. 
 
141. van derWeerd NC, Grooteman MP, Bots ML, et al. Hepcidin-25 is related to 
cardiovascular events in chronic haemodialysis patients. Nephrol Dial Transplant. 2013; 
28:3062–3071. 
 
142. Himmelfarb, J. Uremic toxicity, oxidative stress, and hemodialysis as renal replacement 
therapy. Semin. Dial. 2009;22:636–643. 
134 
 
143. Susantitaphong P, Alqahtani F, Jaber BL. Efficacy and safety of intravenous iron therapy 
for functional iron deficiency anemia in hemodialysis patients: A meta-analysis. Am J 
Nephrol. 2014;39:130–141. 
 
144. Kalantar-Zadeh K, Regidor DL, McAllister CJ, et al. Time-dependent associations 
between iron and mortality in hemodialysis patients. J Am Soc Nephrol. 2005;16:3070–
3080. 
 
145. Bailie GR, Larkina M, Goodkin DA, et al. Data from the Dialysis Outcomes and Practice 
Patterns Study validate an association between high intravenous iron doses and mortality. 
Kidney Int. 2015;87:162–168. 
 
146. Kuo KL, Hung SC, Lin YP, et al. Intravenous ferric chloride hexahydrate 
supplementation induced endothelial dysfunction and increased cardiovascular risk 
among hemodialysis patients. PLoS ONE. 2012;7:e50295. 
 
147. Feldman HI, Joffe M, Robinson B, et al. Administration of parenteral iron and mortality 
among hemodialysis patients. J Am Soc Nephrol. 2004;15:1623–1632. 
 
148. Gupta A, Zhuo J, Zha J, et al. Effect of different intravenous iron preparations on 
lymphocyte intracellular reactive oxygen species generation and subpopulation survival. 
BMC Nephrol. 2010;11:16. 
 
149. Parkkinen J, von Bonsdorff L, Peltonen S, et al. Catalytically active iron and bacterial 
growth in serum of haemodialysis patients after i.v. iron-saccharate administration. 
Nephrol Dial Transplant. 2000;15:1827–1834. 
 
150. Barton PA, Pai MP, Depczynski J, et al. Non-transferrin bound iron is associated with 
enhanced Staphylococcus aureus growth in hemodialysis patients receiving intravenous 
iron sucrose. Am J Nephrol. 2006;26:304–309. 
 
151. Anker SD. Ferric carboxymaltose in patients with heart failure and iron deficiency. N 
Engl J Med. 2009;361:2436–2448. 
 
152. Agarwal R, Kusek JW, Pappas MK. A randomized trial of intravenous and oral iron in 
chronic kidney disease. Kidney Int. 2015;88:905–914. 
 
153. Macdougall IC, Bock AH, Carrera F, et al. FIND-CKD: a randomized trial of intravenous 
ferric carboxymaltose versus oral iron in patients with chronic kidney disease and iron 
deficiency anaemia. Nephrol Dial Transplant. 2014;29:2075–2084. 
 
154. Fishbane S. Review of issues relating to iron and infection. Am J Kidney Dis. 1999;34(4 
Suppl 2): S47–S52. 
 
155. Besarab A, Frinak S, Yee J. An indistinct balance: the safety and efficacy of parenteral 
iron therapy. J Am Soc Nephrol 1999;10(9):2029–2043. 
135 
 
156. Eschbach JW, Adamson JW. Iron overload in renal faiure patients: changes since the 
introduction of erythropoietin therapy. Kidney Int Suppl. 1999;69:S35–S43. 
 
157. Ishida JH, Johansen KL. Iron and infection in hemodialysis patients. Sem Dial. 
2014;27(1):26–36. 
 
158. Litton E, Xiao J, Ho KM. Safety and efficacy of intravenous iron therapy in reducing 
requirement for allogeneic blood transfusion: systematic review and meta-analysis of 
randomised clinical trials. BMJ. 2013;347:f4822. 
 
159. Sirken G, Raja R, Rizkala AR. Association of different intravenous iron preparations 
with risk of bacteremia in maintenance hemodialysis patients. Clin Nephrol. 
2006;66:348–356. 
 
160. Diskin CJ, Stokes TJ, Dansby LM, et al. Is systemic heparin a risk factor for catheter-
related sepsis in dialysis patients? An evaluation of various biofilm and traditional risk 
factors. Nephron Clin Pract. 2007;107:c128–c132. 
 
161. Kuragano T, Matsumura O, Matsuda A, et al. Association between hemoglobin 
variability, serumferritin levels, and adverse events/mortality in maintenance 
hemodialysis patients. Kidney Int. 2014;86:845–854. 
 
162. Zitt E, Sturm G, Kronenberg F, et al. Iron Supplementation and Mortality in Incident 
Dialysis Patients: An Observational Study. PLoS ONE. 2014;9(12):e114144.  
 
163. Robins JM, Hernán M. Estimation of the causal effects of time varying exposures. In 
Longitudinal Data Analysis. Fitzmaurice G, Davidian M, Verbeke G, Molenberghs G 
(eds). Chapman and Hall/CRC Press: New York, NY, 2008;553–599. 
 
164. European AIDS Clinical Society. Guidelines: clinical management and treatment of HIV 
infected adults in Europe. 2009. 
http://www.europeanaidsclinicalsociety.org/guidelinespdf/1_Treatment_of_HIV_Infected
_Adults.pdf [Accessed 17 November 2016] 
 
165. World Health Organization. Rapid advice: antiretroviral therapy for HIV infection in 
adults and adolescents. 2009. http://www.who.int/hiv/pub/arv/rapid_advice_art.pdf 
[Accessed 17 November 2016] 
 
166. Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of 
antiretroviral agents in HIV-1 infected adults and adolescents. Department of Health and 
Human Services. 2008. 
https://aidsinfo.nih.gov/contentfiles/lvguidelines/adultandadolescentgl.pdf [Accessed 17 
November 2016] 
  
167. American Diabetes Association. Standards of Medical Care in Diabetes. Diabetes Care 
2016;39(Suppl 1):S1–S119. 
136 
 
168. Stone NJ, Robinson JG, Lichtenstein AH, et al. 2013 ACC/AHA guideline on the 
treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a 
report of the American College of Cardiology/American Heart Association Task Force on 
Practice Guidelines. Circulation. 2014;129(Suppl 2):S1–S45. 
 
169. Robins JM. Information recovery and bias adjustment in proportional hazards regression 
analysis of randomized trials using surrogate markers. In Proceedings of the 
Biopharmaceutical Section, American Statistical Association 24–33. American Statistical 
Association, Alexandria, VA. 1993. 
 
170. Robins JM, Rotnitzky A, Zhao LP. Analysis of semiparametric regression models for 
repeated outcomes in the presence of missing data. J Amer Statist Assoc. 1995;90:106–
121.  
 
171. Robins JM, Hernán MA, Brumback B. Marginal structural models and causal inference 
in epidemiology. Epidemiology 2000;11:550–560. 
 
172. Satten GA, Datta S. The Kaplan-Meier estimator as an inverse-probability-of-censoring 
weighted average. Am Stat. 2001; 55(3): 207–210. 
 
173. Hernán MA, Lanoy E, Costagliola D, Robins JM. Comparison of dynamic treatment 
regimes via inverse probability weighting. Basic Clin Pharmacol Toxicol. 2006;98:37–
242. 
 
174. van der Lann MJ, Petersen ML. Causal effect models for realistic individualized 
treatment and intention to treat rules. Int J Biostat. 2007;3(1):Article 3. 
 
175. Robins J, Orellana L, Rotnitzky A. Estimation and extrapolation of optimal treatment and 
testing strategies. Stat Med. 2008;27:4678–4721.  
 
176. Orellana L, Rotnitzky A, Robins JM. Dynamic regime marginal structural mean models 
for estimation of optimal dynamic treatment regimes, Part I: Main content. Int J Biostat. 
2010;6:Article 8.  
 
177. Cain LE, Robins JM, Lanoy E, et al. When to start treatment? A systematic approach to 
the com- parison of dynamic regimes using observational data. Int J Biostat. 
2010;6(2):Article18. 
 
178. Cain LE, Logan R, Robins JM, et al. When to initiate combined antiretroviral therapy to 
reduce mortality and AIDS-defining illness in HIV-infected persons in developed 
countries: An observational study. Ann Intern Med. 2010;154:509–515. 
 
179. Cotton CA, Heagerty PJ. A data augmentation method for estimating the causal effect of 
adherence to treatment regimens targeting control of an intermediate measure. Stat 
Biosci. 2011;3:28–44. 
137 
 
180. Cotton CA, Heagerty PJ. Evaluating epoetin dosing strategies using observational 
longitudinal data. Ann Appl Stat. 2014;8(4);2356–2377. 
 
181. Shortreed SM, Moodie EEM. Estimating the optimal dynamic antipsychotic treatment 
regime: Evidence from the sequential multiple-assignment randomized clinical 
antipsychotic trials of intervention and effectiveness schizophrenia study. J R Stat Soc 
Ser C Appl Stat. 2012;61:577–599.  
 
182. Robins JM. A new approach to causal inference in mortality studies with a sustained 
exposure period: application to the healthy worker survivor effect. Mathematical 
Modelling. 1986;7:1393–1512. [Errata (1987) in Computers and Mathematics with 
Applications 14,917–921. Addendum (1987) in Computers and Mathematics with 
Applications 14,923–945. Errata 1987 to addendum in Computers and Mathematics with 
Applications 18,477.]. 
 
183. Robins JM, Hernán MA, Siebert U. Effects of multiple interventions. In: Ezzati, M.; 
Lopez, AD.; Rodgers, A.; Murray, CJL., editors. Comparative Quantification of Health 
Risks: Global and Regional Burden of Disease Attributable to Selected Major Risk 
Factors. Geneva: World Health Organization; 2004. 
 
184. Taubman SL, Robins JM, Mittleman MA, Hernán MA. Intervening on risk factors for 
coronary heart disease: an application of the parametric g-formula. Int J Epidemiol. 
2009;38(6):1599–1611.  
 
185. Young J, Cain L, Robins JM, et al. Comparative effectiveness of dynamic treatment 
regimes: An application of the parametric g-formula. Stat Biosci. 2011;3:119–143. 
 
186. The Kidney Care Council. http://kidneycarecouncil.org/the-kidney-care-council-
members-davita-inc/. [Accessed Feb 05, 2014] 
 
187. Manley HJ, Drayer DK, McClaran M, Bend W, Muther RS. Drug record discrepancies in 
an outpatient electronic medical record: frequency, type, and potential impact on patient 
care at a hemodialysis center. Pharmacotherapy. 2003;23(2):231–9. 
 
188. United States Renal Data Systems. 2014 Researcher’s Guide to the USRDS Database. 
2014. http://www.usrds.org/research.aspx [Accessed Feb 05, 2014] 
 
189. Foley RN, Collins AJ. The USRDS: What you needed to know about what it can and 
can’t tell us about ESRD. Clin J Am Soc Nephrol. 2013;8:845–851. 
 
190. Vardi M, Yeh RW, Herzog CA, et al. Strategies for postmarketing surveillance of drugs 
and devices in patients with ESRD undergoing dialysis. Clin J Am Soc Nephrol. 
2013;8:2213–2220.  
 
191. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am 
Statist Assoc. 1958;53:457–481. 
138 
 
 
192. Cole SR, Hernán MA. Constructing Inverse Probability Weights for Marginal Structural 
Models. Am J Epidemiol. 2008;168(6):656–664. 
 
193. Cole SR, Hernán MA. Adjusted survival curves with inverse probability weights. Comput 
Methods Programs Biomed. 2004;75(1):45–49. 
 
194. Young JG, Tchetgen Tchetgen EJ. Simulating from a known Cox MSM using standard 
parametric models for the g-formula. Stat in Med. 2014;33:1001–1014.  
 
195. Murphy SA. An experimental design for the development of adaptive treatment 
strategies. Stat Med 2005;24(10):1455–1481. 
 
196. Lavori PW, Dawson R. Dynamic treatment regimes: practical design considerations. Clin 
Trials 2004;1(1):9–20. 
 
197. Besarab A, Kaiser JW, Frinak S. A study of parenteral iron regimens in hemodialysis 
patients. Am J Kidney Dis. 1999;34(1):21–28. 
 
198. Murphy SA, van der Laan MJ, Robins JM; CPPRG. Marginal mean models for dynamic 
regimes. J Am Stat Assoc. 2001;96(456):1410–1423.  
 
199. Krishnan M, Wilfehrt HM, Lacson E, Jr. In data we trust: the role and utility of dialysis 
provider databases in the policy process. Clin J Am Soc Nephrol. 2012;7(11):1891–1896.  
 
200. R Core Team. R: A language and environment for statistical computing. R Foundation 
for Statistical Computing, Vienna, Austria, 2016.  
 
201. Breiman L, Friedman JH, Stone CJ, et al. Classification and Regression Trees. CRC 
Press, 1984. 
 
202. Breiman L. Random forests. Mach Learn. 2001;45:5–32. 
 
203. Brookhart MA. Counterpoint: the treatment decision design. Am J Epidemiol. 
2015;182(10):840–845. 
 
204. U.S. DOPPS Practice Pattern Monitor, August 2014. http://www.dopps.org/DPM 
[Accessed 19 November 2014] 
 
